

Mass General Brigham Incorporated and Affiliates

**Report on Federal Awards in Accordance with the
OMB Uniform Guidance**

September 30, 2024

EIN 04-3230035

Mass General Brigham Incorporated and Affiliates

Index

September 30, 2024 and 2023

Page(s)

Part I – Financial Statements

Report of Independent Auditors 1–3

Mass General Brigham Consolidated Financial Statements
and Notes to Financial Statements 4–49

Schedule of Expenditures of Federal Awards
and Notes to Schedule of Expenditures of Federal Awards 50–93

Part II – Reports on Compliance and Internal Controls

Report on Independent Auditors on Internal Control Over Financial Reporting and on Compliance and
Other Matters Based on an Audit of Financial Statements
Performed in Accordance with Government Auditing Standards..... 94–95

Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material
Effect on Each Major Program and on Internal Control
Over Compliance in Accordance with the OMB Uniform Guidance..... 96–98

Part III – Federal Award Findings and Questioned Costs

Schedule of Findings and Questioned Costs..... 99–102

Summary Schedule of Prior Audit Findings and Status 103

Management's Views and Corrective Action Plan 104



Report of Independent Auditors

To the Board of Directors of
Mass General Brigham Incorporated

Opinion

We have audited the accompanying consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheets as of September 30, 2024 and 2023, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company and its affiliates as of September 30, 2024 and 2023, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute



assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company and its affiliates' ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended September 30, 2024 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In



our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated December 18, 2024 on our consideration of the Company and its affiliates' internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended September 30, 2024. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company and its affiliates' internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 18, 2024

Mass General Brigham Incorporated and Affiliates
Consolidated Balance Sheets
September 30, 2024 and 2023

(in thousands of dollars)

	2024	2023
Assets		
Current assets		
Cash and equivalents	\$ 105,924	\$ 279,459
Investments	4,479,974	3,397,634
Current portion of investments limited as to use	3,651,727	3,505,987
Patient accounts receivable, net	1,731,496	1,638,306
Research grants receivable, net	248,415	228,117
Other current assets	1,205,371	946,875
Total current assets	11,422,907	9,996,378
Investments limited as to use, less current portion	6,443,033	5,440,702
Long-term investments	3,138,592	2,713,547
Property and equipment, net	7,471,740	6,777,363
Right-of-use operating lease assets	920,702	1,024,336
Other assets	2,360,443	2,722,977
Total assets	<u>\$ 31,757,417</u>	<u>\$ 28,675,303</u>
Liabilities and Net Assets		
Current liabilities		
Current portion of long-term obligations	\$ 353,249	\$ 481,130
Accounts payable and accrued expenses	1,426,104	1,305,876
Accrued medical claims and related expenses	258,520	192,435
Accrued employee compensation and benefits	1,281,714	1,150,128
Current portion of operating lease obligations	203,879	207,671
Unexpended funds on research grants	369,851	377,730
Total current liabilities	3,893,317	3,714,970
Accrued professional liability	573,796	576,038
Accrued employee benefits	891,868	718,087
Interest rate swaps liability	139,170	67,075
Accrued other	463,907	331,166
Operating lease obligations, less current portion	598,065	696,740
Long-term obligations, less current portion	5,837,579	5,469,626
Total liabilities	<u>12,397,702</u>	<u>11,573,702</u>
Commitments and contingencies		
Net assets		
Without donor restrictions	15,413,590	13,362,445
With donor restrictions	3,946,125	3,739,156
Total net assets	<u>19,359,715</u>	<u>17,101,601</u>
Total liabilities and net assets	<u>\$ 31,757,417</u>	<u>\$ 28,675,303</u>

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Operations
Years Ended September 30, 2024 and 2023

(in thousands of dollars)

	2024	2023
Operating revenues		
Net patient service revenue	\$ 13,439,956	\$ 12,792,586
Premium revenue	2,169,968	1,518,556
Direct research and nonresearch sundry revenue	2,240,832	2,066,518
Indirect research and nonresearch sundry revenue	659,918	641,492
Other revenue	2,039,604	1,807,885
Total operating revenues	20,550,278	18,827,037
Operating expenses		
Employee compensation and benefit expenses	10,264,778	9,659,280
Supplies and other expenses	5,540,276	4,976,156
Medical claims and related expenses	1,505,038	1,086,589
Direct research and nonresearch sundry expenses	2,240,832	2,066,518
Depreciation and amortization expenses	778,337	774,563
Interest expense	175,279	168,765
Total operating expenses	20,504,540	18,731,871
Income from operations	45,738	95,166
Nonoperating gains (loss)		
Income from investments	1,950,070	962,128
Change in fair value of interest rate swaps	(84,228)	130,393
Other nonoperating expenses	(38,624)	(115,822)
Research and nonresearch sundry gifts net of spending	(48,187)	(68,062)
Nonservice related pension income	222,910	233,827
Total nonoperating gains, net	2,001,941	1,142,464
Excess of revenues over expenses	2,047,679	1,237,630
Other changes in net assets		
Funds utilized for property and equipment	434,073	54,110
Change in funded status of defined benefit plans	(445,729)	476,211
Other changes in net assets	15,122	16,692
Increase in net assets without donor restrictions	\$ 2,051,145	\$ 1,784,643

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Changes in Net Assets
Years Ended September 30, 2024 and 2023

<i>(in thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Net assets at September 30, 2022	\$ 11,577,802	\$ 3,047,475	\$ 14,625,277
Increases (decreases)			
Income from operations	95,166	-	95,166
Income from investments	962,128	127,629	1,089,757
Change in fair value of interest rate swaps	130,393	-	130,393
Other nonoperating (expenses) income	(115,822)	589,157	473,335
Research and nonresearch sundry gifts net of spending	(68,062)	-	(68,062)
Nonservice related pension income	233,827	-	233,827
Funds utilized for property and equipment	54,110	(28,088)	26,022
Change in funded status of defined benefit plans	476,211	-	476,211
Other changes in net assets	16,692	2,983	19,675
Change in net assets	1,784,643	691,681	2,476,324
Net assets at September 30, 2023	13,362,445	3,739,156	17,101,601
Increases (decreases)			
Income from operations	45,738	-	45,738
Income from investments	1,950,070	356,508	2,306,578
Change in fair value of interest rate swaps	(84,228)	-	(84,228)
Other nonoperating (expenses) income	(38,624)	240,919	202,295
Research and nonresearch sundry gifts net of spending	(48,187)	-	(48,187)
Nonservice related pension income	222,910	-	222,910
Funds utilized for property and equipment	434,073	(393,305)	40,768
Change in funded status of defined benefit plans	(445,729)	-	(445,729)
Other changes in net assets	15,122	2,847	17,969
Change in net assets	2,051,145	206,969	2,258,114
Net assets at September 30, 2024	\$ 15,413,590	\$ 3,946,125	\$ 19,359,715

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates
Consolidated Statements of Cash Flows
Years Ended September 30, 2024 and 2023

(in thousands of dollars)

	2024	2023
Cash flows from operating activities		
Change in net assets	\$ 2,258,114	\$ 2,476,324
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Change in funded status of defined benefit plans	445,729	(476,211)
Gain on refunding of debt	(7,010)	-
Change in fair value of interest rate swaps	84,228	(130,393)
Depreciation and amortization	778,337	774,563
Amortization of bond discount, premium and issuance costs	(11,164)	(10,646)
Loss (gain) on disposal of property	324	(13,086)
Change in right-of-use operating lease assets	120,409	174,612
Net realized and unrealized change in investments	(2,570,863)	(1,266,094)
Donor restricted contributions and investment income	(292,309)	(239,437)
Cash premium received upon issuance of bonds	34,049	-
Increases (decreases) in cash resulting from a change in		
Patient accounts receivable	(93,190)	(199,894)
Other assets	(371,302)	(466,316)
Accounts payable and other accrued expenses	378,627	241,617
Accrued medical claims and related expenses	66,085	73,198
Operating lease obligations	(119,242)	(166,138)
Settlements with third-party payers	185,245	(13,271)
Net cash provided by operating activities	<u>886,067</u>	<u>758,828</u>
Cash flows from investing activities		
Purchases of property and equipment	(1,492,907)	(1,098,913)
Proceeds from sale of property	1,392	14,696
Purchase of investments	(1,734,338)	(2,273,363)
Proceeds from sales of investments	<u>1,649,745</u>	<u>2,550,984</u>
Net cash used for investing activities	<u>(1,576,108)</u>	<u>(806,596)</u>
Cash flows from financing activities		
Borrowings under taxable commercial paper	-	169,885
Repayments of borrowings under taxable commercial paper	(119,870)	(50,015)
Borrowings under lines of credit	270,000	-
Repayments of borrowings under lines of credit	(270,000)	-
Payments on long-term obligations	(110,891)	(106,306)
Proceeds from long-term obligations	524,802	100,230
Deposits into refunding trusts	(69,844)	(219,923)
Donor restricted contributions and investment income	<u>292,309</u>	<u>239,437</u>
Net cash provided by financing activities	<u>516,506</u>	<u>133,308</u>
Net (decrease) increase in cash and equivalents	(173,535)	85,540
Cash and equivalents		
Beginning of year	<u>279,459</u>	<u>193,919</u>
End of year	<u>\$ 105,924</u>	<u>\$ 279,459</u>
Noncash purchases of property and equipment in accounts payable and accrued expenses	<u>\$ 110,631</u>	<u>\$ 129,552</u>

The accompanying notes are an integral part of these consolidated financial statements.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

1. Organization and Community Benefit Commitments

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in these consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as the Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), Medicare Advantage program, ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations.

Community Health

Under Mass General Brigham's *United Against Racism* system-wide initiative, the Health Equity & Community Health programs aims to make measurable, impactful and sustainable improvements in clinical equity for our patients, along with better health outcomes for the communities we serve.

We are focused on health conditions that are the greatest contributor to premature mortality and reduced life expectancy in these communities: cardiometabolic disease (including hypertension and diabetes), substance use disorder, cancer and maternal-child health.

We are committed to addressing the root causes of health disparities by building and strengthening our community-based partnerships to make the greatest impact on issues such as food insecurity, housing instability, limited economic mobility and educational opportunities, and barriers to accessing care.

Charity Care

We provide charity care to all emergent patients regardless of their ability to pay. The cost of and reimbursement for providing that care, as reflected in the consolidated statements of operations, is summarized below.

State Programs

Massachusetts

Acute care hospitals in The Commonwealth of Massachusetts (the Commonwealth or Massachusetts) are partially reimbursed for charity care services through the statewide Health Safety Net Trust Fund (HSN). A portion of the funding for the HSN is paid by an assessment on acute care hospitals' charges for private sector payers. The statewide assessment was \$165,231 and \$165,313 in 2024 and 2023, respectively, and the assessment expense on our acute care hospitals was \$57,819 in both 2024 and 2023.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Acute care hospitals are reimbursed for charity care based on claims for eligible patients and services that are submitted to and adjudicated by the HSN. Payments are based on Medicare rates and payment policies. The Commonwealth reported that HSN was under-funded by approximately \$133,027 and \$115,828 as of September 30, 2024 and 2023, respectively. This shortfall is allocated to acute care hospitals based on their share of total statewide patient care costs. We have estimated our share being approximately \$67,980 and \$48,547 as of September 30, 2024 and 2023, respectively. Each hospital's share of the overall state shortfall cannot exceed its total charity care reimbursement. Hospitals with a high proportion of charity care and government funding receive more favorable reimbursement, including limiting their shortfall allocation to no more than 15% of their payments for charity care. In aggregate, our acute care hospitals received charity care funding covering 14% and 41% of the estimated cost of charity care provided in 2024 and 2023, respectively.

The Commonwealth levies an additional assessment on Massachusetts acute care hospitals that is redistributed back to hospitals based on provisions within the MassHealth Section 1115 Demonstration. A new five-year waiver period began effective October 1, 2022. The total assessment was \$709,685 and \$709,602 in 2024 and 2023, respectively, and our assessment expense was \$197,473 in both 2024 and 2023. The total amount redistributed to hospitals across Massachusetts was \$1,613,052 and \$1,387,500 in 2024 and 2023, respectively, of which we recognized \$179,114 and \$188,084 in 2024 and 2023, respectively.

There is an assessment for our post-acute hospitals which totaled \$5,756 in both 2024 and 2023.

New Hampshire

The State of New Hampshire (New Hampshire) imposes a Medicaid Enhancement Tax (MET) on hospital net patient service revenue. For both of New Hampshire's fiscal years ended June 30, 2024 and 2023, the MET imposed was 5.4%. We incurred \$30,343 and \$25,724 of MET in 2024 and 2023, respectively.

New Hampshire acute care hospitals receive disproportionate share payments based on a portion of their charity care relative to other acute care hospitals. We received \$17,582 and \$14,992 in 2024 and 2023, respectively.

Medicaid

Medicaid is a health insurance program jointly funded by the states and the federal government. Each state administers its own program and sets rules for eligibility, benefits and provider payments within broad federal guidelines and in some cases, including the Commonwealth and New Hampshire, within a Waiver Agreement between each state and the federal government. The program provides health care coverage to low-income adults and children. Eligibility is determined by a variety of factors which include income relative to the federal poverty line, age, immigrant status and assets.

Medicaid payments to our providers do not cover the full cost of services provided to Medicaid patients. In aggregate, our reimbursement from Medicaid covered approximately 64% and 70% of the estimated cost of services that we provided in 2024 and 2023, respectively.

On April 1, 2023, Mass General Brigham Health Plan, Inc. entered into an Accountable Care Organization (ACO) contract with the Executive Office of Health and Human Services of the

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Commonwealth (EOHHS) covering over 150,000 MassHealth members whose providers participate in the Mass General Brigham ACO.

Federal Program

Medicare

Medicare is a federally sponsored health insurance program for people age 65 or older, under age 65 with certain disabilities and any age with End-Stage Renal Disease. Medicare's payments historically have not kept pace with increases in the cost of care provided at many hospitals. Compounding this shortfall in payments is the continued shift of care from higher paying inpatient services to lower paying outpatient services.

Consequently, Medicare payments to our providers do not cover the full cost of services provided. In aggregate, our reimbursement from Medicare covered approximately 71% and 68% of the estimated cost of services that we provided in 2024 and 2023, respectively.

Mass General Brigham Health Plan, Inc. was authorized by the Centers for Medicare & Medicaid Services (CMS) to offer Medicare Advantage products to its eligible members effective January 1, 2023.

Summary

For charity care, Medicaid and Medicare, the estimated cost of services provided is either obtained directly from a costing system or based on an entity specific ratio of cost to gross charges. In the latter case, cost is derived by applying this ratio to gross charges associated with providing care to charity care, Medicaid and Medicare patients. The following summarizes, by program, the cost of services provided, net reimbursement and cost of services in excess of reimbursement for each year:

	Years Ended September 30,	
	2024	2023
Cost of services provided		
Charity care	\$ 171,217	\$ 113,167
Medicaid	2,002,532	1,777,454
Medicare	5,780,976	5,585,749
	<u>\$ 7,954,725</u>	<u>\$ 7,476,370</u>
Net reimbursement		
Charity care	\$ 20,259	\$ 38,035
Medicaid	1,285,520	1,250,916
Medicare	4,110,328	3,790,457
	<u>\$ 5,416,107</u>	<u>\$ 5,079,408</u>
Cost of services in excess of reimbursement		
Charity care	\$ 150,958	\$ 75,132
Medicaid	717,012	526,538
Medicare	1,670,648	1,795,292
	<u>\$ 2,538,618</u>	<u>\$ 2,396,962</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

In addition to charity care and inadequate funding from the Medicaid and Medicare programs, there are significant losses related to self-pay patients who fail to make payment for services rendered or insured patients who fail to remit co-payments and deductibles as required under the applicable health insurance arrangement. The estimated cost of providing these services was approximately \$105,896 and \$82,938 for 2024 and 2023, respectively.

2. Summary of Significant Accounting Policies

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting and include the accounts of the Company and its affiliates. Interaffiliate accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are made in the areas of patient accounts receivable, research grants receivable, investments, receivables and accrual for settlements with third-party payers, accrued medical claims and related expenses, accrued employee compensation and benefits, accrued professional liability, interest rate swaps liability and accrued other.

Income Taxes

The Company and substantially all of its affiliates are tax-exempt organizations under Sections 501(c)(3) or 501(c)(4) of the Internal Revenue Code (IRC) or are disregarded entities for tax purposes and therefore are exempt from federal and state income tax except on unrelated business taxable income. No provision for income taxes related to these tax-exempt entities has been made as the effect of any unrelated business income tax is not material to the accompanying consolidated financial statements.

Fair Value of Financial Instruments

The fair value of financial instruments approximates the carrying amount reported in the consolidated balance sheets for cash and equivalents, investments and investments limited as to use, patient accounts receivable, research grants receivable, accounts payable and accrued expenses and interest rate swaps liability.

Cash and Equivalents

Cash and equivalents represent cash, registered money market funds and highly liquid debt instruments with a maturity at the date of purchase of three months or less. Our cash and equivalents are maintained with several national banks, and cash deposits typically exceed federal insurance limits. Our policy is to monitor these banks' financial strength on an ongoing basis, and no losses have been experienced to date.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Investments

Investments in equity securities with readily determinable fair values, debt securities and alternative investments are measured at fair value. Alternative investments, consisting of various hedge funds, private equity funds, private debt funds, other private partnerships and restricted securities of public companies that are not traded on a national securities exchange, are valued based on amounts reported by the fund manager and evaluated by management. Investments in securities sold short or traded on a national securities exchange are valued based on quoted market prices.

Income from investments (including realized gains and losses, unrealized change in value of investments, interest, dividends and endowment income distributions) is included in excess of revenues over expenses unless the income or loss is restricted by donor or law. Income from investments is reported net of investment-related expenses.

Each year as part of our endowment spending policy, we establish a fixed distribution rate for spending. Distributions will come from either income and/or net accumulated appreciation. Effective July 1, 2023 we changed the endowment spending policy and adopted the Tobin Distribution Rule. The Tobin Distribution Rule sets the annual distribution through a quantitative formula that has a stability term (a percentage of the prior year's spending, adjusted for inflation) and a market term (a percentage of the long-term sustainable rate of distribution times the market value of the endowment).

Investments Limited as to Use

Investments limited as to use primarily include assets whose use is contractually limited by external parties as well as assets set aside by the boards (or management) for identified purposes and over which the boards (or management) retain control such that the boards (or management) may, at their discretion, subsequently use such assets for other purposes. Certain investments corresponding to deferred compensation are accounted for such that all income and appreciation (depreciation) is recorded as a direct addition (reduction) to the asset and corresponding liability.

Derivative Instruments

Derivatives are recognized on the balance sheets at fair value with changes in the fair value recorded in excess of revenues over expenses.

Patient Accounts Receivable

The payments received for healthcare services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care payers, commercial insurance companies and patients are subject to explicit and implicit discounts. These discounts are based on contractual agreements, discount policies and management's assessment of historical experiences and are reflected in the period of service.

Research Grants Receivable

Mass General Brigham receives direct and pass through research funding from the National Institutes for Health and other federal agencies, industry, corporate, foundation, nonprofits and other sponsors. Research grants receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor, or in limited circumstances, represent accelerated spending in anticipation of future funding. Research grants receivable are recognized at net realizable value.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

As of September 30, 2024 and 2023, we have approximately \$4,598,252 and \$4,408,631, respectively, of conditional research grants for future research to be performed. The timing and amounts of funds received under such grants are subject to continued government funding and may change over time.

Other Current Assets

Other current assets include prepaid expenses, inventory, nonpatient receivables, current portion of receivable for settlements with third-party payers, current portion of pledges receivable and premiums receivable. Inventory (primarily supplies and pharmaceuticals) is accounted for on a first-in, first-out method basis and is recorded at the lower of average weighted cost or net realizable value.

Property and Equipment

Property and equipment is reported on the basis of cost less accumulated depreciation. Donated items are recorded at fair value at the date of contribution. All research grants received for capital are recorded in the year of expenditure as a change in net assets without donor restrictions. Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Depreciation of property and equipment is calculated by use of the straight-line method at rates intended to depreciate the cost of assets over their estimated useful lives, which generally range from three to fifty years. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized, net of any interest earned, as a component of the cost of acquiring those assets.

Asset Retirement Obligations

Asset retirement obligations, reported in accrued other, are legal obligations associated with the retirement of long-lived assets. These liabilities are initially recorded at fair value and the related asset retirement costs are capitalized by increasing the carrying amount of the related assets by the same amount as the liability. Asset retirement costs are subsequently depreciated over the useful lives of the related assets. Any changes to the liability due either to the passage of time, better information or the settlement of an obligation are reflected in the current period.

Other Assets

Other assets consist of long-term receivables, intangible assets, malpractice insurance receivables, receivable for settlements with third-party payers, investments in healthcare related limited partnerships, long-term pledges and contributions receivable and defined benefit pension plan and postretirement healthcare benefit plan assets in excess of plan benefit obligations. The carrying value of other assets is evaluated for impairment if the facts and circumstances suggest that the carrying value may not be recoverable.

Compensated Absences

In accordance with formal policies concerning vacation and other compensated absences, accruals of \$443,417 and \$422,745 were recorded as of September 30, 2024 and 2023, respectively.

Unexpended Funds on Research Grants

Research grants received in advance of corresponding grant expenditures are accounted for as a direct addition to investments limited as to use and unexpended funds on research grants.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Self-Insurance Reserves

We are generally self-insured for employee healthcare, disability, workers' compensation and certain other employee benefits. These costs are accounted for on an accrual basis to include estimates of future payments for claims incurred prior to year-end and are included in accrued employee compensation and benefits and long-term accrued employee benefits.

Net Assets

Net assets with donor restrictions include (a) the historical dollar amounts of contributions and the income and gains on such contributions which are required by donors to be retained and (b) contributions and the income and gains on these contributions which can be expended but for which restrictions have not yet been met. Such restrictions include purpose restrictions where donors have specified the purpose for which the net assets are to be spent, or time restrictions imposed by donors or implied by the nature of the contribution (capital projects, pledges to be paid in the future and life income funds) or by interpretations of law (gains available for appropriation but not appropriated in the current period). All remaining net assets are considered to be without donor restrictions.

Realized gains and losses are classified as net assets without donor restrictions unless they are restricted by the donor or law. Realized gains and net unrealized appreciation on contributions with donor restrictions are classified as net assets with donor restrictions until appropriated for spending in accordance with policies established by Mass General Brigham and applicable provisions of the Uniform Prudent Management of Institutional Funds Acts (UPMIFA). Net losses on donor endowment funds with donor restrictions are classified as a reduction to net assets with donor restrictions.

Contributed Securities

Our policy is to sell securities contributed by donors upon receipt, unless prevented from doing so by donor request. For the years ended September 30, 2024 and 2023, contributed securities of \$146,236 and \$58,257, respectively, were received and liquidated. Donors restricted \$85,180 and \$25,545 of the proceeds received from the sale of these contributed securities for long-term purpose for the years ended September 30, 2024 and 2023, respectively.

Statement of Operations

Activities deemed by management to be ongoing, major and central to the provision of healthcare services, teaching, research activities and health insurance are reported as operating revenues and expenses. Other activities are deemed to be nonoperating and include contributions without donor restrictions (net of fundraising expenses), external community benefit program support, net change in unexpended research and nonresearch sundry contributions, change in fair value of interest rate swaps, substantially all income from investments, interest on advanced borrowings and nonservice related pension income. Research and nonresearch sundry contributions largely consist of donor contributions (and the related investment income including realized gains and losses) designated to support the clinical, teaching or research efforts of a physician or department as directed by the donor. These contributions are reported as being without donor restrictions, net of related support expenses, when donor restrictions are of a general nature that are inherent in the normal activities of the organization.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

The consolidated statements of operations include excess of revenues over expenses. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction were to be used for acquisition of such assets) and change in funded status of defined benefit plans.

Revenues

To determine the appropriate revenue recognition policy, we first assess whether the transaction is an exchange or nonexchange transaction in accordance with accounting guidance. In general, an exchange transaction consists of an exchange of goods and/or services for commensurate value. Transactions that consist of transferring goods and/or services without receiving commensurate value in return are considered nonexchange transactions.

For exchange transactions, revenue is recognized as goods and/or services are provided and is based on the amount expected to be received in exchange for those goods and/or services. Revenue recognized as exchange transactions include net patient service revenue, premium revenue and other revenue.

Nonexchange transactions include contributions and grants for which the service provider does not receive commensurate value in return for the funding.

Contributions

Contributions are generally reported as other nonoperating gains in the consolidated statements of operations. Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give are recognized when the conditions are substantially met and totaled \$403,143 and \$371,648 as of September 30, 2024 and 2023, respectively. Contributions are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Contributions with donor restrictions whose restrictions are met within the same year as received are reported as contributions without donor restrictions in the consolidated statements of operations.

Contributions of long-lived assets with explicit restrictions that specify use of assets and contributions of cash or other assets that must be used to acquire long-lived assets are reported as additions to net assets with donor restrictions if the assets are not placed in service during the year.

Grants

Grants and contracts normally provide for the recovery of direct and indirect costs, subject to audit. Revenue associated with direct and indirect costs is recognized as direct costs are incurred. The recovery of indirect costs is based on predetermined rates for U.S. Government grants and contracts and negotiated rates for other grants and contracts.

Medical Claims and Related Expenses

The Health Plan contracts with various hospitals, community health centers, primary care and specialty physician practices and other health care providers for the delivery of services to its members and compensates these providers on a capitated, fee-for-service, per diem or diagnosis-related group basis.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

The cost of contracted health care services is accrued in the period in which services are provided and include certain estimated amounts. The estimated liability for medical claims and related expenses is actuarially determined based on analysis of historical claims-paid experience, modified for changes in enrollment, inflation and benefit coverage. The liability for medical claims and related expenses represents the anticipated cost of claims incurred but unpaid at the balance sheet date. Estimates for claims expense may be more or less than the amounts ultimately paid when claims are settled. Such changes in estimates are reflected in the current period in the consolidated statements of operations.

In the normal course of business, overpayments are recouped through reductions in future payments made to hospitals and other providers. Such overpayments are the result of, among other things, coordination of benefits and provider claim audits. For the years ended September 30, 2024 and 2023, we recorded a reduction in medical claims expense of \$59,115 and \$53,299, respectively, for such overpayments. As of September 30, 2024 and 2023, respectively, approximately \$1,767 and \$2,346 are recorded as receivables related to such overpayments.

Reinsurance

Reinsurance premiums are reported as reductions in premium revenue and reinsurance recoveries are reported as reductions in medical claims and related expenses.

Settlements

The Health Plan contracts with certain providers at negotiated rates based on historical and anticipated experience. These methods of reimbursement result in settlements based on actual versus anticipated experience which could result in payments due from (to) these providers. Settlements receivable of \$702 and \$3,647 were recorded in other current assets as of September 30, 2024 and 2023, respectively. Settlements payable of \$6,616 and \$4,633 were recorded in accrued medical claims and related expenses as of September 30, 2024 and 2023, respectively. The settlements are intended to include both reported and unreported incurred claims as of September 30, 2024 and 2023.

In 2014, the Patient Protection and Affordable Care Act (ACA) introduced new settlements related to a risk adjustment program, a risk corridor program and a reinsurance program designed to mitigate the transitional impact on insurers for new members. The risk corridor program and reinsurance program ended on December 31, 2016 in accordance with the provision of the ACA. Our estimated net receivable due from the federal government for the risk adjustment program was \$79,841 and \$73,299 as of September 30, 2024 and 2023, respectively. Similar to the federal program, EOHHS has a risk sharing arrangements, and our estimated net payable due to EOHHS was \$10,712 and \$95,619 as of September 30, 2023.

The ACA requires commercial health plans with medical loss ratios (MLR) on fully insured products that fall below certain targets to rebate ratable portions of their premium annually. The Health Plan's management thereby regularly monitors MLR calculations by market type and records the applicable liability and expense if the MLR falls below the minimum requirements pursuant to the ACA. The Health Plan's estimated payable for MLR rebate as of September 30, 2024 and 2023 was \$7,936 and \$0, respectively.

Premium Deficiency Reserves

Premium deficiency reserves are assessed and recognized on a product line basis based upon expected premium revenue, medical expense and administrative expense levels, and remaining

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

contractual obligations using historical experience. As of September 30, 2024 and 2023, a premium deficiency reserve of \$33,254 and \$24,071, respectively, is included in accrued medical claims and related expenses in the accompanying consolidated financial statements.

Claims Adjustment Expenses

Claims adjustment expenses (CAE) are those costs expected to be incurred in connection with the adjustment and recording of health claims. We have recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in medical claims and related expenses in the accompanying consolidated statements of operations. Management believes the amount of the liability for unpaid CAE as of September 30, 2024, is adequate to cover the cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified.

3. Operating Revenues

Net Patient Service Revenue

Mass General Brigham's providers maintain agreements with CMS under the Medicare program, the Commonwealth under the Medicaid program and various managed care payers that govern payment for services rendered to patients covered by these agreements. The agreements generally provide for per case or per diem rates or payments based on discounted charges for inpatient care and discounted charges or fee schedules for outpatient care. Certain contracts also provide for payments that are contingent upon meeting agreed upon quality and efficiency measures.

We recognize net patient service revenue for services provided to patients who have third-party payer coverage based on contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, we recognize revenue based on our standard rates (subject to discounts) for services provided. Based on our historical experience, a significant portion of uninsured patients are unable or fail to pay for the services provided. Consequently, we have provided implicit discounts to uninsured patients. These discounts represent the difference between amounts billed to patients and amounts expected to be collected based on historical experience. The following summarizes net patient service revenue, net of contractual adjustments and discounts by significant payer:

	Years Ended September 30,			
	2024		2023	
Net patient service revenue (net of contractual adjustments and discounts)				
Medicare	\$ 2,957,873	22.0%	\$ 2,822,694	22.1 %
Medicare managed care	1,152,455	8.6%	967,763	7.6 %
Medicaid	449,718	3.4%	689,718	5.4 %
Medicaid managed care	835,802	6.2%	561,198	4.4 %
Massachusetts managed care organizations	4,710,345	35.0%	4,569,756	35.7 %
Other commercial	2,989,867	22.2%	2,729,703	21.3 %
All others	343,896	2.6%	451,754	3.5 %
Total all payers	<u>\$ 13,439,956</u>	<u>100.0%</u>	<u>\$ 12,792,586</u>	<u>100.0 %</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Net patient service revenue includes estimated retroactive revenue adjustments due to future audits, reviews and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews and investigations. Contracts, laws and regulations governing the Medicare, Medicaid and charity care programs and managed care payer arrangements are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. A portion of the accrual for settlements with third-party payers has been classified as long-term because such amounts, by their nature or by virtue of regulation or legislation, will not be paid within one year.

Third-party payers (accrual) receivable consists of the following:

Balance Sheet Classification		September 30,	
		2024	2023
Current portion			
Receivable for settlements with third-party payers	Other current assets	\$ 153,064	\$ 159,813
Accrual for settlements with third-party payers	Accounts payable and accrued expenses	(115,461)	(59,584)
		<u>37,603</u>	<u>100,229</u>
Long-term portion			
Receivable for settlements with third-party payers	Other assets	26,956	6,700
Accrual for settlements with third-party payers	Accrued other	(171,401)	(28,526)
		<u>(144,445)</u>	<u>(21,826)</u>
Third-party payers (accrual) receivable		<u>\$ (106,842)</u>	<u>\$ 78,403</u>

We recognize changes in third-party payer settlements and other estimates in the year of the change in estimate. For the years ended September 30, 2024 and 2023, adjustments to prior year estimates resulted in an increase to net patient service revenue of \$120,290 and \$47,842, respectively. Subsequent changes to estimated discounts are generally recorded as adjustments to net patient service revenue in the period of change.

We provide either full or partial charity care to patients who cannot afford to pay for their medical services based on income and family size. Charity care is generally available to qualifying patients for medically necessary services. We report certain bad debts related to emergency services as charity care. As there is no expectation of collection, there is no net patient service revenue recorded related to charity care.

Premium Revenue

Premiums are due monthly and are recorded as earned during the period in which members are eligible to receive services. Premiums received prior to the first day of the coverage period are recorded as unearned premiums in accounts payable and accrued expenses.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Research and Nonresearch Sundry Revenue

Research and nonresearch sundry revenue is recognized as either an exchange or nonexchange transaction, depending on the contract type. The following table sets forth total research and nonresearch sundry revenue received by funding source:

	Years Ended September 30,			
	2024		2023	
National Institute of Health and other federal agencies	\$ 1,265,919	43.6%	\$ 1,155,306	42.7 %
Federal subcontracts	288,087	9.9%	260,323	9.6 %
Industry/corporate	233,394	8.1%	224,821	8.3 %
Foundations/nonprofits and other sponsors	821,146	28.3%	771,579	28.5 %
Total research revenue	2,608,546		2,412,029	
Nonresearch sundry revenue	292,204	10.1%	295,981	10.9 %
Total research and nonresearch sundry revenue	\$ 2,900,750	100.0 %	\$ 2,708,010	100.0 %

Other Revenue

Other revenue includes all other operating revenue sources, the most significant being the following:

	Years Ended September 30,	
	2024	2023
Specialty and retail pharmacy operations	\$ 1,211,649	\$ 928,501
Contract revenue	119,258	132,070
COVID-19 reimbursement	19,699	99,372
Parking and office rentals	80,848	77,249
Tuition	66,570	62,482
Outsourced services	59,013	58,801
Blood factor sales	57,482	53,308
Cafeteria sales	40,163	36,198
Intellectual property and royalties	40,713	14,916
Contract administrative fees	34,330	27,397
Consulting services	15,435	14,248
International contracts	16,458	10,498
ACO administration fees	1,998	24,926
Investment income	13,482	13,560
Other	262,506	254,359
Total other revenue	\$ 2,039,604	\$ 1,807,885

COVID-19 Economic support

We received Provider Relief Funds (PRF) in 2020 and 2021 that were used to prevent, prepare for and respond to COVID-19. As of September 30, 2024 and 2023, we have deferred \$86,487 of PRF received.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

We submitted applications to the Federal Emergency Management Agency (FEMA) for the reimbursement of COVID-19 expenses and recognized grant revenue totaling \$19,699 and \$99,372, in 2024 and 2023, respectively, as other operating revenue in the consolidated statements of operations. As of September 30, 2024 and 2023, we have deferred \$54,792 and \$35,092, respectively, of FEMA payments received.

4. Liquidity and Availability

Cash and investments are managed centrally under policies developed by the Investment Committee and reviewed by the Finance Committee of the Company's Board of Directors. Wherever possible, funds are commingled and are assigned to one of three investment pools (the Money Market Pool, the Aggregate Bond Pool and the Long Term Pool, collectively, the Pools) which have been structured to provide a range of investment objectives, risk profiles and rates of return appropriate for our assets. Funds are allocated among the Pools based on expected liquidity needs as determined by multi-year financial plans, restrictions and management judgment.

The tiered time horizon structure of the Pools is designed to meet anticipated and contingent liquidity needs. The following tables set forth the periods within which funds are available to meet liquidity needs and based on redemption provisions with investment managers, the specific Pools from which such funds would be drawn as of:

Investment Pool	September 30, 2024						Total
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	
Money Market Pool	\$ 2,314	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 2,314
Aggregate Bond Pool	404,374	3,311	-	-	-	-	407,685
Long Term Pool	851,883	807,904	2,285,293	4,204,208	1,425,925	6,299,312	15,874,525
Total	<u>\$ 1,258,571</u>	<u>\$ 811,215</u>	<u>\$ 2,285,293</u>	<u>\$ 4,204,208</u>	<u>\$ 1,425,925</u>	<u>\$ 6,299,312</u>	<u>\$ 16,284,524</u>
Cumulative total	<u>\$ 1,258,571</u>	<u>\$ 2,069,786</u>	<u>\$ 4,355,079</u>	<u>\$ 8,559,287</u>	<u>\$ 9,985,212</u>	<u>\$ 16,284,524</u>	

Investment Pool	September 30, 2023						Total
	Same Day	1 Week	1 Month	3 Months	1 Year	> 1 Year	
Money Market Pool	\$ 167,997	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 167,997
Aggregate Bond Pool	327,089	2,985	-	-	-	-	330,074
Long Term Pool	364,584	533,078	2,205,916	3,264,619	1,176,742	5,905,179	13,450,118
Total	<u>\$ 859,670</u>	<u>\$ 536,063</u>	<u>\$ 2,205,916</u>	<u>\$ 3,264,619</u>	<u>\$ 1,176,742</u>	<u>\$ 5,905,179</u>	<u>\$ 13,948,189</u>
Cumulative total	<u>\$ 859,670</u>	<u>\$ 1,395,733</u>	<u>\$ 3,601,649</u>	<u>\$ 6,866,268</u>	<u>\$ 8,043,010</u>	<u>\$ 13,948,189</u>	

As of September 30, 2024 and 2023, we had cash and equivalents not included in the Pools of \$105,823 and \$228,351, respectively. As of September 30, 2024 and 2023, we had net patient accounts receivable of \$1,731,496 and \$1,638,306, respectively, that would be available for general expenditures within one year of the balance sheet dates.

5. Investments and Investments Limited as to Use

Investments are either invested in the Pools or separately managed. Substantially all affiliates participate in the Pools. Their respective ownership interests are tracked and updated monthly and are accounted for using the fair value method. Income (including realized gains and losses) from the Pools is allocated to each participant on a monthly basis based on its proportionate interest in the Pools.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Oversight of the management of the investable assets, including the Pools and pension assets, is provided by the Investment Committee of the Company's Board of Directors which seeks to achieve incremental returns by manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations). The Committee is supported by a professional staff, an outside investment consultant and a pension actuarial consultant.

We utilize a target allocation policy and balance projected returns, correlation and volatility of various asset classes within the overall risk tolerance. Asset allocations are managed based on relative valuations among and within asset classes and the perceived ability of managers to outperform passive benchmarks. Exposure by asset class is the sum of allocation to those managers whose mandates most closely fit the listed asset classes. Asset allocation can and will deviate from target exposures and is regularly monitored for rebalancing.

The Pools invest in a variety of assets which include private partnerships whose assets include equity, fixed income and other investments. The Pools have unfunded commitments as follows:

	September 30,	
	2024	2023
Private equity	\$ 1,676,110	\$ 1,702,731
Private energy	89,816	109,042
Private real estate	102,876	49,481
Timber and agriculture	1,524	1,498
Private alternatives and hedge funds	195,972	200,062
	<u>\$ 2,066,298</u>	<u>\$ 2,062,814</u>

The unfunded commitments will be drawn down by the various general partners over the next several years. The maximum annual drawdown is expected to be 3% to 5% of investments and investments limited as to use.

Short-term Investments in Investment Pools

Within the Aggregate Bond Pool and the Long Term Pool, there are assets that meet the definition of short-term investments. These short-term investments are considered part of the Aggregate Bond Pool and the Long Term Pool and are not included in cash equivalents on the consolidated balance sheets. Accordingly, transactions within the Aggregate Bond Pool and the Long Term Pool that result in the purchase of investments or result in proceeds from the sales of investments are excluded from the statements of cash flows purchases of investments and proceeds from the sales of investments. Within the Aggregate Bond Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were \$247,387 and \$187,061 for the year ended September 30, 2024, and \$100,124 and \$340,979 for the year ended September 30, 2023, respectively. Within the Long Term Pool, purchases of investments and proceeds from the sales of investments not included in the statements of cash flows were \$1,632,747 and \$1,966,849 for the year ended September 30, 2024, and \$1,250,769 and \$1,326,573 for the year ended September 30, 2023, respectively.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Investments limited as to use consist of the following:

	September 30, 2024		September 30, 2023	
	Current Portion	Long-Term Portion	Current Portion	Long-Term Portion
Internally designated funds				
Reserved for capital expenditures	\$ 1,244,666	\$ -	\$ 1,257,712	\$ -
Unexpended research and nonresearch sundry gifts	-	5,131,842	-	4,363,810
Deferred compensation	-	798,484	-	614,318
Other	2,030,166	461,821	1,868,784	419,512
	<u>3,274,832</u>	<u>6,392,147</u>	<u>3,126,496</u>	<u>5,397,640</u>
Externally limited funds				
Unexpended funds on research	369,851	-	377,730	-
Contributions held for others	1,519	-	1,531	-
Professional liability trust fund	-	50,886	-	43,062
Held by trustees under debt and other agreements	5,525	-	230	-
	<u>376,895</u>	<u>50,886</u>	<u>379,491</u>	<u>43,062</u>
	<u>\$ 3,651,727</u>	<u>\$ 6,443,033</u>	<u>\$ 3,505,987</u>	<u>\$ 5,440,702</u>

Investment activity included in excess of revenues over expenses consists of the following:

	Years Ended September 30,	
	2024	2023
Investment income included in operations and reported in other revenue	\$ 13,482	\$ 13,560
Investment income included in nonoperating gains and reported in		
Income from investments		
Investment income and realized gains on investments	327,105	42,213
Unrealized change in investments	1,622,965	919,915
Research and nonresearch sundry gifts net of spending	<u>291,979</u>	<u>172,738</u>
Total investment activity included in excess of revenues over expenses	<u>\$ 2,255,531</u>	<u>\$ 1,148,426</u>

6. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (also referred to as exit price). Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. In determining fair value, the use of various valuation approaches, including market, income and cost approaches, is permitted.

Fair Value Hierarchy

A fair value hierarchy has been established based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the reporting entity's assumptions about the inputs

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

market participants would use. The fair value hierarchy requires the reporting entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. In addition, for hierarchy classification purposes, the reporting entity should not look through the form of an investment to the nature of the underlying securities held by an investee.

The hierarchy is described below:

- Level 1 Valuations using quoted prices in active markets for identical assets or liabilities. Valuations of these products do not require a significant degree of judgment. Level 1 assets and liabilities primarily include debt and equity securities that are traded in an active exchange market.
- Level 2 Valuations using observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; broker or dealer quotations; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities primarily include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities and derivative contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
- Level 3 Valuations using unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the reporting entity's assumptions about the assumptions market participants would use as well as those requiring significant management judgment.

Valuation Techniques

Pooled investments, separately invested short-term investments and debt and equity securities are classified within Level 1 or Level 2 of the fair value hierarchy as they are valued using quoted market prices, broker or dealer quotations, or other observable pricing sources. Certain types of investments are classified within Level 3 of the fair value hierarchy because they have little or no market activity and therefore have little or no observable inputs with which to measure fair value.

The valuation of interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

The following tables summarize financial assets and liabilities measured at fair value on a recurring basis as of:

	September 30, 2024				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
Assets					
Pooled investments					
Short-term investments	\$ 756,519	\$ -	\$ -	\$ -	\$ 756,519
Separately managed investments	1,199,960	119,041	-	-	1,319,001
Mutual funds	3,310	-	-	-	3,310
Private partnerships, commingled funds and other	-	-	-	14,205,694	14,205,694
	<u>1,959,789</u>	<u>119,041</u>	<u>-</u>	<u>14,205,694</u>	<u>16,284,524</u>
Separately invested					
Short-term investments	31,248	-	-	-	31,248
Equities	41,395	-	-	-	41,395
Mutual funds	838,661	68,469	-	-	907,130
Private partnerships, commingled funds and other	-	-	-	223,540	223,540
Beneficial interests in perpetual assets	-	-	56,033	-	56,033
	<u>911,304</u>	<u>68,469</u>	<u>56,033</u>	<u>223,540</u>	<u>1,259,346</u>
	<u>\$ 2,871,093</u>	<u>\$ 187,510</u>	<u>\$ 56,033</u>	<u>\$ 14,429,234</u>	<u>\$ 17,543,870</u>
Interest rate swaps					
Assets		\$ 43,855			\$ 43,855
Liabilities		(139,170)			(139,170)
Net interest rate swaps		<u>\$ (95,315)</u>			<u>\$ (95,315)</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

	September 30, 2023				
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Investments Valued Using NAV as a Practical Expedient	Total
Assets					
Pooled investments					
Short-term investments	\$ 324,630	\$ -	\$ -	\$ -	\$ 324,630
Separately managed investments	850,001	197,971	-	-	1,047,972
Mutual funds	2,985	-	-	-	2,985
Private partnerships, commingled funds and other	-	-	-	12,572,601	12,572,601
	<u>1,177,616</u>	<u>197,971</u>	<u>-</u>	<u>12,572,601</u>	<u>13,948,188</u>
Separately invested					
Short-term investments	52,846	-	-	-	52,846
Equities	25,033	-	-	-	25,033
Mutual funds	649,706	64,637	-	-	714,343
Private partnerships, commingled funds and other	-	-	-	187,458	187,458
Beneficial interests in perpetual assets	-	-	51,876	-	51,876
	<u>727,585</u>	<u>64,637</u>	<u>51,876</u>	<u>187,458</u>	<u>1,031,556</u>
	<u>\$ 1,905,201</u>	<u>\$ 262,608</u>	<u>\$ 51,876</u>	<u>\$ 12,760,059</u>	<u>\$ 14,979,744</u>
Interest rate swaps					
Assets		\$ 55,987			\$ 55,987
Liabilities		(67,075)			(67,075)
Net interest rate swaps		<u>\$ (11,088)</u>			<u>\$ (11,088)</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

7. Pledges and Contributions Receivable

Pledges receivable represent unconditional promises to give and are net of allowances for uncollectible amounts. Pledges are recorded at the present value of their estimated future cash flows. Pledges collectible within one year are classified as other current assets, net of allowances, and total \$221,076 and \$255,239 as of September 30, 2024 and 2023, respectively. Pledges collectible in one year or greater are classified as other assets. Estimated cash flows due after one year are discounted using published treasury bond and note yields that are commensurate with estimated collection risks. The blended discount rate was 3.6% and 4.8% for 2024 and 2023, respectively. Pledges are expected to be collected as follows:

	September 30,	
	2024	2023
Amounts due		
Within one year	\$ 240,290	\$ 277,559
In one to five years	330,412	400,728
In more than five years	112,107	118,502
Total pledges receivable	682,809	796,789
Less: Unamortized discount	45,623	69,667
	637,186	727,122
Less: Allowance for uncollectibles	27,441	33,682
Net pledges receivable	609,745	693,440
Contributions receivable from trusts	51,932	49,497
	<u>\$ 661,677</u>	<u>\$ 742,937</u>

8. Property and Equipment

Property and equipment consists of the following:

	September 30,	
	2024	2023
Land and land improvements	\$ 355,891	\$ 353,988
Buildings and building improvements	10,244,802	9,655,999
Equipment	2,961,248	2,981,003
Construction in progress	1,545,009	1,042,827
Finance right-of-use lease assets	108,623	102,843
	15,215,573	14,136,660
Less: Accumulated depreciation	7,743,833	7,359,297
Property and equipment, net	<u>\$ 7,471,740</u>	<u>\$ 6,777,363</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Depreciation expense for the years ended September 30, 2024 and 2023 was \$777,893 and \$772,556, respectively. Interest costs, net of interest earned, aggregating \$12,322 and \$2,720 were capitalized in 2024 and 2023, respectively.

For the years ended September 30, 2024 and 2023, fully depreciated assets with an original cost of \$393,357 and \$325,076, respectively, were written off.

9. Levels of Capital and Surplus

Risk-based capital (RBC) is a methodology adopted by the National Association of Insurance Commissioners for determining the minimum level of capital and surplus deemed necessary for an insurer based upon the types of assets held and business written. The Company has guaranteed to the Massachusetts Division of Insurance (DOI) (the RBC Guaranty) to maintain the Health Plan's capital and surplus at a specified minimum level, measured quarterly in accordance with an RBC methodology permitted by DOI. The RBC Guaranty may be enforced by the DOI. The Company provided capital to the Health Plan of \$0 and \$75,000 in 2024 and 2023, respectively. Mass General Brigham Health Plan, Inc.'s current contract with EOHHS requires it to maintain a minimum net worth and/or financial insolvency insurance in an amount equal to the Minimum Net Worth calculation as defined in Massachusetts General Law 176G, Section 25. At December 31, 2023 and 2022 (Mass General Brigham Health Plan, Inc.'s statutory year end), the minimum net worth requirement, as determined in accordance with EOHHS guidelines, was \$69,306 and \$50,357, respectively. Mass General Brigham Health Plan, Inc.'s GAAP net worth was \$212,686 and \$124,286 at December 31, 2023 and 2022, respectively, and thus exceeded the EOHHS requirements by \$143,380 and \$73,929, respectively.

10. Accrued Medical Claims and Related Expenses

Accrued medical claims and related expenses include estimates of expected trends in claims severity, frequency, and other factors, which could vary as the claims are ultimately settled and are based principally upon historical experience. For the years ended September 30, 2024 and 2023, changes in estimates resulted in an increase (decrease) of accrued medical claims and related expense of \$17,283 and (\$38,421), respectively. Changes of this nature occur as the result of claim settlements and recoveries during the current year and as additional information is received regarding individual claims, causing changes from the original estimates of the cost of these claims. Ongoing analysis of the recent loss development trends is also taken into account in evaluating the overall adequacy of the reserves.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

Changes in accrued medical claims and related expenses are as follows:

	2024	2023
Balance at beginning of year	\$ 192,435	\$ 119,237
Less		
Premium deficiency reserve	(24,071)	(21,120)
Accrual for claims adjustment expenses	(2,962)	(1,608)
Accrued medical payables - other	(19,646)	(16,818)
Plus: Settlements payable, net	135,763	91,230
Net balance at beginning of year	<u>281,519</u>	<u>170,921</u>
Incurred related to		
Current year	1,487,755	1,125,010
Prior years	17,283	(38,421)
Total incurred	<u>1,505,038</u>	<u>1,086,589</u>
Paid related to		
Current year	1,270,729	928,975
Prior years	161,002	47,016
Total paid	<u>1,431,731</u>	<u>975,991</u>
Net balance at end of year	354,826	281,519
Plus		
Premium deficiency reserve	33,254	24,071
Accrual for claims adjustment expenses	4,204	2,962
Accrued medical payables - other	30,414	19,646
Less: Settlements payable, net	<u>(164,178)</u>	<u>(135,763)</u>
Balance at end of year	<u>\$ 258,520</u>	<u>\$ 192,435</u>

Medical claims and related expenses in the accompanying consolidated statements of operations include other nonclaims related costs. These nonclaims related expenses were for directly delivered services and medical cost risk sharing and incentives.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

11. Long-Term Obligations

Mass General Brigham's long-term obligations consist of the following:

	Final Maturity	September 30,	
		2024	2023
Massachusetts Health and Educational Facilities Authority Revenue Bonds			
Series 1997 P*, variable interest rate of 2.99% and 4.03%	2027	\$ 90,000	\$ 120,000
Series 2005 F*, variable interest rate of 3.03% and 3.99%	2040	222,250	224,250
Series 2007 G*, variable interest rate of 3.00% and 4.00%	2042	75,000	75,000
Series 2008 H*, variable interest rate of 3.44% and 3.43%	2042	153,675	156,780
Massachusetts Development Finance Agency (Agency) Revenue Bonds			
Series 2011 K*, variable interest rate of 3.03% and 3.90%	2046	100,000	100,000
Series 2014 M*, average fixed interest rate of 3.50%	2026	1,835	9,335
Series 2014 N*, variable interest rate of 4.86% and 4.94%	2044	122,250	124,250
Series 2015 O*, average fixed interest rate of 4.35%	2045	159,870	169,830
Series 2016 Q*, average fixed interest rate of 4.81%	2047	384,395	394,920
Series 2017 S*, average fixed interest rate of 4.54%	2047	652,785	740,480
Series 2019 T*, variable interest rate of 3.72% and 4.54%	2049	108,250	123,250
Series 2020 A*, average fixed interest rate of 4.81%	2050	268,130	276,530
Series 2022 B*, variable interest rate of 4.67% and 4.74%	2052	100,230	100,230
Series 2023 C, variable interest rate of 4.78% and n/a	2038	69,870	-
Series 2024 D, average fixed interest rate of 5.00%	2054	309,185	-
Series 2024 E*, variable interest rate 3.50% and n/a	2052	150,000	-
New Hampshire Health and Education Facilities Authority Revenue Bonds			
Series 2017, average fixed interest rate of 5.00%	2041	84,445	87,830
MGB Taxable Debt			
Series 2007 Bonds, fixed interest rate of 6.26%	2037	100,000	100,000
2012 Senior Notes, fixed interest rate of 4.11%	2052	400,000	400,000
2014 Senior Notes, fixed interest rate of 4.73%	2044	150,000	150,000
Series 2015 Bonds, fixed interest rate of 4.12%	2055	300,000	300,000
2016 Senior Notes, fixed interest rate of 3.89%	2046	225,000	225,000
Series 2017 Bonds, fixed interest rate of 3.77%	2048	303,644	303,644
2018 Senior Notes, fixed interest rate of 4.60%	2049	400,000	400,000
Series 2020 Bonds, average fixed interest rate of 3.29%	2060	1,017,135	1,017,135
Series B-1 Commercial Paper Notes, variable interest rate of n/a and 5.40%	2024	-	119,870
Other obligations		1,880	2,452
Total long-term obligations, par value		5,949,829	5,720,786
Net unamortized bond premiums		265,952	252,112
Deferred financing costs		(24,953)	(22,142)
Total long-term obligations, net		6,190,828	5,950,756
Less			
Current portion		353,249	481,130
		<u>\$ 5,837,579</u>	<u>\$ 5,469,626</u>

* Denotes series is issued in multiple subseries

Variable interest rates are presented at September 30, 2024 and 2023, respectively

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Scheduled maturities of long-term obligations (including the impact of net unamortized bond premiums and deferred financing costs) during the next five years and thereafter and other amounts classified as current liabilities, are as follows:

	Scheduled Maturities	Bonds Supported by Self Liquidity	Bonds Supported by Bank Facilities	Total
2025	\$ 124,694	\$ 212,305	\$ 16,250	\$ 353,249
2026	93,686	-	-	93,686
2027	97,398	-	-	97,398
2028	91,996	-	-	91,996
2029	93,785	-	-	93,785
Thereafter	5,460,714	-	-	5,460,714
	<u>\$ 5,962,273</u>	<u>\$ 212,305</u>	<u>\$ 16,250</u>	<u>\$ 6,190,828</u>

The scheduled maturities represent annual payments as required under debt repayment schedules. The current portion of long-term obligations includes the payments scheduled to be made in 2025, bonds supported by self-liquidity that can be tendered prior to September 30, 2025, and bonds supported by bank facilities with financial institutions (standby bond purchase agreements or letters of credit) that expire prior to September 30, 2025 or have potential principal amortization under bank facilities' term out provisions due during 2025. The bonds supported by self-liquidity provide the bondholder with an option to tender the bonds to the Company. Accordingly, these bonds are classified as a current liability. The bonds supported by bank facilities provide the bondholder with an option to tender the bonds to the liquidity provider. Generally accepted accounting principles require bonds backed by bank facilities expiring within one year of the balance sheet date as well as potential principal amortization under bank facilities' term out provisions due within one year of the balance sheet date to be classified as a current liability.

If bonds supported by bank facilities cannot be remarketed, the repayment terms of those bank facilities would result in repayments of \$46,250 in 2025, \$167,000 in 2026, \$133,250 in 2027, \$47,000 in 2028, \$18,750 in 2029 and \$0 thereafter. If the bonds supported by self-liquidity cannot be remarketed, the bonds would be tendered to the Company on their respective earliest tender dates, which differ from scheduled maturity dates, and would result in payments of \$212,305 in 2025, \$80,000 in 2026, \$0 in 2027, \$0 in 2028, \$0 in 2029 and \$239,515 thereafter.

Scheduled payments of long-term debt (excluding the impact of net unamortized bond premiums and deferred financing costs) for each of the next five years, assuming bonds backed by bank facilities are remarketed and the standby purchase agreements are renewed and bonds supported by self-liquidity are remarketed, are as follows:

2025	\$ 124,694
2026	93,686
2027	101,148
2028	99,032
2029	100,945
Thereafter	5,430,324
	<u>\$ 5,949,829</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Interest expense paid during the years ended September 30, 2024 and 2023 was \$247,287 and \$244,096, respectively.

In January 2024, we issued \$309,185 of Mass General Brigham Series 2024 D Revenue Bonds, plus bond premium of \$34,049. The bond proceeds, net of issuance costs of \$2,594, were used to refund Partners HealthCare System Series 2017 S-4 Bonds (\$69,481) and to finance certain capital projects (\$271,158).

In January 2024, we issued \$150,000 of Mass General Brigham Series 2024 E Revenue Bonds. The bond proceeds, net of issuance costs of \$1,659, were used to refund Taxable Commercial Paper Notes (\$50,000) that refinanced, on an interim basis, Partners HealthCare System Series 2016 R-2 Revenue Bonds, and to finance certain capital projects (\$98,341).

In December 2023, we issued \$69,870 of Mass General Brigham Series 2023 C Revenue Bonds. The bond proceeds were used to refund Taxable Commercial Paper Notes that refinanced, on an interim basis, Partners HealthCare System Series 2017 S-3 Revenue Bonds.

In October 2022, we issued \$100,230 of Mass General Brigham Series 2022 B Revenue Bonds. The bond proceeds were used to refund Partners HealthCare System Series 2016 R-1 Revenue Bonds (\$50,000) and Taxable Commercial Paper Notes (\$50,230) that refinanced, on an interim basis, Partners HealthCare System Series 2017 S-5 Revenue Bonds.

Mass General Brigham bonds are general obligations of the Company supported by guarantees from Brigham, Inc., The Brigham and Women's Hospital, Inc., The Massachusetts General Hospital and The General Hospital Corporation (the General) which may be suspended under certain conditions.

Our debt agreements contain certain covenants, including a minimum debt service coverage ratio and limitations on additional indebtedness and asset transfers.

Lines of Credit

The Company maintains two lines of credit aggregating \$375,000 that provide access to same day funds. Advances under the lines of credit bear a variable rate of interest based on the Bloomberg Short-Term Bank Yield Index rate (BSBY) for the \$250,000 line of credit and the Secured Overnight Financing Rate (SOFR) for the \$125,000 line of credit. As of September 30, 2024 and 2023, there were no amounts outstanding under the lines of credit. The \$250,000 line of credit expires in July 2025. The \$125,000 line of credit expires in July 2026.

Taxable Commercial Paper

The Company maintains a \$500,000 Taxable Commercial Paper (CP) program. As of September 30, 2024 and 2023, there was \$0 and \$119,870, respectively, outstanding under the CP program.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

12. Derivatives

Interest Rate Swaps

We utilize swap contracts to lock in long-term synthetic fixed rates and manage fluctuations in cash flows resulting from interest rate risk on certain of our variable rate bonds. These bonds expose us to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit this variability. To meet this objective and to take advantage of low interest rates, we have entered into various swap contracts involving the exchange of fixed rate payments by us for variable rate payments from several counterparties. These variable rate payments are currently based on a percentage of SOFR (based on compound average of daily SOFR in arrears) plus a spread.

By using swap contracts to manage the risk of changes in interest rates, we expose ourselves to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the swap contracts. When the fair value of a swap contract is positive, the counterparty has a liability to us, which creates credit risk. We minimize our credit risk by entering into swap contracts with several counterparties and requiring the counterparty to post collateral for our benefit based on the credit rating of the counterparty and the fair value of the swap contract. Conversely, when the fair value of a swap contract is negative, we have a liability to the counterparty and, therefore, we do not have credit risk. Under certain circumstances, we may be required to post collateral for the benefit of the counterparty. Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degree of market risk that we may undertake.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

The following is a summary of the outstanding positions under our swap contracts as of September 30, 2024:

Effective Date	Notional Amount	Maturity	Rate Paid	Rate Received
5/1/03	\$ 141,113	7/1/45	3.33%	67% 1M SOFR + 0.0767%
10/15/03	8,440	1/1/31	3.85%	70% 1M SOFR + 0.08014%
7/1/05	150,000	7/1/50	3.09%	67% 1M SOFR + 0.0767%
7/1/05	4,300	7/1/25	5.11%	67% 6M SOFR + 0.28693%
7/1/07	150,000	7/1/52	2.96%	67% 1M SOFR + 0.0809%
7/1/09	100,000	7/1/50	3.58%	67% 1M SOFR + 0.0767%
7/1/11	100,000	7/1/50	3.66%	67% 1M SOFR + 0.0767%
7/1/13	100,000	7/1/48	3.80%	67% 1M SOFR + 0.0767%
7/1/15	50,000	7/1/50	3.80%	67% 1M SOFR + 0.0767%
4/1/16	100,000	7/1/52	3.76%	67% 1M SOFR + 0.0767%
7/1/17	50,000	7/1/52	3.74%	67% 1M SOFR + 0.083%
7/1/24	50,000	7/1/54	1.82%	67% 1M SOFR + 0.0767%
7/1/25	50,000	7/1/55	1.77%	67% 1M SOFR + 0.083%
7/1/26	50,000	7/1/56	1.78%	67% 1M SOFR + 0.0767%
7/1/27	100,000	7/1/57	1.79%	67% 1M SOFR + 0.07985%
7/1/29	50,000	7/1/49	1.41%	67% 1M SOFR + 0.0767%
7/1/29	50,000	7/1/54	1.51%	67% 1M SOFR + 0.0767%
7/1/31	50,000	7/1/53	1.23%	67% 1M SOFR + 0.0767%
7/1/31	50,000	7/1/56	1.55%	67% 1M SOFR + 0.0767%
7/1/33	50,000	7/1/51	1.03%	67% 1M SOFR + 0.0767%
	<u>\$ 1,453,853</u>			

Our swap contracts contain provisions that require collateral to be posted if the fair value of the swap exceeds certain thresholds. The collateral thresholds reflect the current credit ratings issued by major credit rating agencies on our and the counterparty's debt. Declines in our or the counterparty's credit ratings would result in lower collateral thresholds and, consequently, the potential for additional collateral postings by us or the counterparty. As of September 30, 2024, we posted collateral of \$5,320 and held collateral of \$850 and as of September 30, 2023, we held collateral of \$7,350. We have established procedures to ensure that liquidity and securities are available to meet collateral posting requirements.

Upon the occurrence of certain events of default or termination events identified in the swap contracts, either the Company or the counterparty could terminate the contracts in accordance with their respective terms. Termination results in the payment of a termination amount by one party that attempts to compensate the other party for its economic losses. If interest rates at the time of termination are lower than those specified in the swap contract, we would make a payment to the counterparty. Conversely, if interest rates at such time are higher, the counterparty would make a payment to us.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

13. Leases

We lease property and equipment under both finance and operating lease agreements. We recognize leases with a term greater than twelve months on the balance sheets.

Some lease agreements require us to pay variable costs including property taxes, insurance, maintenance and repairs. Variable costs are excluded from the right-of-use asset and liability. Lease and nonlease components of agreements are not separated. Some leases contain rental escalation clauses and renewal options that are included in lease payment calculations when appropriate. The estimated incremental borrowing rate is used to discount the lease payment amounts.

The components of lease expense consist of the following:

	Year Ended September 30, 2024		
	Supplies and Other Expenses	Research and Nonresearch Sundry Gifts, Net of Expenses	Total
Operating lease expense	\$ 218,534	\$ 2,217	\$ 220,751
Short-term lease expense	14,059	251	14,310
Variable lease expense	78,914	968	79,882
Finance lease expense			
Amortization of leased assets	16,088	174	16,262
Interest on lease liabilities	3,633	16	3,649
Total lease expense	<u>\$ 331,228</u>	<u>\$ 3,626</u>	<u>\$ 334,854</u>

	Year Ended September 30, 2023		
	Supplies and Other Expenses	Research and Nonresearch Sundry Gifts, Net of Expenses	Total
Operating lease expense	\$ 225,101	\$ 3,357	\$ 228,458
Short-term lease expense	14,026	1,001	15,027
Variable lease expense	87,866	1,252	89,118
Finance lease expense			
Amortization of leased assets	14,874	167	15,041
Interest on lease liabilities	3,650	22	3,672
Total lease expense	<u>\$ 345,517</u>	<u>\$ 5,799</u>	<u>\$ 351,316</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

Lease related assets and liabilities are as follows:

		September 30,	
Balance Sheet Classification		2024	2023
Operating lease assets	Right-of-use operating lease assets	\$ 920,702	\$ 1,024,336
Finance lease assets	Property and equipment, net	62,646	68,194
Total lease assets		<u>\$ 983,348</u>	<u>\$ 1,092,530</u>
Current operating lease liability	Current portion of operating lease obligations	\$ 203,879	\$ 207,671
Current finance lease liability	Accounts payable and accrued expenses	16,808	16,939
Noncurrent operating lease liability	Operating lease obligation, less current portion	598,065	696,740
Noncurrent finance lease liability	Accrued other	68,333	73,318
Total lease liabilities		<u>\$ 887,085</u>	<u>\$ 994,668</u>

Supplemental cash flow and other information related to leases are as follows:

	Years Ended September 30,	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flow for operating leases	\$ 213,333	\$ 222,040
Operating cash flow for finance leases	3,453	3,630
Financing cash flows for finance leases	14,249	13,461
Weighted-average remaining term (years)		
Operating leases	12.0	7.0
Finance leases	15.0	16.0
Weighted-average discount rate		
Operating leases	4.07 %	4.05 %
Finance leases	4.07 %	4.05 %

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

Commitments related to noncancelable operating and finance leases for each of the next five years and thereafter are as follows:

	Operating Leases	Finance Leases
2025	\$ 203,879	\$ 16,808
2026	182,825	12,267
2027	148,467	8,179
2028	125,062	4,669
2029	74,009	2,973
Thereafter	<u>221,660</u>	<u>95,323</u>
Total minimum future payments	955,902	140,219
Less: Amount representing interest	<u>(153,958)</u>	<u>(55,078)</u>
Present value of minimum future payments	801,944	85,141
Less: Current portion	<u>(203,879)</u>	<u>(16,808)</u>
Long-term lease obligations	<u>\$ 598,065</u>	<u>\$ 68,333</u>

We are also a lessor and sublessor of real estate under operating leases. Lease income for the years ended September 30, 2024 and 2023 was \$15,488 and \$16,425, respectively, and is included in other revenue in the consolidated statements of operations. Some of these leases include expenses such as utilities and maintenance costs in rent charges, however, this variable lease income is not considered material. We do not separate lease and nonlease components by class of underlying asset for all asset classes. The underlying real estate assets are included in property and equipment, net in the consolidated balance sheets.

The future undiscounted cash flows to be received from these leases for each of the next five years and thereafter is as follows:

2025	\$ 3,721
2026	2,723
2027	2,840
2028	2,483
2029	2,283
Thereafter	<u>157,067</u>
	<u>\$ 171,117</u>

14. Construction Projects

The General is constructing a new clinical building, the Phillip and Susan Ragon Building, that will occupy approximately one million square feet and will contain 482 private medical/surgical and intensive care unit beds, exam and infusion bays associated with a relocated and expanded outpatient oncology service, hybrid and conventional cardiovascular operating rooms, and associated imaging modalities as well as below-grade parking. As of September 30, 2024, accumulated costs incurred related to the new clinical building are approximately \$634,977 with

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

approximately \$996,090 in outstanding construction project contracts. The total cost of the project is expected to be approximately \$3,311,000 with occupancy scheduled for 2027 for Phase 1 and 2030 for Phase 2.

The Brigham and Women's Faulkner Hospital, Inc. is constructing a five-story inpatient addition and a 941 space garage that will replace a garage that is at its end-of-life use. The inpatient addition will include 78 new beds and will expand patient care for observation, imaging and endoscopy services. As of September 30, 2024, accumulated costs incurred related to the project are approximately \$209,724 with approximately \$60,262 in outstanding project costs. The total cost of the project is expected to be approximately \$294,000 with occupancy scheduled for December 2024 for the garage and June 2025 for the inpatient addition.

15. Pension and Postretirement Healthcare Benefit Plans

Substantially all Mass General Brigham employees are covered under noncontributory defined benefit pension plans and various defined contribution pension plans. In addition, certain affiliates provide subsidized healthcare benefits for retired employees on a self-insured basis, with the benefit obligation being partially funded. These retiree healthcare benefits are administered through a third-party administrator and are accounted for on the accrual basis, which includes an estimate of future payments for claims incurred.

Total expense for Mass General Brigham plans consists of the following:

	Years Ended September 30,	
	2024	2023
Defined benefit plans	\$ 106,335	\$ 106,708
Defined contribution plans	213,275	181,814
Postretirement healthcare benefit plans	1,539	422
	\$ 321,149	\$ 288,944

Information regarding benefit obligations, plan assets, funded status, expected cash flows and net periodic benefit cost is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2024	2023	2024	2023
Change in benefit obligations				
Benefit obligations at beginning of year	\$ 7,433,676	\$ 7,391,402	\$ 213,043	\$ 202,696
Service cost	327,945	338,035	2,887	2,922
Interest cost	472,110	435,026	12,535	11,295
Plan amendments (gain)/loss	(1,197)	7,928	-	-
Actuarial (gain)/loss	1,314,353	(384,256)	20,020	(5,882)
Benefits paid	(393,190)	(343,062)	(9,950)	(9,065)
Expenses paid	(12,969)	(11,494)	(1,534)	(1,115)
Employee contributions	91	97	11,846	12,192
Benefit obligations at end of year	\$ 9,140,819	\$ 7,433,676	\$ 248,847	\$ 213,043

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

The estimated actuarial gain in the change in benefit obligation for 2024 and 2023 is due primarily to the change in discount rate, respectively.

The accumulated benefit obligation for all defined benefit pension plans at the end of 2024 and 2023 was \$8,739,071 and \$7,140,057, respectively.

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2024	2023	2024	2023
Weighted-average assumptions used to determine end of year benefit obligation				
Discount rate	5.25%	6.22%	4.91% - 5.05%	6.07% - 6.10%
Rate of compensation increase	3.00% - 5.00%	3.00% - 5.00%	N/A	N/A
Interest crediting rate	5.50%	5.25%	5.50%	5.25% - 6.50%
Postretirement healthcare cost trend rate for next year	N/A	N/A	7.50%	6.75%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2035	2031
Change in plan assets				
Fair value of plan assets at beginning of year	\$ 9,075,320	\$ 8,570,585	\$ 178,090	\$ 151,424
Actual return on plan assets	1,549,878	752,199	44,783	21,950
Employer contributions	106,727	106,995	2,750	2,704
Employee contributions	91	97	11,846	12,192
Benefits paid	(393,190)	(343,062)	(9,950)	(9,065)
Expenses paid	(12,969)	(11,494)	(1,534)	(1,115)
Fair value of plan assets at end of year	<u>\$ 10,325,857</u>	<u>\$ 9,075,320</u>	<u>\$ 225,985</u>	<u>\$ 178,090</u>

The assets of the defined benefit pension plans are aggregated in a single master trust (Master Trust) and managed as one asset pool. The investment objective for the Master Trust is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes and (iv) ability and willingness to incur market risk.

Within the Master Trust, assets are allocated to managers with investment mandates that may range from a single sub-asset class to very broad mandates; with restrictions that range from long-only to unconstrained; and with management structures ranging from separately managed funds to mutual/commingled funds to private partnerships. Less market sensitive managers employ long/short equity and diversified strategies. Investment risks (concentration, correlation, valuation, liquidity, leverage, mandate compliance, etc.) are monitored at the manager level as well as the pool level.

The following table presents the capital allocations and reported exposures by manager mandate within the Master Trust. Some managers, particularly less market sensitive managers, invest

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

capital among multiple asset classes. The Long-Term Policy Benchmark is 70% Morgan Stanley Capital International All Country World Index and 30% Barclays Global Aggregate Bond.

	September 30, 2024		September 30, 2023	
	Dollars	Reported Exposures	Dollars	Reported Exposures
Global equity	\$ 1,805,994	17.6 %	\$ 1,171,312	12.9 %
Traditional U.S. equity	1,400,147	13.7 %	1,124,628	12.4 %
Traditional foreign developed equity	195,010	1.9 %	313,409	3.4 %
Traditional emerging markets equity	316,856	3.1 %	449,983	5.0 %
Private equity	2,575,951	24.3 %	2,313,451	25.4 %
Real assets	571,069	5.5 %	558,524	6.2 %
Less Market Sensitive managers	2,942,049	28.8 %	2,783,007	30.7 %
Fixed income managers	518,781	5.1 %	361,006	4.0 %
	<u>\$ 10,325,857</u>	<u>100.0 %</u>	<u>\$ 9,075,320</u>	<u>100.0 %</u>

The postretirement healthcare benefit plans' assets are invested in commingled funds with the objective of achieving returns to satisfy plan obligations and with a level of volatility commensurate with our overall financial profile.

The following tables summarize plan assets measured at fair value on a recurring basis (using the fair value hierarchy defined in Note 6) as of:

	September 30, 2024			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
Defined benefit pension plans				
Short-term investments	\$ 320,651	\$ -	\$ -	\$ 320,651
Separately managed investments	710,149	-	-	710,149
Private partnerships and commingled funds	-	-	9,295,057	9,295,057
	<u>1,030,800</u>	<u>-</u>	<u>9,295,057</u>	<u>10,325,857</u>
Postretirement healthcare benefit plans				
Commingled funds	47,332	-	178,653	225,985
Total plan assets	<u>\$ 1,078,132</u>	<u>\$ -</u>	<u>\$ 9,473,710</u>	<u>\$ 10,551,842</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

	September 30, 2023			
	Fair Value Measurements Using			
	Quoted Prices in Active Markets for Identical Items (Level 1)	Significant Other Observable Inputs (Level 2)	Investments Valued Using NAV as a Practical Expedient	Total
Defined benefit pension plans				
Short-term investments	\$ 175,053	\$ -	\$ -	\$ 175,053
Separately managed investments	370,293	155,452	-	525,745
Private partnerships and commingled funds	-	-	8,374,522	8,374,522
	545,346	155,452	8,374,522	9,075,320
Postretirement healthcare benefit plans				
Commingled funds	49,615	-	128,475	178,090
Total plan assets	\$ 594,961	\$ 155,452	\$ 8,502,997	\$ 9,253,410

In evaluating the Level at which private partnerships have been classified within the fair value hierarchy, management has assessed factors including but not limited to price transparency, the ability to redeem these investments at net asset value at the measurement date and the existence or absence of certain restrictions at the measurement date. Investments in private partnerships generally have limited redemption options for investors and, subsequent to final closing, may or may not permit subscriptions by new or existing investors. These entities may also have the ability to impose gates, lockups and other restrictions on an investor's ability to readily redeem out of their investment interest in the fund. As of September 30, 2024 and 2023, we have excluded all assets from the fair value hierarchy for which fair value is measured using net asset value per share as a practical expedient.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Funded Status

The funded status of the plans recognized in the balance sheet and the amounts recognized in net assets without donor restrictions is as follows:

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2024	2023	2024	2023
End of year				
Fair value of plan assets at measurement date	\$ 10,325,857	\$ 9,075,320	\$ 225,985	\$ 178,090
Benefit obligations at measurement date	(9,140,819)	(7,433,676)	(248,847)	(213,043)
Funded status	<u>\$ 1,185,038</u>	<u>\$ 1,641,644</u>	<u>\$ (22,862)</u>	<u>\$ (34,953)</u>
Amounts recognized in the balance sheet consist of				
Noncurrent asset	\$ 1,206,988	\$ 1,663,197	\$ 257	\$ 319
Current liabilities	(1,650)	(1,620)	(1,166)	(1,248)
Long-term liabilities	(20,300)	(19,933)	(21,953)	(34,024)
	<u>\$ 1,185,038</u>	<u>\$ 1,641,644</u>	<u>\$ (22,862)</u>	<u>\$ (34,953)</u>
Amounts not yet recognized in net periodic benefit cost and included in net assets without donor restrictions consist of				
Actuarial net gain	\$ (184,574)	\$ (615,642)	\$ (19,451)	\$ (9,901)
Prior service credit	(34,197)	(60,127)	(1,331)	-
	<u>\$ (218,771)</u>	<u>\$ (675,769)</u>	<u>\$ (20,782)</u>	<u>\$ (9,901)</u>
Amounts recognized in net assets without donor restrictions consist of				
Current year actuarial (gain)/loss	\$ 422,524	\$ (498,000)	\$ (14,463)	\$ (19,070)
Amortization of actuarial (gain)/loss	8,544	-	3,582	1,969
Current year prior service cost	(1,197)	7,928	-	-
Amortization of prior service credit	27,127	27,899	-	3,064
	<u>\$ 456,998</u>	<u>\$ (462,173)</u>	<u>\$ (10,881)</u>	<u>\$ (14,037)</u>

As of September 30, 2024 and 2023, the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of plan assets were as follows:

	September 30,	
	2024	2023
Accumulated benefit obligation in excess of, or below plan assets		
Projected benefit obligation	\$ 9,140,819	\$ 7,433,676
Accumulated benefit obligation	8,739,071	7,140,057
Fair value of plan assets	10,325,857	9,075,320

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Expected Cash Flows

Information about the expected cash flows for the defined benefit and postretirement healthcare benefit plans is as follows:

	Defined Benefit Pension Plans	Postretirement Healthcare Benefit Plans	
Expected employer contributions			
2025	\$ 189,493	\$ 4,739	Medicare Subsidy
Expected benefit payments (receipts)			
2025	393,991	18,615	(3)
2026	427,448	18,836	(3)
2027	450,018	19,329	(2)
2028	478,611	19,850	(2)
2029	511,332	20,233	(2)
2030-2033	2,938,364	100,893	(6)

Net Periodic Benefit Cost

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2024	2023	2024	2023
Service cost	\$ 327,945	\$ 338,035	\$ 2,887	\$ 2,922
Interest cost	472,110	435,026	12,535	11,295
Expected return on plan assets	(658,049)	(638,454)	(10,301)	(8,762)
Amortization of				
Prior service credit	(27,127)	(27,899)	-	(3,064)
Actuarial net gain	(8,544)	-	(3,582)	(1,969)
Nonservice related pension income	(221,610)	(231,327)	(1,348)	(2,500)
Net periodic benefit cost	\$ 106,335	\$ 106,708	\$ 1,539	\$ 422

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

	Defined Benefit Pension Plans		Postretirement Healthcare Benefit Plans	
	2024	2023	2024	2023
Weighted-average assumptions used to determine net periodic pension and postretirement cost				
Discount rate	6.22%	5.76%	6.07% - 6.10%	5.71% - 5.72%
Expected return on plan assets	7.00%	7.00%	6.00%	6.00%
Interest crediting rate	5.25%	5.25%	5.25% - 6.50%	5.25% - 6.50%
Rate of compensation increase	3.00% - 5.00%	3.00% - 5.00%	N/A	N/A
Healthcare cost trend rate for this year	N/A	N/A	6.75%	7.00%
Rate to which the cost trend rate is to decline	N/A	N/A	5.00%	5.00%
Year that rate reaches the ultimate trend rate	N/A	N/A	2031	2031

We use a long-term return assumption which is validated annually by obtaining long-term asset return, volatility and correlation projections for relevant asset class indexes; modifying volatility and correlations to reflect the actual historical experience of the active managers; calculating the expected return using benchmark weights and indexes; and comparing the return assumption to the sum of the expected return and the historical outperformance of the actual return versus the benchmark. We regularly monitor the active risk of the Master Trust by a statistical regression of the return series of the actual portfolio to that of the policy benchmark.

16. Professional Liability Insurance

We insure substantially all of our professional and general liability risk on a claims-made basis in cooperation with other healthcare organizations in the Greater Boston area through a risk-retention group, Controlled Risk Insurance Company of Vermont, Inc. (CRICO). The Company owns 11% of CRICO. The policies cover claims made during their respective terms, but not those occurrences for which claims may be made after expiration of the policy. Management intends to renew its coverage on a claims-made basis and has no reason to believe that it will be prevented from such renewal.

We follow the accounting policy of establishing reserves to cover the ultimate costs of medical malpractice claims, which include costs associated with litigating or settling claims. The liability also includes an estimated tail liability, established to cover all malpractice claims incurred but not reported to the insurance company as of the end of the year. The total malpractice liability of \$573,796 and \$576,038 as of September 30, 2024 and 2023, respectively, is presented as an accrued professional liability in the consolidated balance sheets. These reserves have been recorded on a discounted basis using an interest rate of 5.0% and 6.0% as of September 30, 2024 and 2023, respectively.

We also recognize an insurance receivable from CRICO at the same time that it recognizes the liability, measured on the same basis as the liability, subject to the need for a valuation allowance for uncollectible amounts. The insurance receivable of \$442,072 and \$441,834 as of September 30, 2024 and 2023, respectively, is reported as a component of other assets in the consolidated balance sheets.

Management is not aware of any claims against us or factors affecting CRICO that would cause the expense for professional liability risks to vary materially from the amount provided.

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

17. Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist of patient accounts receivable, research grants receivable, pledges receivable, premiums receivable, certain investments and interest rate swaps.

Mass General Brigham provider organizations receive a significant portion of payments for services rendered from a limited number of government and commercial third-party payers, including Medicare, Medicaid, Blue Cross and Blue Shield of Massachusetts, Harvard Pilgrim Health Care and Tufts Health Plan. Research funding is provided through many government and private sponsors. The Health Plan receives a portion of premium revenue from the Commonwealth.

Pledges receivable are due from multiple donors. We assess the credit risk for pledges based on history and the financial wherewithal of donors, most of which are individuals or organizations well known to us.

Investments, which include government and agency securities, stocks and corporate bonds, private partnerships and other investments, are not concentrated in any corporation or industry or with any single counterparty. Alternative investments are less liquid than other investments. The reported values of the alternative investments may differ significantly from the values that would have been used had a ready market for those securities existed. These instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of oversight, dependence upon key individuals, emphasis on speculative investments and nondisclosure of portfolio composition.

We minimize our credit risk exposure under interest rate swap agreements by utilizing several counterparties and requiring the counterparties to post collateral for our benefit when the fair value of the swap is positive. We minimize our counterparty risk by contracting with nine counterparties, none of which accounts for more than 20% of the aggregate notional amount of the swap contracts.

18. Net Assets

Net assets with donor restrictions are available for the following purposes:

	September 30,	
	2024	2023
Net assets with donor restrictions		
Charity care	\$ 223,251	\$ 193,671
Buildings and equipment	506,830	851,037
Clinical care, research and academic	3,216,044	2,694,448
	<u>\$ 3,946,125</u>	<u>\$ 3,739,156</u>

Endowment

Our endowment consists of numerous individual funds established for a variety of purposes and includes both endowment funds with donor restrictions and funds designated by boards to function as endowment. We have interpreted UPMIFA as requiring the preservation of the value of the original contribution of the endowment funds with donor restrictions absent explicit donor

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

stipulations to the contrary. As a result of this interpretation, we classify net assets with donor restrictions, the original value of all contributions with donor stipulations to maintain in perpetuity, accumulated gains required to be maintained in perpetuity by explicit donor stipulation or accumulated gains which have been appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, we consider several factors in making a determination to appropriate or accumulate endowment funds with donor restrictions. These factors include: the duration and preservation of the fund; the purposes of the organization and the endowment fund with donor restrictions; general economic conditions; the possible effect of inflation and deflation; the expected total return from income and the appreciation of investments; other resources of the organization; and the investment policies of the organization.

Endowment Funds with Deficits

From time to time, the value of assets associated with individual endowment funds with donor restrictions may fall below the value of the initial and subsequent donor contribution amounts. These deficits generally result from unfavorable market fluctuations that occurred after the investment of new contributions with donor restrictions or subsequent endowment additions. When such endowment deficits exist, they are classified as a reduction to net assets with donor restrictions.

The following presents the endowment net asset composition by type of fund as of September 30, 2024 and 2023 and the changes in endowment assets for the years ended September 30, 2024 and 2023:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2024			
Endowment funds with donor restrictions	\$ -	\$ 2,929,226	\$ 2,929,226
Endowment funds with board designations	1,662,338	-	1,662,338
Total funds	<u>\$ 1,662,338</u>	<u>\$ 2,929,226</u>	<u>\$ 4,591,564</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2023	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>
Investment return			
Investment income	1,660	2,851	4,511
Net realized and unrealized appreciation	<u>261,492</u>	<u>452,078</u>	<u>713,570</u>
Total investment return	263,152	454,929	718,081
Contributions	10,624	142,349	152,973
Appropriation of endowment assets for expenditure	(61,076)	(107,076)	(168,152)
Other changes	<u>81,633</u>	<u>(2,967)</u>	<u>78,666</u>
Total changes	<u>294,333</u>	<u>487,235</u>	<u>781,568</u>
Endowment net assets at September 30, 2024	<u>\$ 1,662,338</u>	<u>\$ 2,929,226</u>	<u>\$ 4,591,564</u>
	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net asset composition by type of fund as of September 30, 2023			
Endowment funds with donor restrictions	\$ -	\$ 2,441,991	\$ 2,441,991
Endowment funds with board designations	<u>1,368,005</u>	<u>-</u>	<u>1,368,005</u>
Total funds	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	Total
Changes in endowment net assets			
Endowment net assets at September 30, 2022	<u>\$ 1,285,916</u>	<u>\$ 2,167,346</u>	<u>\$ 3,453,262</u>
Investment return			
Investment loss	(296)	(498)	(794)
Net realized and unrealized appreciation	129,862	216,938	346,800
Total investment return	129,566	216,440	346,006
Contributions	9,396	151,356	160,752
Appropriation of endowment assets for expenditure	(59,336)	(101,597)	(160,933)
Other changes	2,463	8,446	10,909
Total changes	82,089	274,645	356,734
Endowment net assets at September 30, 2023	<u>\$ 1,368,005</u>	<u>\$ 2,441,991</u>	<u>\$ 3,809,996</u>

19. Functional Expenses

Expenses by functional classification are allocated based on management's judgement, the nature of the expense and historical experience. Such classifications and allocations are as follows:

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2024
Operating expenses					
Employee compensation and benefit expense	\$ 8,762,016	\$ -	\$ 82,892	\$ 1,419,870	\$ 10,264,778
Supplies and other expenses	5,182,240	-	94,827	263,209	5,540,276
Medical claims and related expenses	-	-	1,505,038	-	1,505,038
Direct research and noresearch sundry expenses	-	2,240,832	-	-	2,240,832
Depreciation and amortization expenses	691,739	-	-	86,598	778,337
Interest expense	100,276	-	-	75,003	175,279
Total operating expenses	<u>\$ 14,736,271</u>	<u>\$ 2,240,832</u>	<u>\$ 1,682,757</u>	<u>\$ 1,844,680</u>	<u>\$ 20,504,540</u>

Mass General Brigham Incorporated and Affiliates

Notes to Consolidated Financial Statements

September 30, 2024 and 2023

(in thousands of dollars)

Direct research and nonresearch sundry expenses include \$1,339,705 of employee compensation and benefit expense and \$901,127 of supplies and other expenses for the year ended September 30, 2024.

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2024
Nonoperating expenses					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 85,449	\$ 85,449
Supplies and other expenses	-	-	-	24,244	24,244
Interest expense	-	-	-	57,567	57,567
Pension related interest costs	368,476	52,972	-	63,197	484,645
Total nonoperating expenses	<u>\$ 368,476</u>	<u>\$ 52,972</u>	<u>\$ -</u>	<u>\$ 230,457</u>	<u>\$ 651,905</u>

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2023
Operating expenses					
Employee compensation and benefit expense	\$ 8,296,219	\$ -	\$ 72,326	\$ 1,290,735	\$ 9,659,280
Supplies and other expenses	4,644,283	-	80,980	250,893	4,976,156
Medical claims and related expenses	-	-	1,086,589	-	1,086,589
Direct research and nonresearch sundry expenses	-	2,066,518	-	-	2,066,518
Depreciation and amortization expenses	687,592	-	-	86,971	774,563
Interest expense	104,199	-	-	64,566	168,765
Total operating expenses	<u>\$ 13,732,293</u>	<u>\$ 2,066,518</u>	<u>\$ 1,239,895</u>	<u>\$ 1,693,165</u>	<u>\$ 18,731,871</u>

Direct research and nonresearch sundry expenses include \$1,228,043 of employee compensation and benefit expense and \$838,475 of supplies and other expenses for the year ended September 30, 2023.

	Healthcare Services	Research and Academic	Insurance	General and Administrative	Year Ended September 30, 2023
Nonoperating expenses					
Employee compensation and benefit expense	\$ -	\$ -	\$ -	\$ 78,209	\$ 78,209
Supplies and other expenses	-	-	-	37,363	37,363
Interest expense	-	-	-	63,720	63,720
Pension related interest costs	341,062	49,229	-	56,030	446,321
Total nonoperating expenses	<u>\$ 341,062</u>	<u>\$ 49,229</u>	<u>\$ -</u>	<u>\$ 235,322</u>	<u>\$ 625,613</u>

20. Contingencies

We are subject to complaints, claims and litigation which arise in the normal course of business. In addition, we are subject to reviews and investigations by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. Governmental review of compliance by healthcare organizations has increased.

Mass General Brigham Incorporated and Affiliates
Notes to Consolidated Financial Statements
September 30, 2024 and 2023

(in thousands of dollars)

21. Subsequent Events

We have assessed the impact of subsequent events through December 18, 2024, the date the audited financial statements were issued. During this period, there were no subsequent events that require adjustment to the audited financial statements.

Schedule of Expenditures of Federal Awards

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research and Development and Research Training					
Research and Development					
ADMINISTRATION FOR CHILDREN AND FAMILIES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF Assistance for Torture Victims	93.604	Center for Victims of Torture	90ZT0214-01-00	143,142	-
			Subtotal	143,142	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Direct		2,260,232	352,368
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Shepherd Center Inc.	90DPHF0004	72,103	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPBU0008-03-00	50,164	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPCP0008-04-00	20,671	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPKT0013-01-00	9,881	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90DPTB0027-02-00	25,476	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Spaulding Rehabilitation Hospital	90SIMS0017-01-00	22,839	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Trustees of Indiana University	90DPHF0006-04-00	6,339	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	Trustees of Indiana University	90DPTB0035-01-00	98,580	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	University of Alabama, Birmingham	90REG0019-03-00	10,812	-
			Subtotal	2,577,097	352,368
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Agency for Healthcare Research and Quality Contracts	93.RD9	Abt Associates, Inc.	HHSP2332015000131	(19,141)	-
Agency for Healthcare Research and Quality Contracts	93.RD9	RAND Corporation	75Q80123F32011	12,471	-
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	COVID-19 President and Fellows of Harvard College	5R01HS028240-02	2,494	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	1P30HS029762-01	28,584	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	5R01HS029781-02	21,676	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Boston Medical Center	5R13HS028936-02	2,726	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Cincinnati Children's Hospital Medical Center	5R01HS028976-02	11,268	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		6,374,746	1,772,517
Research on Healthcare Costs, Quality and Outcomes	93.226	Harvard Pilgrim Health Care	5R01HS027170-04	69,401	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Oregon Health & Science University (OHSU)	5R18HS029345-02	276,475	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	1R01HS026753-05	30,743	-
Research on Healthcare Costs, Quality and Outcomes	93.226	President and Fellows of Harvard College	1R01HS029454-01	51,747	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of California, San Francisco	5R01HS027369-03	(4,105)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of California, San Francisco	5R18HS029366-02	199,540	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of Michigan	5R01HS025707-05	4,725	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Regents of the University of Michigan	5R01HS028975-02	100,165	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Tufts Medical Center, Inc.	5R01HS029319-02	564,248	-
Research on Healthcare Costs, Quality and Outcomes	93.226	University of Utah	5R18HS027960-03	29,789	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Yale University	5U18HS029307-02	256,402	-
			Subtotal	8,013,954	1,772,517
AGRICULTURAL RESEARCH SERVICE, AGRICULTURE, DEPARTMENT OF					
Agricultural Research Basic and Applied Research	10.001	Direct		153,514	89,061
			Subtotal	153,514	89,061
BUREAU OF DEMOCRACY, HUMAN RIGHTS AND LABOR, STATE, DEPARTMENT OF					
International Programs to Support Democracy, Human Rights and Labor	19.345	International Coalition of Sites of Conscience	S-LMAQM-19-CA- 2383	102,051	-
			Subtotal	102,051	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	Children's Hospital Corporation dba Boston Children's Hospital	NU27DD000020-04-00	35,868	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	Trustees of Columbia University in the City of New York (The)	6U01DP006436-01-02	13,215	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Abt Associates, Inc.		37,632	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01093 & P01116	78,175	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01094 & P01117	77,367	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01145	41,051	-
Centers for Diseases Control and Prevention Contracts	93.RD7	American Society for Microbiology	P01146	53,767	-
Centers for Diseases Control and Prevention Contracts	93.RD7	Direct		1,004,638	127,011
Centers for Diseases Control and Prevention Contracts	93.RD7	Harvard Pilgrim Health Care	200-2016-91779/75D30121F00002	1,348	-
Centers for Diseases Control and Prevention Contracts	93.RD7	The Broad Institute, Inc.	75D30122C15113	(201,499)	-
Centers for Diseases Control and Prevention Contracts	93.RD7	University of Maryland, Baltimore	75D30122C15467	101,439	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	Emory University	6U48DP006377-05-02	34,560	-
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	Vanderbilt University Medical Center	5NU58DP007307 02 00	57,907	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Brown University	200-2016-91773-T.O.2	366,557	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Direct		18,624	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 The Broad Institute, Inc.	75D30120CO9605	(83,403)	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 The Broad Institute, Inc.	75D30123C17983	533,952	-
COVID-19 Centers for Diseases Control and Prevention Contracts	93.RD7	COVID-19 Wayne State University	75D30121C11813	147,232	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 Olive View/UCLA Education and Research Institute, Inc.	6U01CK000643-01-03	165,339	-
COVID-19 Emerging Infections Sentinel Networks	93.860	COVID-19 Regents of the University of California, Los Angeles, The	5U01CK000643-02	19,179	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
COVID-19 PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Preventic	93.738	COVID-19 Partners in Health	6NU58DP006594-03-01	11,436	-
COVID-19 Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	COVID-19 Direct		183,831	30,573
COVID-19 Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prev	93.326	COVID-19 Direct		(73,205)	-
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2GGH002212-02-00	65,608	-
Global AIDS	93.067	Beth Israel Deaconess Medical Center	5NU2GGH002212-04-00	11,344	-
HIV Demonstration, Research, Public and Professional Education Projects	93.941	Vanderbilt University Medical Center	5U01PS005240-03-00	101,344	-
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement	93.185	Association of Immunization Managers	NH231P922569	25,000	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	Direct		569,555	82,183
Occupational Safety and Health Program	93.262	Direct		436,765	-
Occupational Safety and Health Program	93.262	Icahn School of Medicine at Mount Sinai	5U01OH010401-10-00	69	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5R01OH002421-26	20,636	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-17-00	216	-
Occupational Safety and Health Program	93.262	President and Fellows of Harvard College	5U19OH008861-18	13,304	-
Occupational Safety and Health Program	93.262	The Broad Institute, Inc.	R01MH132968	86,565	-
Packaging and Spreading Proven Pediatric Weight Management Interventions for Use by Low-Income Families	93.349	Direct		407,576	135,659
PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Prevention and Heal	93.738	Partners in Health	NU58DP006594-02-00	78,151	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Direct		1,090,245	266,046
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02	24,924	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Harvard Pilgrim Health Care	5U54CK000611-02-00	17,218	-
Sexually Transmitted Diseases (STD) Prevention and Control Grants	93.977	Direct		227,035	-
Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention	93.326	Direct		78,357	15,161
			Subtotal	5,878,922	656,633
CONSUMER PRODUCT SAFETY COMMISSION, CONSUMER PRODUCT SAFETY COMMISSION					
Consumer Product Safety Commission Contracts	93.RD5	Direct		51,394	-
			Subtotal	51,394	-
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA), DEPT OF DEFENSE					
Research and Technology Development	12.910	Charles Stark Draper Laboratory, Inc (The	N6600123C4018	14,461	-
Research and Technology Development	12.910	Charles Stark Draper Laboratory, Inc (The	N66001-23-C-4018	644,254	-
Research and Technology Development	12.910	Direct		2,559,036	524,675
Research and Technology Development	12.910	President and Fellows of Harvard College	HR00111920022	71,211	-
Research and Technology Development	12.910	The Broad Institute, Inc.	HR00112120010	(6,345)	-
			Subtotal	3,282,617	524,675
DEFENSE THREAT REDUCTION AGENCY (DTRA), DEPT OF DEFENSE					
Scientific Research - Combating Weapons of Mass Destruction	12.351	Direct		225,283	13,207
			Subtotal	225,283	13,207
DEPARTMENT OF DEFENSE, DEPT OF DEFENSE					
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Advanced Technology International	2017-605	21,224	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Geneva Foundation, The	W81XWH1590001	168,413	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Mitre Corporation	1160555	732	-
COVID-19 Department of Defense Contracts	93.RD10	COVID-19 Nihon Kohden OrangeMed, Inc.	W81XWH159001	(509)	-
Department of Defense Contracts	93.RD10	Advanced Technology International	W81XWH189000411	868,008	-
Department of Defense Contracts	93.RD10	Coalesenz, Inc	W81XWH20C0119	4,869	-
Department of Defense Contracts	93.RD10	Dephy Inc	FA864924P0119	35,404	-
Department of Defense Contracts	93.RD10	Direct		2,976,503	428,193
Department of Defense Contracts	93.RD10	Geneva Foundation, The	HU00011920056	2,886,657	672,336
Department of Defense Contracts	93.RD10	Massachusetts General Hospital	HT94252310948	83,666	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology	FA86502127120	47,450	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology	FA870215D0001	95,910	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology Lincoln Laboratories	7000561749	101,513	-
Department of Defense Contracts	93.RD10	Massachusetts Institute of Technology Lincoln Laboratories	FA870215D0001	373,263	-
Department of Defense Contracts	93.RD10	Medical Technology Enterprise Consortium (MTEC)	W81XWH2290004	588,498	-
Department of Defense Contracts	93.RD10	Meso Scale Diagnostics, LLC	HT94252310312	56,314	-
Department of Defense Contracts	93.RD10	Metro International Biotech, LLC	H924051890002	1,524,595	-
Department of Defense Contracts	93.RD10	President and Fellows of Harvard College	W81XWH22C0128	572,588	-
Department of Defense Contracts	93.RD10	QLEDcures, LLC	W911NF22P0018	(2,331)	-
Department of Defense Contracts	93.RD10	Real-Time Analyzers, Inc.	W81XWH20C0037	10,144	-
Department of Defense Contracts	93.RD10	Regents of the University of California, San Francisco	W81XWH1590001	105,513	-
Department of Defense Contracts	93.RD10	The Broad Institute, Inc.	HR0012120010	30,037	-
Department of Defense Contracts	93.RD10	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	470FWA20C0012	57,173	-
Department of Defense Contracts	93.RD10	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HT942524C0053	22,518	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	HT942523C0012	97,811	-
Department of Defense Contracts	93.RD10	Triton Systems, Inc.	W81XWH21C0024	57,048	-
Department of Defense Contracts	93.RD10	University of Houston	W81XWH2010755	(14,011)	-
Department of Defense Contracts	93.RD10	University of North Carolina at Chapel Hill, The	W81XWH22C0122	263,669	-
Department of Defense Contracts	93.RD10	University of South Florida	H9240520D0001	1,742	-
Department of Defense Contracts	93.RD10	Vivionics, Inc.	W81XWH21900006	11,307	-
Department of Defense Contracts	93.RD10	Wake Forest University Health Sciences	W15QKN1691002	7,035	-
			Subtotal	11,052,753	1,100,529

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
DEPT OF THE AIR FORCE, DEPT OF DEFENSE					
Air Force Defense Research Sciences Program	12.800	Direct		4,979,825	-
Air Force Defense Research Sciences Program	12.800	Massachusetts Institute of Technology	FA870215D0001	222,073	-
			Subtotal	5,201,898	-
DEPT OF THE ARMY, DEPT OF DEFENSE					
Basic Scientific Research	12.431	Tufts University	W911NF2310276	581,061	-
Basic Scientific Research	12.431	University of Pittsburgh Of the Commonwealth System of Higher Education	W911NF2320022	323,987	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Dana-Farber Cancer Institute, Inc.	W81XWH2110080	(1,107)	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Direct		505,261	-
COVID-19 Military Medical Research and Development	12.420	COVID-19 Trustees of the University of Pennsylvania	W81XWH2110422	22,620	-
Military Medical Research and Development	12.420	American University	W81XWH2220012	239,288	-
Military Medical Research and Development	12.420	Axogen Corporation	W81XWH18PRORPCTRA	89,781	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2020023	23,124	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2110471	110,077	-
Military Medical Research and Development	12.420	Beth Israel Deaconess Medical Center	W81XWH2210349	14,528	-
Military Medical Research and Development	12.420	Board of Trustees of the Leland Stanford Junior University, The	W81XWH2010855	10,477	-
Military Medical Research and Development	12.420	Board of Trustees of the University of Alabama for the University of Alabama	W81XWH1510705	(10,592)	-
Military Medical Research and Development	12.420	Board of Trustees of the University of Illinois, The	W81XWH1810661	40,915	-
Military Medical Research and Development	12.420	Boston University School of Medicine	W81XWH2110980	20,155	-
Military Medical Research and Development	12.420	Boston VA Research Institute Inc	W81XWH2210568	13,803	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252310846	170,881	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	HT94252310880	218,436	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1910708	500	-
Military Medical Research and Development	12.420	Brigham and Women's Hospital, Inc.	W81XWH1820058	16,106	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH1720037	80	-
Military Medical Research and Development	12.420	Children's Hospital Corporation dba Boston Children's Hospital	W81XWH1910219	2	-
Military Medical Research and Development	12.420	Colorado State University	W81XWH2210925	15,078	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH1910780	82,376	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2010057	13,280	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2110482	(1,361)	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2110981	1,085	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH2210705	30,141	-
Military Medical Research and Development	12.420	Dana-Farber Cancer Institute, Inc.	W81XWH221109002	93,252	-
Military Medical Research and Development	12.420	Dartmouth-Hitchcock Clinic	W81XWH2010319	(1,961)	-
Military Medical Research and Development	12.420	Direct		43,302,431	2,750,612
Military Medical Research and Development	12.420	Duke University	PR221120HT94252310386	55,352	-
Military Medical Research and Development	12.420	Geneva Foundation, The	W81XWH2010833	(33)	-
Military Medical Research and Development	12.420	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	W81XWH2020061	15,100	-
Military Medical Research and Development	12.420	Icahn School of Medicine at Mount Sinai	W81XWH2210999	498,100	-
Military Medical Research and Development	12.420	Joan & Sanford I. Weill Medical College of Cornell University	W81XWH1810667	402,955	-
Military Medical Research and Development	12.420	Johns Hopkins University	HT94252310589	274,150	-
Military Medical Research and Development	12.420	Massachusetts Eye and Ear Infirmary	HT94252310284	96,262	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	243076	7,116	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	HT94252310219	11,713	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	HT94252410311	4,320	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2010293	10,017	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2210293	162,128	-
Military Medical Research and Development	12.420	Massachusetts General Hospital	W81XWH2211053	15,598	-
Military Medical Research and Development	12.420	Massachusetts Institute of Technology	W81XWH1820010	92,898	-
Military Medical Research and Development	12.420	Massachusetts Institute of Technology	W81XWH1910151	1,567	-
Military Medical Research and Development	12.420	Massachusetts Institute of Technology	W81XWH2110235	339	-
Military Medical Research and Development	12.420	Mayo Clinic	W81XWH1510293	400	-
Military Medical Research and Development	12.420	MD Anderson Cancer Center	W81XWH2210890	45,636	-
Military Medical Research and Development	12.420	MD Anderson Cancer Center	W81XWH2210952	41,776	-
Military Medical Research and Development	12.420	Melanoma Research Alliance	W81XWH2110819	38,164	-
Military Medical Research and Development	12.420	Metis Foundation, The	HT94252311011	42,776	-
Military Medical Research and Development	12.420	Michigan State University	W81XWH2110744	52,566	-
Military Medical Research and Development	12.420	Moberg Research, Inc.	W81XWH1920013	713	-
Military Medical Research and Development	12.420	NeuroDex, Inc.	HT94252310077	14,653	-
Military Medical Research and Development	12.420	New York University Grossman School of Medicine	W81XWH2220078	335,251	-
Military Medical Research and Development	12.420	Northwestern University	W81XWH2210166	69,580	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310226	257,098	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310523	47,188	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	HT94252310871	146,032	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH1920011	(389)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH2010303	4,297	-
Military Medical Research and Development	12.420	President and Fellows of Harvard College	W81XWH2110326	9,875	-
Military Medical Research and Development	12.420	Rector and Visitors of the University of Virginia, The	HT94252310219	385,575	-
Military Medical Research and Development	12.420	Regents of the University of California, Davis	HT94252310153	136,232	-
Military Medical Research and Development	12.420	Regents of the University of California, Los Angeles, The	W81XWH2110869	27,316	-
Military Medical Research and Development	12.420	Regents of the University of California, San Diego	W81XWH1710671	165,144	-
Military Medical Research and Development	12.420	Regents of the University of California, San Francisco	W81XWH1820042	(1,894)	-
Military Medical Research and Development	12.420	The Broad Institute, Inc.	HT94252310890	9,512	-
Military Medical Research and Development	12.420	The Broad Institute, Inc.	W81XWH2010533	3,246	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH1910765	162,296	-
Military Medical Research and Development	12.420	Trustees of Boston University	W81XWH2110980	49,271	-
Military Medical Research and Development	12.420	Trustees of the University of Pennsylvania	W81XWH1910861	19,414	-
Military Medical Research and Development	12.420	Trustees of Tufts College	W81XWH2211065	61,638	-
Military Medical Research and Development	12.420	University of Alabama, Birmingham	W81XWH1720037	1,809	-
Military Medical Research and Development	12.420	University of Kentucky	W81XWH2010449	31,180	-
Military Medical Research and Development	12.420	University of Pittsburgh Of the Commonwealth System of Higher Education	W81XWH2110542	26,491	-
Military Medical Research and Development	12.420	University of Texas Health Science Center at San Antonio	HT94252311046	63,077	-
Military Medical Research and Development	12.420	University of Texas Health Science Center at San Antonio	W81XWH2120044	34,154	-
			Subtotal	49,851,363	2,750,612
DEPT OF THE NAVY, DEPT OF DEFENSE					
Basic and Applied Scientific Research	12.300	National Marrow Donor Program	C10831	11,884	-
Basic and Applied Scientific Research	12.300	Ohio State University	N000142012163	309,471	-
Basic and Applied Scientific Research	12.300	Regents of the University of Michigan	N00014-20-1-2479	208,291	-
			Subtotal	529,646	-
ENERGY, DEPARTMENT OF, ENERGY, DEPARTMENT OF					
Advanced Research Projects Agency - Energy	81.135	Texas A&M University	DE-AR0000823	272,301	-
Office of Science Financial Assistance Program	81.049	North Carolina State University	DE-SC0023334	214,212	-
U.S. Department of Energy Contracts	93.RD4	Direct		216,128	-
			Subtotal	702,641	-
FEDERAL AVIATION ADMINISTRATION, TRANSPORTATION, DEPARTMENT OF					
Federal Aviation Administration Contracts	93.RD14	Boston University School of Public Health	13-C-AJFE-BU-027	123,433	-
Federal Aviation Administration Contracts	93.RD14	Direct		(550,871)	-
Federal Aviation Administration Contracts	93.RD14	Guidehouse, Inc.	693JJ318A000007	92,662	-
			Subtotal	(334,776)	-
FEDERAL COMMUNICATIONS COMMISSION, FEDERAL COMMUNICATIONS COMMISSION					
Federal Communications Commission Contracts	93.RD11	Direct		171,801	-
			Subtotal	171,801	-
FOOD AND DRUG ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 U.S. Food & Drug Administration Contracts	93.RD8	COVID-19 American College of Medical Toxicology, Inc.	75F40122D00028	45,590	-
Food and Drug Administration Research	93.103	Children's Research Institute	5P50FD007965-02	71,630	-
Food and Drug Administration Research	93.103	Direct		2,893,342	239,794
Food and Drug Administration Research	93.103	Institute for Advanced Clinical Trials for Children	1U18FD006297-02	2,143	-
Food and Drug Administration Research	93.103	Johns Hopkins University	1U01FD008129-01	142,719	-
Food and Drug Administration Research	93.103	President and Fellows of Harvard College	1U01FD007929-01	254,612	-
Food and Drug Administration Research	93.103	Regents of the University of California, San Diego	1U01FD007773-01	11,799	-
Food and Drug Administration Research	93.103	Regents of the University of Minnesota	1R01FD007630-01	22,874	-
Food and Drug Administration Research	93.103	Vanderbilt University Medical Center	1R01FD007627-01	(91)	-
U.S. Food & Drug Administration Contracts	93.RD8	Direct		1,794,659	29,132
U.S. Food & Drug Administration Contracts	93.RD8	Harvard Pilgrim Health Care	75F40119D10037	1,852,330	-
U.S. Food & Drug Administration Contracts	93.RD8	International Consulting Associates, Inc.	ICA-SK-21-300-MA001	42,433	-
U.S. Food & Drug Administration Contracts	93.RD8	Jaeb Center for Health Research	4050	756	-
U.S. Food & Drug Administration Contracts	93.RD8	Regents of the University of Michigan	75F40121C00148	95,743	-
			Subtotal	7,230,539	268,926
HEALTH AND HUMAN SERVICES, DEPARTMENT OF, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Congressional Directives	93.493	Direct		1,698,717	-
			Subtotal	1,698,717	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Mental and Behavioral Health Education and Training Grants	93.732	COVID-19 Massachusetts League of Community Health Centers, Inc.	1U3MHP45385 01 00	334,517	-
Health Systems Strengthening and HIV/AIDS Prevention, Care and Treatment under the President's Emergency PI	93.266	Boston Medical Center	5R18HS026177-05	(2,678)	-
HIV Emergency Relief Project Grants	93.914	Fenway Community Health Center	U69HA31067	2,481	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	5U28HA376440100	(2,930)	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	6U1OHA29294 09	2,103	-
HIV-Related Training and Technical Assistance	93.145	Fenway Community Health Center	U1OHA29294	6,877	-
Maternal and Child Health Federal Consolidated Programs	93.110	Ann & Robert H. Lurie Children's Hospital of Chicago	U11MC45814	10,836	-
Maternal and Child Health Federal Consolidated Programs	93.110	Direct		14,455	-
Maternal and Child Health Federal Consolidated Programs	93.110	Education Development Center, Inc.	2UF4MC26525	86,706	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Maternal and Child Health Federal Consolidated Programs	93.110	HHT Foundation International Inc.	1UP4MC46404-01-00	100,673	-
Maternal and Child Health Federal Consolidated Programs	93.110	Icahn School of Medicine at Mount Sinai	5H30MC24048 13 00	3,978	-
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	RS20210327-01	4,247	-
Special Projects of National Significance	93.928	Fenway Community Health Center	5U90HA42153-04	44,561	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	2U30CS22742-14	49,658	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	5U30CS22742	2,262	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	U30CS22742 . .	37,902	-
Technical and Non-Financial Assistance to Health Centers	93.129	Fenway Community Health Center	U3FCS41777	(61)	-
Telehealth Programs	93.211	President and Fellows of Harvard College	5U3IRH43510 02 00	33,634	-
Telehealth Programs	93.211	President and Fellows of Harvard College	5U3IRI143510-03	84,086	-
			Subtotal	813,307	-
IMMED OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Biomedical Advanced Research and Development Authority	93.RD13	Locus Biosciences, Inc.	75A50120C00169	1,708	-
Biomedical Advanced Research and Development Authority	93.RD13	Mitre Corporation	75FCMC18D0047/75A501 22F80009	127,821	-
Biomedical Advanced Research and Development Authority	93.RD13	Mitre Corporation	OVH001.FINA.201.A2 TO: 1163811	29,862	-
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Beckman Coulter, Inc.	75A0120C00189	(1,717)	-
COVID-19 Biomedical Advanced Research and Development Authority	93.RD13	COVID-19 Beckman Coulter, Inc.	75A50122C00036	437,812	136,808
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 Emory University	6U3REP150549-05-16	1,048	-
COVID-19 National Ebola Training and Education Center (NETEC)	93.825	COVID-19 Emory University	6U3REP150549-05-20	97,709	-
			Subtotal	694,243	136,808
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION, NATIONAL AERONAUTICS AND SPACE ADMINISTRATION					
Exploration	43.003	Direct		1,718,537	431,720
Exploration	43.003	Massachusetts Institute of Technology	7000000324/NNX16A069A	194,976	-
Exploration	43.003	Thomas Jefferson University	NNX15AC14G	5,796	-
Exploration	43.003	Trustees of the University of Pennsylvania	NNX15AK76A	(835)	-
National Aeronautics and Space Administration Contracts	93.RD17	Direct		708,132	321,995
National Aeronautics and Space Administration Contracts	93.RD17	KBRWyle	NNU15HK11B	123,754	-
National Aeronautics and Space Administration Contracts	93.RD17	Wake Forest University Health Sciences	80ARC022CA008	39,915	-
Science	43.001	Beth Israel Deaconess Medical Center	80NSSC23K0774	69,919	-
Science	43.001	Direct		162,083	-
Science	43.001	Georgia Institute of Technology	80NSSC21K0234	14,176	-
			Subtotal	3,036,453	753,715
NATIONAL INSTITUTE OF FOOD AND AGRICULTURE, AGRICULTURE, DEPARTMENT OF					
COVID-19 Food Insecurity Nutrition Incentive Grants Program	10.331	COVID-19 Community Outreach and Patient Empowerment Program, Inc.	2021-70034-34991	(859)	-
			Subtotal	(859)	-
NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY, COMMERCE, DEPARTMENT OF					
Measurement and Engineering Research and Standards	11.609	Direct		15,732	-
			Subtotal	15,732	-
NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Brigham and Women's Hospital, Inc.	1R37CA288557-01	6,050	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	U001CA250549-01	(139)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	U001CA274276-02	14,413	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	U001DE029188-01	106,376	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U2CCA233195-04	(253)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U2CCA233195-06	5,518	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	1U54CA231637-01	68,790	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	2P01CA163222	7,922	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	2U24CA224331	31,412	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	3SL2CCA233195-05S1	127,477	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	3U54CA231637-01S2	282,528	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Dana-Farber Cancer Institute, Inc.	U24CA224331	(1,236)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Direct		975,508	92,380
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Massachusetts Institute of Technology	5U01CA250554-03	516	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233262-01	(13,572)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233262-01	(13,620)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	1U2CCA233280	12,567	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3P50CA244433-04S1	(18)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3U01CA253912-03S2	(1,663)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	3U2CCA233262-01S2	113,266	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5P50CA244433-03	(886)	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	5P50CA244433-05	160,521	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	President and Fellows of Harvard College	P50CA244433-05	307,893	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	1U2CCA252974-01	7,673	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	5U2CCA252974-04	2,645	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	5U2CCA33195	2,817	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U01DE029188	8,971	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U01DE029188-01	2,756	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U2CCA233238	2,819	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	The Broad Institute, Inc.	U2CCA252974	2,898	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	University of Texas - Southwestern Medical Center	5UM1CA221940-06	62,134	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Wyss Institute at Harvard University	1U54CA244726-01	116,489	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93.353	Yale University	5U2CCA252979-03	166,827	-
21st Century Cures Act - Precision Medicine Initiative	93.368	The Broad Institute, Inc.	3OT2OD002750	52,248	-
21st Century Cures Act - Precision Medicine Initiative	93.368	The Broad Institute, Inc.	3OT2OD002750-01S5	119,093	-
21st Century Cures Act - Precision Medicine Initiative	93.368	The Broad Institute, Inc.	OT20D002750	165,633	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	President and Fellows of Harvard College	152048.5128031.0043	121,510	-
Advanced Research Projects Agency for Health (ARPA-H)	93.384	President and Fellows of Harvard College	1AYSAX0000005-01	42,969	-
Aging Research	93.866	Advanced Brain Monitoring, Inc.	2R44AG050326-03A1	234,253	-
Aging Research	93.866	Albert Einstein College of Medicine	1R01AG080635-01A1	22,978	-
Aging Research	93.866	Altec, Inc.	2R44AG072991-03	96,427	-
Aging Research	93.866	Aromha Inc	2R42AG062130-04	411,136	-
Aging Research	93.866	Banner Alzheimer's Institute	5R01AG055444-05	(7,157)	-
Aging Research	93.866	Banner Alzheimer's Institute	5R01AG058468-04	714,137	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	1R21AG083421-01	25,999	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	1R56AG075017-01A1	20,469	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG065554-05	290,707	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG080598-02	36,307	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	5R01AG082093-02	187,488	-
Aging Research	93.866	Beth Israel Deaconess Medical Center	7R21AG070644-02	7,324	-
Aging Research	93.866	BioSensics	5R42AG059491	(2,012)	-
Aging Research	93.866	BioSensics	5R42AG059491-03	(303)	-
Aging Research	93.866	BioSensics LLC	5R44AG080861-02	438,903	-
Aging Research	93.866	Board of Regents of the University of Wisconsin System, The	1U01AG082350-01A1	50,006	-
Aging Research	93.866	Board of Regents of the University of Wisconsin System, The	U19AG024904	68,856	-
Aging Research	93.866	Boston University School of Medicine	1RF1AG061706-01	84,250	-
Aging Research	93.866	Boston University School of Medicine	5R01AG066914-05	16,027	-
Aging Research	93.866	Boston University School of Medicine	5U19AG073172-03	656,294	-
Aging Research	93.866	Boston University School of Medicine	7R01AG069917-04	112,830	-
Aging Research	93.866	Boston VA Research Institute Inc	5R01AG081809-02	296,927	-
Aging Research	93.866	Boston VA Research Institute Inc	7RF1AG061774-02	285,266	-
Aging Research	93.866	Brain Thrive Technology LLC	1R41AG082591-01	129,328	-
Aging Research	93.866	Brandeis University	5P30AG048785-09	16,398	-
Aging Research	93.866	Brandeis University	5R01AG074330-03	1,268,491	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1P01AG071463-01A1	119,076	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	1P01AG071463-02	335,215	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	2P01AG015379-25	263,158	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P01AG015379-25	581,966	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5P30AG064199-04	(754)	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG042512-10	54,805	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG053184-05	577,379	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG054029-05	100,841	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG058825-05	606,012	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG061083-05	123,185	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG063689-05	236,420	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG066921-04	39,991	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG067507-05	156,480	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG070252-04	17,902	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG077486-03	60,430	-
Aging Research	93.866	Brigham and Women's Hospital, Inc.	5R01AG080429-02	2,473	-
Aging Research	93.866	Brown University	5P01AG027296-14	(5,352)	-
Aging Research	93.866	Brown University	5U54AG063546-03	(1,241)	-
Aging Research	93.866	Brown University	5U54AG063546-04	41,032	-
Aging Research	93.866	Brown University	5U54AG063546-05	201,705	-
Aging Research	93.866	Case Western Reserve University	5R03AG077132-02	55,450	-
Aging Research	93.866	Cedar-Sinai Medical Center	5R01AG058911-05	810	-
Aging Research	93.866	Cedar-Sinai Medical Center	5U54AG085141-05	21,531	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	1R01AG078929-02	10,613	-
Aging Research	93.866	Children's Hospital Corporation dba Boston Children's Hospital	5R01AG070921-04	223,540	-
Aging Research	93.866	CND Life Sciences	1R44AG076072-01	1,305	-
Aging Research	93.866	Collagen Medical, LLC	R44AG059524	(3,060)	-
Aging Research	93.866	Dana-Farber Cancer Institute, Inc.	5UH3AG060626-05	99,387	-
Aging Research	93.866	Dimagi, Inc	1R43AG084434-01	56,952	-
Aging Research	93.866	Direct		123,342,054	24,755,241

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Aging Research	93.866	Duke University	5R01AG084098-02	232,956	-
Aging Research	93.866	Einsenca, Inc.	R44AG079734	2,520	-
Aging Research	93.866	Einsenca, Inc.	R44AG079734-03	417,126	-
Aging Research	93.866	Emory University	5R01AG058704-05	3,118	-
Aging Research	93.866	Emory University	5R01AG066956-04	48,799	-
Aging Research	93.866	Emory University	5R01AG070704-04	46,298	-
Aging Research	93.866	ExQor Technologies Inc	2R44AG058343-04	394,327	-
Aging Research	93.866	Function Promoting Therapies, LLC	1R33AG068234-01	25,634	-
Aging Research	93.866	Function Promoting Therapies, LLC	2R44AG045011-04	266,206	-
Aging Research	93.866	General Biophysics LLC	2R42AG073059-02	201,963	-
Aging Research	93.866	George Washington University	5U19AG078558-02	430,701	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	1R01AG059089	(4,997)	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5P01AG031720-10	(24,685)	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5R01AG076708-02	100,643	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	5R03AG075434-02	40,699	-
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	90083	(4,721)	-
Aging Research	93.866	Hebrew Senior Life	5P01AG031720-10	23,090	-
Aging Research	93.866	Hennepin Healthcare Research Institute	3U19AG062682-03S1	3	-
Aging Research	93.866	Hennepin Healthcare Research Institute	5U19AG062682-05	135,895	-
Aging Research	93.866	Icahn School of Medicine at Mount Sinai	5P01AG066605-05	47,111	-
Aging Research	93.866	Imaginostics, Inc.	1R43AG079732-01	150,891	-
Aging Research	93.866	Johns Hopkins University	1R01AG078948-01	210,873	-
Aging Research	93.866	Johns Hopkins University School of Medicine	5R01AG050515 05	106,436	-
Aging Research	93.866	Massachusetts AI & Technology Center for Connected Care in Aging & Alzheimer's Disease	3P30AG073107-04	40,810	-
Aging Research	93.866	Massachusetts General Hospital	1R01AG080678-01	2,661	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG067744-01	38,745	-
Aging Research	93.866	Massachusetts General Hospital	1RF1AG074008-01	63,058	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG062667-05	50,578	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG065254-04	35,645	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG067019-05	78,744	-
Aging Research	93.866	Massachusetts General Hospital	5R01AG071865-04	252,492	-
Aging Research	93.866	Massachusetts General Hospital	7R01AG065254-04	20,385	-
Aging Research	93.866	Massachusetts Institute of Technology	5R01AG058002-04	281	-
Aging Research	93.866	Massachusetts Institute of Technology	5R01AG070135-05	12,051	-
Aging Research	93.866	Massachusetts Institute of Technology	5R01AG081017-02	278,393	-
Aging Research	93.866	Massachusetts Institute of Technology	P30AG064190-03	(1,019)	-
Aging Research	93.866	Mayo Clinic	5R01AG077706-03	83,166	-
Aging Research	93.866	Mayo Clinic	5U19AG063911-04	165,133	-
Aging Research	93.866	Mayo Clinic	5U19AG063911-05	440,606	-
Aging Research	93.866	Melax Technologies	1R44AG081006-01	441,144	-
Aging Research	93.866	Methodist Hospital Research Institute dba Houston Methodist Research Institute	R01AG071496	360,129	-
Aging Research	93.866	Michigan State University	1RF1AG072449-01	391,187	136,840
Aging Research	93.866	National Bureau of Economic Research (NBER)	5P01AG005842	(1,098)	-
Aging Research	93.866	National Bureau of Economic Research (NBER)	5P30AG034532-14	(1,356)	-
Aging Research	93.866	Northeastern University	RF1AG079946	24,886	-
Aging Research	93.866	Northern California Institute for Research and Education, Inc.	5R24AG064025	54,607	-
Aging Research	93.866	Northern California Institute for Research and Education, Inc.	5U19AG024904-17	71,189	-
Aging Research	93.866	Northwestern University	1RF1AG064006-01	202,110	-
Aging Research	93.866	Northwestern University	2U2CAG060426-06	45,051	-
Aging Research	93.866	Northwestern University	5U2CAG057441-03S1	(44,738)	-
Aging Research	93.866	Northwestern University	5U2CAG060426-05	43,146	-
Aging Research	93.866	NYU Langone Health	5R01AG068248-05	460,177	-
Aging Research	93.866	Ohio State University	5R01AG058822-05	10,338	-
Aging Research	93.866	Ohio State University	5R01AG073113-04	37,924	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	1RF1AG069782-01	17,344	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	3RF1AG069782-01S1	45,342	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5P30AG024978-20	61,652	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5R01AG056102-05	275,742	-
Aging Research	93.866	Oregon Health & Science University (OHSU)	5R01AG082931-02	396,796	-
Aging Research	93.866	Pennsylvania State University	5R01AG077016-03	24,160	-
Aging Research	93.866	Pennsylvania State University	5U2CAG060408-05	23,203	-
Aging Research	93.866	President and Fellows of Harvard College	1R21AG072516-01	(1,065)	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG074372-01A1	270,210	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG078377-01	585,369	-
Aging Research	93.866	President and Fellows of Harvard College	1RF1AG081475-01	315,274	-
Aging Research	93.866	President and Fellows of Harvard College	2P01AG032952-13	66,861	-
Aging Research	93.866	President and Fellows of Harvard College	5P01AG041710-10	442,086	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG011085-29	(169)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance		Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number	Direct Agency/Pass-Through Program	Number	Expenditures	Expenditures
Aging Research	93.866	President and Fellows of Harvard College	5R01AG011085-31	263,692	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG060935-03	7,158	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG066793-04	45,774	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG067420-05	62,972	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG068122-03	17,379	-
Aging Research	93.866	President and Fellows of Harvard College	5R01AG081151-02	170,496	-
Aging Research	93.866	President and Fellows of Harvard College	R01HS026753	(8,778)	-
Aging Research	93.866	Regents of the University of California, San Diego	7R56AG069107-02	12,119	-
Aging Research	93.866	Regents of the University of California, San Francisco	1R01AG078457-01A1	477,884	-
Aging Research	93.866	Regents of the University of California, San Francisco	5R01AG066137-05	80,084	-
Aging Research	93.866	Regents of the University of Michigan	7R01AG061034-06	259,001	-
Aging Research	93.866	Research Foundation for Mental Hygiene, Inc.	5R01AG066828-04	59,758	-
Aging Research	93.866	RetiSpec Inc.	1R01AG053184-01	402	-
Aging Research	93.866	Rip Road, Inc.	7R42AG069629-02	174,352	3,782
Aging Research	93.866	Rush University Medical Center	1RF1AG059621	(333)	-
Aging Research	93.866	Rush University Medical Center	5R01AG015819-18	147,912	-
Aging Research	93.866	Rush University Medical Center	5R01AG017917-20	111,682	-
Aging Research	93.866	Rush University Medical Center	5R01AG052583-05	(10)	-
Aging Research	93.866	Rush University Medical Center	5R01AG061798-03	(21,098)	-
Aging Research	93.866	Rush University Medical Center	5R01AG062637-02	681,834	-
Aging Research	93.866	Sanford Burnham Prebys Medical Discovery Institute	5R56AG080525-05	388,776	-
Aging Research	93.866	Seattle Institute for Biomedical and Clinical Research	5R01AG061558-04	389,278	28,484
Aging Research	93.866	Seer Biosciences, Inc.	5R44AG065051-02	69,579	-
Aging Research	93.866	Stanford University Medical Center	7R01AG080678-02	119,811	-
Aging Research	93.866	State University of New York Upstate Medical University	5R01AG061798-06	70,916	-
Aging Research	93.866	The Methodist Hospital Research Institute	5R01AG057635-05	198,861	-
Aging Research	93.866	The University of Texas Health Science Center at Houston	5R01AG082751-02	62,912	-
Aging Research	93.866	Translational Genomics Research Institute	5U19AG073153-02	(1,904)	-
Aging Research	93.866	Translational Genomics Research Institute	5UH3AG064706-05	479,339	-
Aging Research	93.866	Trustees of Boston University	1R01AG073179-01	73,339	-
Aging Research	93.866	Trustees of Boston University	1RF1AG068121-01	39,394	-
Aging Research	93.866	Trustees of Boston University	3U19AG073172-03S1	3,482	-
Aging Research	93.866	Trustees of Boston University	5R01AG066010-04	42,677	-
Aging Research	93.866	Trustees of Boston University	5R01AG067394-04	92,667	-
Aging Research	93.866	Trustees of Boston University	5R01AG070135-03	(237)	-
Aging Research	93.866	Trustees of Boston University	5R01AG074213-02	30,630	-
Aging Research	93.866	Trustees of Boston University	5R01AG083941-02	22,621	-
Aging Research	93.866	Trustees of Boston University	5U19AG068753-04	411,448	-
Aging Research	93.866	Trustees of Boston University	5U19AG073172-03	547,706	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	1RF1AG072167-01A1	862,176	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5R01AG081155-02	33,154	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5R21AG080464-02	63,542	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG061356-03S1	(1,091)	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG061356-05	135,824	-
Aging Research	93.866	Trustees of Columbia University in the City of New York (The)	5U01AG072572-04	632,155	-
Aging Research	93.866	Trustees of Indiana University	5U01AG057195-03S1	(480)	-
Aging Research	93.866	Trustees of Indiana University	5U01AG057195-05	571,836	-
Aging Research	93.866	Trustees of the University of Pennsylvania	1U19AG079774-01	36,025	-
Aging Research	93.866	Trustees of the University of Pennsylvania	5R01AG072796-03	259,523	-
Aging Research	93.866	Trustees of the University of Pennsylvania	5U01AG032984-15	23,322	-
Aging Research	93.866	Tufts Medical Center, Inc.	5R01AG064064-03	8,751	-
Aging Research	93.866	Tufts Medical Center, Inc.	7R01AG066892-04	1,030,853	-
Aging Research	93.866	Tufts Medical Center, Inc.	R01AG066892	63,021	-
Aging Research	93.866	Tufts University	5R01AG059011-05	81,754	-
Aging Research	93.866	University of Cincinnati	5R01AG072087-04	196,962	-
Aging Research	93.866	University of Kansas Medical Center Research Institute, Inc.	5R01AG079422-02	110,193	-
Aging Research	93.866	University of Maryland, Baltimore	1RF1AG073236-01	899,714	-
Aging Research	93.866	University of Massachusetts Amherst	2R01AG051600-06	159,654	-
Aging Research	93.866	University of Massachusetts Amherst	3P30AG073107-03S3 AS5	79,896	-
Aging Research	93.866	University of Massachusetts Amherst	3P30AG073107-04	73,383	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-02	(167)	-
Aging Research	93.866	University of Massachusetts Amherst	5P30AG073107-04	338,275	-
Aging Research	93.866	University of Massachusetts Amherst	5R21AG083468-02	28,313	-
Aging Research	93.866	University of Massachusetts Amherst	P30AG073107	121,940	-
Aging Research	93.866	University of Massachusetts Medical School	5U01AG068221-03	76,958	-
Aging Research	93.866	University of Miami	5R01AG067568-03	215,155	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	3R01AG065394-03S1	5,258	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-02	(2,280)	-
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-04	80,667	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Aging Research	93.866	University of North Carolina at Chapel Hill, The	5R01AG065394-05	34,781	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	3U19AG068054-03S3	(1,746)	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AG066198-05	187,568	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	5U19AG063720-04	528,760	-
Aging Research	93.866	University of Pittsburgh Of the Commonwealth System of Higher Education	U19AG068054	1,588,218	-
Aging Research	93.866	University of Rochester	5P01AG047200-09	395,123	-
Aging Research	93.866	University of Southern California	1R01AG061848-04	57,760	-
Aging Research	93.866	University of Southern California	1RF1AG057892-01A1	127,742	-
Aging Research	93.866	University of Southern California	2U24AG057437-06	983,820	-
Aging Research	93.866	University of Southern California	4U19AG010483-25	(1,482)	-
Aging Research	93.866	University of Southern California	5R01AG051125-09	42,352	-
Aging Research	93.866	University of Southern California	5R01AG053798-04	1,567	-
Aging Research	93.866	University of Southern California	5R01AG053798-05	92,147	-
Aging Research	93.866	University of Southern California	5R01AG054029-02	259,959	-
Aging Research	93.866	University of Southern California	5R01AG061848-05	303,389	-
Aging Research	93.866	University of Southern California	5R01AG063689-02	96,668	-
Aging Research	93.866	University of Southern California	5R01AG065248-02	4,212	-
Aging Research	93.866	University of Southern California	5U24AG057437-02	(103)	-
Aging Research	93.866	University of Southern California	5U24AG057437-05	(7,932)	-
Aging Research	93.866	University of Southern California	5U24AG057437-07	452,398	-
Aging Research	93.866	University of Tennessee Medical Center	A22-1001-S001-A02	45,048	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG062531-04	140,754	-
Aging Research	93.866	University of Texas Health Science Center at San Antonio	5R01AG066524-02	255,568	-
Aging Research	93.866	University of Texas Southwestern Medical Center	5R01AG056426-05	76,594	-
Aging Research	93.866	University of Washington	5R03AG073990-02	11,712	-
Aging Research	93.866	University of Washington	5U24AG072122-02	601	-
Aging Research	93.866	University of Washington - Seattle	5U24AG072122-03	16,953	-
Aging Research	93.866	Vanderbilt University Medical Center	5R01AG062499-05	8,007	-
Aging Research	93.866	Vanderbilt University Medical Center	5R01AG073439-04	51,744	-
Aging Research	93.866	Virginia Commonwealth University	1RF1AG076912-01A1	294,184	-
Aging Research	93.866	Virginia Commonwealth University	5R01AG076360-03	15,938	-
Aging Research	93.866	Virginia Commonwealth University	5U01AG076481-03	206,695	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG064440-05	69,640	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG074562-03	106,361	-
Aging Research	93.866	Wake Forest University Health Sciences	5R01AG075959-03	60,709	-
Aging Research	93.866	Washington University, The	2RF1AG047644-06	138,635	-
Aging Research	93.866	Washington University, The	5R01AG084739-02	142,258	-
Aging Research	93.866	Washington University, The	5U01AG052564-04	(4,313)	-
Aging Research	93.866	Washington University, The	5U19AG032438-12	112,324	-
Aging Research	93.866	Washington University, The	5U19AG071754-03	190,389	-
Aging Research	93.866	Washington University, The	5U19AG073585-03	1,354,073	-
Aging Research	93.866	WellSIM BioMedical Technologies, Inc.	1R41AG076098-01	(15,639)	-
Aging Research	93.866	Yale University	1RF1AG081413-01	85,897	-
Aging Research	93.866	Yale University	5R01AG065403-05	295,754	-
Aging Research	93.866	Yale University	5R01AG071528-03	208,173	-
Aging Research	93.866	Yale University	7R01AG061811-06	31,284	-
Alcohol Research Programs	93.273	Brown University	5R01AA027760-05	31,635	-
Alcohol Research Programs	93.273	Clintech, Inc.	2R44AA026123-02	292	-
Alcohol Research Programs	93.273	Direct		2,265,643	207,731
Alcohol Research Programs	93.273	Fenway Community Health Center	5P01AA029544-04	40,637	-
Alcohol Research Programs	93.273	Planned Parenthood League of Massachusetts, Inc.	1R01AA030529-01	15,579	-
Alcohol Research Programs	93.273	President and Fellows of Harvard College	5R01AA029267-04	31,021	-
Alcohol Research Programs	93.273	Seton Hall University	R21AA029825	173,971	-
Alcohol Research Programs	93.273	University of Texas at Austin	5R01AA029090-02	37,332	-
Allergy and Infectious Diseases Research	93.855	Africa Health Research Institute (AHRI)	5R01AI145305-05	15,710	-
Allergy and Infectious Diseases Research	93.855	Arkansas Children's Hospital Research Institute	R01AI139032	10,336	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-06	38,835	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-07	122,240	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-09	11,996	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-10	406,190	-
Allergy and Infectious Diseases Research	93.855	Benaroya Research Institute at Virginia Mason	5UM1AI109565-11	992,607	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	1P01AI179405-01	15,254	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	4U01AI145801-05	36,891	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5P01AI177687-02	251,628	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5R01AI149670-04	362,746	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5U01AI145801-04	48,122	-
Allergy and Infectious Diseases Research	93.855	Beth Israel Deaconess Medical Center	5UM1AI164556-04	211,200	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	1R01AI168370-01A1	88,717	-
Allergy and Infectious Diseases Research	93.855	Board of Regents of the University of Wisconsin System, The	2U01AI102456-06	(111)	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the Leland Stanford Junior University, The	5U19AI057229-20	25,421	-
Allergy and Infectious Diseases Research	93.855	Board of Trustees of the University of Alabama for the University of Alabama	5R01AI147727-05	269,116	-
Allergy and Infectious Diseases Research	93.855	Boston University School of Public Health	5R01AI168424-02	118,000	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	1R01AI175582-01A1	171,029	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	1R01AI181221-01	66,632	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	1R01AI184094-01	3,503	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138800-05	5,218	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI138999-05	33,409	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI150295-04	(66,148)	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5R01AI176579-02	200,838	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI148306-05	22,317	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5U01AI170056-02	20,360	-
Allergy and Infectious Diseases Research	93.855	Brigham and Women's Hospital, Inc.	5UM1AI069412-18	840,654	-
Allergy and Infectious Diseases Research	93.855	Brown University	5R01AI167694-03	16,840	-
Allergy and Infectious Diseases Research	93.855	Cedars-Sinai Medical Center	1U01AI170424-02	73,055	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1R01AI175556-01	245,212	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	1U19AI168643-01	(32)	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5P01AI089618-12	437,525	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5R01AI151180-03	11,997	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI126614-07	41,850	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI143514-05	141,272	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U01AI163072-03	70,519	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Corporation dba Boston Children's Hospital	5U19AI168643-03	189,542	-
Allergy and Infectious Diseases Research	93.855	Children's Hospital Medical Center	5R01AI148276-04	30,848	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5P01AI143565-04	9,461	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5U01AI165442-03	141,932	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5U01AI165442-03	66,806	-
Allergy and Infectious Diseases Research	93.855	Direct		110,621,084	25,494,145
Allergy and Infectious Diseases Research	93.855	Duke University	5R01AI139425-04	3,082	-
Allergy and Infectious Diseases Research	93.855	Duke University	5UM1AI104681-11	190,344	-
Allergy and Infectious Diseases Research	93.855	Emory University	3U19AI110483-08S4	579,281	-
Allergy and Infectious Diseases Research	93.855	Emory University	5R01AI166988-02	25,081	-
Allergy and Infectious Diseases Research	93.855	Emory University	5R01AI051231-21	(50,277)	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-10	595,975	-
Allergy and Infectious Diseases Research	93.855	Emory University	5U19AI110483-10	175,741	-
Allergy and Infectious Diseases Research	93.855	Emory University	5UM1AI164562-04	227,096	-
Allergy and Infectious Diseases Research	93.855	Erasmus University Medical Center	1R01AI147330-01	551,339	-
Allergy and Infectious Diseases Research	93.855	Fenway Community Health Center	5UM1AI068619-18	12,184	-
Allergy and Infectious Diseases Research	93.855	FHI 360	5UM1AI1068619-16	8,190	-
Allergy and Infectious Diseases Research	93.855	FHI 360	UM1AI068619	10,205	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-18	239,571	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	5UM1AI068614-19	293,717	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068614-17	6,923	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068614-19	18,782	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Center	6UM1AI068617-19	233,786	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Research Center	5UM1AI068614-14	(90)	-
Allergy and Infectious Diseases Research	93.855	Fred Hutchinson Cancer Research Center	5UM1AI068614-16	(36,446)	-
Allergy and Infectious Diseases Research	93.855	GHE/SKIO Centers	4UM1AI069421-18	55,018	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	1R21AI178021-01	107,617	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5P01AI168258-01A2	24,987	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5P01AI168258-02	1,147,715	-
Allergy and Infectious Diseases Research	93.855	Icahn School of Medicine at Mount Sinai	5R01AI174902-02	66,026	-
Allergy and Infectious Diseases Research	93.855	Joan & Sanford I. Weill Medical College of Cornell University	5R01AI171390-02	153,053	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	1UM1AI182034-01	114,329	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2UM1AI068632-15	(3,451)	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	2UM1AI068632-18	29,936	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5R01AI172092-02	15,307	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U01AI134591-05	1,029	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U01AI138897-05	10,089	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5U19AI159822-03	233,203	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM1AI164566-04	77,691	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UM2AI130836-07	195,886	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	5UMAI164566-03	291,219	-
Allergy and Infectious Diseases Research	93.855	Johns Hopkins University	UH3AI133669	(4,346)	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U01AI167892-03	21,442	-
Allergy and Infectious Diseases Research	93.855	La Jolla Institute for Immunology	5U19AI142790-05	150,528	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Eye and Ear Infirmary	5P01AI083214-16	373,281	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	1R01AI155171-03	273,880	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	4R37AI058736-19	58,958	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R01AI042006-27	63,990	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R01AI155662-04	74,708	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5R37AI058736-18	14	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI136816-04	62,499	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U01AI163086-04	55,918	-
Allergy and Infectious Diseases Research	93.855	Massachusetts General Hospital	5U19AI174967-02	22,136	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Institute of Technology	5R61AI161805-02	16,502	-
Allergy and Infectious Diseases Research	93.855	Massachusetts Institute of Technology	5U19AI167899-03	617,793	-
Allergy and Infectious Diseases Research	93.855	New York University Grossman School of Medicine	1U01AI174997-01	21,984	-
Allergy and Infectious Diseases Research	93.855	Oregon Health & Science University (OHSU)	5R01AI157807-04	92,977	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P01AI039671-25	37,093	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-19	(4,259)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2P30AI060354-20	87,710	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	2UM1AI069456-18	48,126	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	3P30AI060354-20S1	534,051	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	4U01AI135940-07	43,346	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P01AI056299-20	560,149	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-19	(24,996)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20	1,281,067	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20S1	104,942	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI143723-05	277,871	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5R01AI148338-04	363,391	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-04	(23,958)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-05	(20)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI135940-07	244,637	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U01AI179561-02	119,952	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U19AI133524-05	(135)	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5U19AI142793-05	172,933	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	U01AI135940	7,534	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	U01AI179561	9,225	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	UM1AI069456-18	99,904	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	2UM1AI068636-17	2,290	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S2	4,832	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-16S4	(1,826)	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	3UM1AI068636-17S2	19,684	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5R01AI166313-03	266,623	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-16	6,716	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-17	3,740	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI068636-18	969,353	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, Los Angeles, The	5UM1AI106701-11	322,764	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Diego	5U19 AI070535-17	7,676	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Diego	5U19AI070535-18	131,673	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-03	269,191	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of California, San Francisco	5UM1AI164560-04	417,263	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Colorado	R01AI141452	163,470	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	5R01AI084913-13	14,991	-
Allergy and Infectious Diseases Research	93.855	Regents of the University of Minnesota	5U01AI169587-02	164,220	-
Allergy and Infectious Diseases Research	93.855	Rutgers, the State University of New Jersey	5R01AI175315-02	109,740	-
Allergy and Infectious Diseases Research	93.855	Sanaria Inc	U01AI155354	46,605	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5P01AI177683-02	366,896	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5R01AI147826-05	429,788	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5R61AI161818-03	(37,055)	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-03	(24)	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-05	(5,889)	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-06	1,006,433	-
Allergy and Infectious Diseases Research	93.855	Scripps Research Institute	5UM1AI144462-06	28,546	-
Allergy and Infectious Diseases Research	93.855	Stellenbosch University	1R01AI175235-01	86,724	-
Allergy and Infectious Diseases Research	93.855	Sylvatica Biotech, Inc	R44AI145782	(47,284)	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	1R01AI153405	131,002	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	1R01AI172147-01	36,685	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5R01AI158495	47,515	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5R01AI172147-03	28,784	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5U19AI110818-010	92,981	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	5U19AI142780-05	863,398	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	CNVAA00059942 1316161	233,294	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	GMO 190409	11,055	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	P01AI148102	40,634	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	R01AI132300	(4,931)	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	R21AI178690	4,373	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI082630	(2,117)	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI142737	7,758	-
Allergy and Infectious Diseases Research	93.855	The Broad Institute, Inc.	U19AI142780	31,802	-
Allergy and Infectious Diseases Research	93.855	Trustees of Boston University	5R01AI162850-03	101,774	-
Allergy and Infectious Diseases Research	93.855	Trustees of Columbia University in the City of New York (The)	4U54AI138370-06	(2,999)	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U01AI163087-03	87,730	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	5U19AI149680-05	514,787	-
Allergy and Infectious Diseases Research	93.855	Trustees of the University of Pennsylvania	7R61AI161818-04	60,049	-
Allergy and Infectious Diseases Research	93.855	Tufts University	5R01AI169786-03	107,522	-
Allergy and Infectious Diseases Research	93.855	University of Alabama, Birmingham	1R37AI179640-01	608,876	-
Allergy and Infectious Diseases Research	93.855	University of California at Berkeley	1R01AI155634-04	40,013	-
Allergy and Infectious Diseases Research	93.855	University of Connecticut	1R01AI167884	36,004	-
Allergy and Infectious Diseases Research	93.855	University of Georgia Research Foundation, Inc. (UGARF)	U01AI148114	17,762	-
Allergy and Infectious Diseases Research	93.855	University of Maryland	5R01AI155716-03	(200)	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	1R01AI167367-01A1	248,406	-
Allergy and Infectious Diseases Research	93.855	University of Maryland, Baltimore	5U19AI145825-03	418,316	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Chan Medical School	5U01AI172987-02	16,722	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	5R01AI159159-03	93,766	-
Allergy and Infectious Diseases Research	93.855	University of Massachusetts Medical School	5U01AI165524-03	92,068	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	1R01AI184980-01	894	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	2P01AI08545-06	130,388	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5P01AI129880-05	35,569	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI155345-04	128,535	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01AI164970-03	133,594	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	1R34AI134569-01A1	(71)	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern Medical Center	5U19AI142784-05	212,858	-
Allergy and Infectious Diseases Research	93.855	University of Utah	R01AI135115	13,860	-
Allergy and Infectious Diseases Research	93.855	Vanderbilt University Medical Center	5P30AI110527-10	285,673	-
Allergy and Infectious Diseases Research	93.855	Volatylx, Inc.	5R44AI141264-03	394,014	-
Allergy and Infectious Diseases Research	93.855	Wayne State University	1R21AI180183-01	22,189	-
Allergy and Infectious Diseases Research	93.855	Wistar Institute of Anatomy and Biology	5UM1AI164570-04	227,217	-
Allergy and Infectious Diseases Research	93.855	Yale University	5P01AI039671-26	1,245,955	-
Allergy and Infectious Diseases Research	93.855	Yale University	5R01AI104824-10	916	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	3R01AR075964-03S1	5,374	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Beth Israel Deaconess Medical Center	5R01AR075964-04	87,877	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Board of Trustees of the University of Alabama for the University of Alabama	5P50AR060772-10	66,858	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	3U01AR070498-04S1	58,303	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR065807-25	6,682	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR077607-03	75,765	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5R01AR080193-03	24,851	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brigham and Women's Hospital, Inc.	5U01AR070498-04	687,344	162,612
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Brixton Biosciences, Inc.	1R41AR080620-01A1	125,975	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	1R01AR080079	46,904	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Corporation dba Boston Children's Hospital	5R01AR065538-10	104,670	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Dartmouth-Hitchcock Clinic	R01AR077157	(2,282)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		29,316,620	5,605,061
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Senior Life	5R01AR075346-03	49,080	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Highland Instruments	4R44AR076885-02	31,895	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Johns Hopkins University	5UH3AR077360-05	107,994	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	1U01AR080385-01A1	730,190	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR065944-08	245,658	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR077023-05	11,297	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5U01AR070498-04	108,047	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northwestern University	1R01AR081854-01A1	42,281	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Oklahoma Medical Research Foundation	5UC2AR081032-03	11,256	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of California, Irvine	5R01AR078340-03	8,568	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Colorado, a body corporate, for and on behalf	5R01AR069060-06	11,922	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Michigan	1U24AR076730-01	(8,950)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Regents of the University of Michigan	4U24AR076730-02	63,281	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Terasaki Family Foundation	5R01AR073135-06	25,153	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Broad Institute, Inc.	1UC2AR081031-01	(15,043)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Broad Institute, Inc.	5R21AR080274-02	46,695	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Broad Institute, Inc.	5UC2AR081031	25,075	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5R01AR078299-02	18,701	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Boston University	5R01AR080950-03	8,329	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR077187-02	346,701	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of Columbia University in the City of New York (The)	5R01AR077187-03	10,930	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees of the University of Pennsylvania	1U01AR079752-01	40,913	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Tufts Medical Center, Inc.	R01AR077146	17,342	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	1R01AR078187-01S1	194,996	(111,497)
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Arizona	5R01AR080742-03	182,553	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Colorado at Denver	5R01AR075033-04	4,410	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Connecticut	5R01AR073822-06	(2,176)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Massachusetts Chan Medical School	7R21AR079633-02	21,773	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Massachusetts Medical School	5R01AR078230-03	282,868	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of North Carolina at Chapel Hill, The	1U24AR076730-01	(103,011)	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of North Carolina at Chapel Hill, The	4U24AR076730-02	466,571	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3AR076568-05	220,049	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Rochester	5UC2AR081025-03	281,674	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University of Texas Health Science Center at San Antonio	5R01AR077445-03	1,844	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Wake Forest University	1U01AR082121-01	382,851	-
Biomedical Research and Research Training	93.859	Brandeis University	1R01GM152811-01	114,540	-
Biomedical Research and Research Training	93.859	Brigham and Women's Hospital, Inc.	5R01GM132825-04	44,097	-
Biomedical Research and Research Training	93.859	Dana-Farber Cancer Institute, Inc.	5R01GM136859-05	9,461	-
Biomedical Research and Research Training	93.859	Direct		19,736,643	1,076,105
Biomedical Research and Research Training	93.859	President and Fellows of Harvard College	5R01GM148494-02	71,568	-
Biomedical Research and Research Training	93.859	Regents of the University of California, San Francisco	R01GM117163	(120,603)	-
Biomedical Research and Research Training	93.859	The Broad Institute, Inc.	1R01GM137606-01A1	76,150	-
Biomedical Research and Research Training	93.859	The Broad Institute, Inc.	R21GM1448826	25,274	-
Biomedical Research and Research Training	93.859	Trustees of Dartmouth College	5R35GM128745-05	(8,404)	-
Biomedical Research and Research Training	93.859	Trustees of the University of Pennsylvania	5R01GM132668-05	190,528	-
Biomedical Research and Research Training	93.859	Trustees of Tufts College	5R21GM141683-02	67,895	-
Biomedical Research and Research Training	93.859	University of Utah	2R01GM134069-05	112,071	-
Biomedical Research and Research Training	93.859	University of Utah	R01GM134069	(18,804)	-
Biomedical Research and Research Training	93.859	Vox Biomedical LLC	1R43GM149051-01A1	739	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	1P01HL158688-01A1	37,560	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	1R01HL167513-01	86,450	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5P01HL046925-25	269,945	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL095791-14	46,297	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL158192-02	83,427	-
Blood Diseases and Resources Research	93.839	Children's Hospital of Philadelphia (The)	1R01HL169401-01A1	21,377	-
Blood Diseases and Resources Research	93.839	Cleveland Clinic Lerner College of Medicine	UH3HL140097-04	27,129	-
Blood Diseases and Resources Research	93.839	Cleveland Clinic Lerner College of Medicine	UH3HL140097-05	137,985	-
Blood Diseases and Resources Research	93.839	Cornell University	1R01HL167139-01A1	284,180	-
Blood Diseases and Resources Research	93.839	Dana-Farber Cancer Institute, Inc.	5UG1HL069249-23	9,795	-
Blood Diseases and Resources Research	93.839	Direct		11,269,308	3,626,439
Blood Diseases and Resources Research	93.839	Emory University	5U54HL141981-04	23,102	-
Blood Diseases and Resources Research	93.839	Joan & Sanford I. Weill Medical College of Cornell University	5R01HL167139-02	88,885	-
Blood Diseases and Resources Research	93.839	Johns Hopkins University	7R01HL138714-04	279,150	-
Blood Diseases and Resources Research	93.839	Massachusetts Institute of Technology	5R01HL158102-04	99,274	-
Blood Diseases and Resources Research	93.839	New York University Grossman School of Medicine	1UG3HL155798-01A1	(5,281)	-
Blood Diseases and Resources Research	93.839	New York University Grossman School of Medicine	4UH3HL155798-02	48,587	-
Blood Diseases and Resources Research	93.839	The Broad Institute, Inc.	1P01HL158505-01	2,908	-
Blood Diseases and Resources Research	93.839	University of Michigan Medical School	5R01HL144550-04	59,538	-
Blood Diseases and Resources Research	93.839	University of Minnesota	5R01HL132906-08	53,500	-
Blood Diseases and Resources Research	93.839	University of Southern California	5U19HL156247-05	29,238	-
Blood Diseases and Resources Research	93.839	University of Washington	5R01HL154385-04	17,704	-
Blood Diseases and Resources Research	93.839	University of Washington - Seattle	5R01HL147894-04	39,381	-
Blood Diseases and Resources Research	93.839	Washington University, The	5UH3HL138325-06	51,648	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	1U19CA264504-03	67,060	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5P01CA120964-15	(7,543)	-
Cancer Biology Research	93.396	Brigham and Women's Hospital, Inc.	5U19CA264504-03	91,111	-
Cancer Biology Research	93.396	Brown University	5R01CA263324-02	25,789	-
Cancer Biology Research	93.396	Cincinnati Children's Hospital Medical Center	5R01CA240317-05	100,544	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	1R01CA279221-01A1	15,467	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	2R01CA181217-09	76,943	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5P01CA233412-05	418,994	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA238039-05	21,763	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA246653-05	140,675	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA251589-04	9,024	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5R01CA251599-05	12,046	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	5U01CA232161-05	94	-
Cancer Biology Research	93.396	Dana-Farber Cancer Institute, Inc.	P01CA250959	129,181	-
Cancer Biology Research	93.396	Direct		17,919,279	3,604,984

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Biology Research	93.396	Florida International University	7U01CA225644-03	10,390	-
Cancer Biology Research	93.396	Joan & Sanford I. Weill Medical College of Cornell University	5U01CA275301-02	74,390	-
Cancer Biology Research	93.396	Kaiser Foundation Research Institute	3R01CA251589-04S1	59,600	-
Cancer Biology Research	93.396	Kaiser Permanente Division of Research	3R01CA251589-04S1	37,504	-
Cancer Biology Research	93.396	Kaiser Permanente Division of Research	R01CA251589	(1,431)	-
Cancer Biology Research	93.396	Massachusetts Institute of Technology	1UG3CA275687-01	300,587	-
Cancer Biology Research	93.396	Massachusetts Institute of Technology	7R01CA248280-03	4,746	-
Cancer Biology Research	93.396	MD Anderson Cancer Center	5P01CA117969-19	233,550	-
Cancer Biology Research	93.396	Memorial Sloan-Kettering Institute Cancer Center	5U01CA228963-04	229,184	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	1R01CA279550-01	35,502	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	1U01CA284207-01	30,459	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA240924-05	42,050	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA273461-03	83,018	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R01CA276866-02	35,621	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5R35CA220523-06	66,057	-
Cancer Biology Research	93.396	President and Fellows of Harvard College	5U01CA267827-03	16,012	-
Cancer Biology Research	93.396	The Broad Institute, Inc.	1R35CA263817-01A1	3,287	-
Cancer Biology Research	93.396	The Broad Institute, Inc.	1R61CA281807-01	26,889	-
Cancer Biology Research	93.396	Tufts Medical Center, Inc.	R01CA243542	(21,329)	-
Cancer Biology Research	93.396	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01CA256068-04	151,319	-
Cancer Biology Research	93.396	University of Texas Southwestern Medical Center	5U01CA221940-06	256,989	-
Cancer Biology Research	93.396	Wistar Institute of Anatomy and Biology	5P01CA269043-02	156,000	-
Cancer Biology Research	93.396	Yale University	5R01CA230275-05	(8,686)	-
Cancer Cause and Prevention Research	93.393	Albert Einstein College of Medicine	5R01CA275521-02	151,448	-
Cancer Cause and Prevention Research	93.393	Baylor College of Medicine	5P01CA263025-02	238,821	-
Cancer Cause and Prevention Research	93.393	BC Cancer, a part of the Provincial Health Services Authority	5U01CA253858-05	177,119	-
Cancer Cause and Prevention Research	93.393	Beth Israel Deaconess Medical Center	5R01CA242747-04	56,933	-
Cancer Cause and Prevention Research	93.393	Children's Hospital of Philadelphia (The)	1R37CA282153-01	40,427	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	1R01CA279414-01A1	11,613	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	1R01CA283395-01	489,885	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA256877-02	26,475	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA258924-04	72,271	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5R01CA279044-02	47,974	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	R01CA248857	32,691	-
Cancer Cause and Prevention Research	93.393	Direct		22,083,661	6,486,552
Cancer Cause and Prevention Research	93.393	Duke University	1U54CA231630-01A1	125,824	-
Cancer Cause and Prevention Research	93.393	Duke University	5R01CA235677-05	71,737	-
Cancer Cause and Prevention Research	93.393	ECOG-ACRIN Medical Research Foundation, Inc.	1U01CA274996-01	267,646	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Center	5R01CA248857-06	184,030	-
Cancer Cause and Prevention Research	93.393	Fred Hutchinson Cancer Research Center	5R01CA215134-05	(25,660)	-
Cancer Cause and Prevention Research	93.393	HealthPartners Institute	5R01CA263542-02	9,250	-
Cancer Cause and Prevention Research	93.393	Icahn School of Medicine at Mount Sinai	5R01CA260889-03	66,648	-
Cancer Cause and Prevention Research	93.393	Joan & Sanford I. Weill Medical College of Cornell University	5R01CA260352-02	(20,847)	-
Cancer Cause and Prevention Research	93.393	Joan & Sanford I. Weill Medical College of Cornell University	5U01CA260352-04	214,838	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	1R37CA275914-01A1	22,912	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	5R01CA218123-05	18,101	-
Cancer Cause and Prevention Research	93.393	Massachusetts General Hospital	5U01CA225451-05	(2,130)	-
Cancer Cause and Prevention Research	93.393	Massachusetts Institute of Technology	5R21CA256081-02	4,288	-
Cancer Cause and Prevention Research	93.393	Mayo Clinic	5R01CA248288-04	88,298	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	1R21CA263489-01A1	31,995	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	1R37CA276322-01A1	41,046	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5R01CA244185-05	92,020	-
Cancer Cause and Prevention Research	93.393	Memorial Sloan-Kettering Institute Cancer Center	5U01CA253913-04	140,220	-
Cancer Cause and Prevention Research	93.393	Northeastern University	5R01CA252966-03	15,637	-
Cancer Cause and Prevention Research	93.393	Ohio State University	5R01CA266402-03	220,408	-
Cancer Cause and Prevention Research	93.393	Physical Sciences, Inc.	4R44CA224853-02	2,765	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA167552-12	(1,478)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA167552-13	10,839	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA176726-11	1,520,267	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	2U01CA209414-08	72,714	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	3R01CA255035-03S1	2,422	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5P01CA228696-04	5,819	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5P30CA006516-59	5,031	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R01CA194393-07	15,543	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R01CA227237-05	5,774	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R01CA240299-04	5,198	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5R37CA225655-08	5,403	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA167552-12	14,437	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA167552-13	32,971	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA176726-10	84,707	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA209414-06	(2,055)	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA209414-08	254,268	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA253912-04	211,084	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA261339-03	10,242	-
Cancer Cause and Prevention Research	93.393	President and Fellows of Harvard College	5U01CA261961-03	286,821	-
Cancer Cause and Prevention Research	93.393	Regents of the University of California, Irvine	5R37CA252081-04	20,560	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	1R01CA279746-01A1	111,171	-
Cancer Cause and Prevention Research	93.393	Regents of the University of Michigan	5R01CA269367-03	61,868	-
Cancer Cause and Prevention Research	93.393	Research Foundation of the City University of New York	5U24CA180996-11	46,667	-
Cancer Cause and Prevention Research	93.393	Seattle Institute for Biomedical and Clinical Research	5R01CA239208-05	356,535	26,895
Cancer Cause and Prevention Research	93.393	Stratagen Bio	1R43CA281444-01	42,710	-
Cancer Cause and Prevention Research	93.393	The Broad Institute, Inc.	5R01CA231264-04	(1,355)	-
Cancer Cause and Prevention Research	93.393	Trustees of Boston University	1R01CA286064-01A1	6,592	-
Cancer Cause and Prevention Research	93.393	Trustees of Columbia University in the City of New York (The)	5R01CA240080-06	151,563	-
Cancer Cause and Prevention Research	93.393	Trustees of Columbia University in the City of New York (The)	5U01CA265739-03	32,248	-
Cancer Cause and Prevention Research	93.393	Trustees of Indiana University	R01CA157823	16,233	-
Cancer Cause and Prevention Research	93.393	University of Alabama, Birmingham	5R01CA229197-07	24,452	-
Cancer Cause and Prevention Research	93.393	University of Colorado at Denver	3U01CA261614-04S1	46,225	-
Cancer Cause and Prevention Research	93.393	University of Colorado at Denver	5U01CA261614-04	122,600	-
Cancer Cause and Prevention Research	93.393	University of Florida Board of Trustees	5R01CA240341-04	36,401	-
Cancer Cause and Prevention Research	93.393	University of Massachusetts Amherst	5R01CA207369-05	8,380	-
Cancer Cause and Prevention Research	93.393	University of North Carolina at Chapel Hill, The	1R01CA227122-04S1	(2,404)	-
Cancer Cause and Prevention Research	93.393	University of Texas Southwestern Medical Center	5R01CA233794-05	230,306	-
Cancer Cause and Prevention Research	93.393	University of Utah	1R01CA276825-01A1	138,368	-
Cancer Cause and Prevention Research	93.393	University of Washington	5R01CA258590-03	32,539	-
Cancer Cause and Prevention Research	93.393	University of Washington - Seattle	5U01CA194393-08	62,057	-
Cancer Cause and Prevention Research	93.393	Viditics Inc.	1R43CA281547-01A1	60,146	-
Cancer Cause and Prevention Research	93.393	Washington University, The	5R01CA248526-04	(17)	-
Cancer Cause and Prevention Research	93.393	Washington University, The	5R37CA246175-04	63,873	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	2P50CA101942-18	142,630	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	2P50CA101942-19	432,547	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	5P50CA101942-18	26,000	-
Cancer Centers Support Grants	93.397	Beth Israel Deaconess Medical Center	5P50CA101942-19	132,062	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	2P50CA165962-08	146,634	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	5P50CA165962-08	(3,743)	-
Cancer Centers Support Grants	93.397	Brigham and Women's Hospital, Inc.	5P50CA165962-10	276,984	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute	5P50CA127003-15	34,851	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA240243-04	117,872	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA265826-01A1	124,072	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA265826-02	164,586	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA272390-01	160,408	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1P50CA272390-01A1	239,752	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1U54CA274516-01A1	44,642	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	1U54CA274516-01A1	156,282	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P30CA006516-57	9,017	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P30CA006516-58	53,176	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P50CA127003-12	8,577	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P50CA127003-14	3,100	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P50CA168504-07	79,190	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	2P50CA168504-7	12,933	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	3P30CA006516-59S1	317,481	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	3P30CA006516-59S2	121,614	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P30CA006516-58	205,304	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P30CA006516-59	2,330,501	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA100707-19	(8,034)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA127003-14	(4,405)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA127003-14	(3,417)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA127003-15	302,657	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA168504-07	10,782	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA168504-08	177	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA168504-09	(3)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA168504-10	96,300	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA206963-06	(127)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA240243-03	90,349	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA240243-04	382,873	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5P50CA265826-02	761,569	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5U54CA156732-12	(1,332)	-
Cancer Centers Support Grants	93.397	Dana-Farber Cancer Institute, Inc.	5U54CA156732-13	104,523	-
Cancer Centers Support Grants	93.397	Direct		2,384,008	1,356,973
Cancer Centers Support Grants	93.397	Massachusetts Institute of Technology	1U54CA28311401	227,479	-
Cancer Centers Support Grants	93.397	President and Fellows of Harvard College	5U54CA225088-05	(4,733)	-
Cancer Centers Support Grants	93.397	Regents of the University of California, San Francisco	3U54CA254571-04S1	55,631	-
Cancer Centers Support Grants	93.397	Regents of the University of California, San Francisco	5U54CA254571-04	43,899	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	1P50CA272170-01	42,532	-
Cancer Centers Support Grants	93.397	Regents of the University of Michigan	1P50CA272170-02	465,889	-
Cancer Centers Support Grants	93.397	The Broad Institute, Inc.	2P50CA127003-11A1	(940)	-
Cancer Centers Support Grants	93.397	The Broad Institute, Inc.	P01CA229092	9,616	-
Cancer Centers Support Grants	93.397	Washington University, The	3P50CA171963-10S1	116,277	-
Cancer Control	93.399	Alliance NCTN Foundation	5UG1CA189823-10	15,751	-
Cancer Control	93.399	Dana-Farber Cancer Institute, Inc.	5UG1CA233180-04	12,932	-
Cancer Control	93.399	Dana-Farber Cancer Institute, Inc.	5UG1CA233180-06	18,980	-
Cancer Control	93.399	Direct		233,370	86,731
Cancer Control	93.399	ECOG-ACRIN Medical Research Foundation, Inc.	5UG1CA189828-09	18,161	-
Cancer Control	93.399	ECOG-ACRIN Medical Research Foundation, Inc.	5UG1CA189828-10	61,791	-
Cancer Control	93.399	Medical University of South Carolina	7R01CA232888-05	11,982	-
Cancer Control	93.399	The Broad Institute, Inc.	U54CA272688	3,021	-
Cancer Detection and Diagnosis Research	93.394	AIQ Solutions, Inc.	2R44CA257253-02	97,318	-
Cancer Detection and Diagnosis Research	93.394	Baylor College of Medicine	2U01CA230997-06	114,816	-
Cancer Detection and Diagnosis Research	93.394	Board of Trustees of the Leland Stanford Junior University, The	5U01CA242879-03	(5,589)	-
Cancer Detection and Diagnosis Research	93.394	Brigham and Women's Hospital, Inc.	5R01CA235589-05	120,270	-
Cancer Detection and Diagnosis Research	93.394	Cedar-Sinai Medical Center	5R01CA201709-06	22,557	-
Cancer Detection and Diagnosis Research	93.394	Cedars-Sinai Health System	5R01CA260955-03	25,316	-
Cancer Detection and Diagnosis Research	93.394	Children's Hospital of Philadelphia (The)	5R01CA258524-04	68,166	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	1R44CA250771-01	149,826	-
Cancer Detection and Diagnosis Research	93.394	Collagen Medical, LLC	1R44CA275590-01A1	134,394	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	1R01CA266424-03	364,590	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	2U01CA210171	8,556	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	2U01CA210171-06	31,668	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	3U01CA210171-05S1	7	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA188446-10	40,309	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA214385-05	28,787	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA240592-05	18,567	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	5R01CA255184-02	32,515	-
Cancer Detection and Diagnosis Research	93.394	Dana-Farber Cancer Institute, Inc.	R01CA240582-04	58,991	-
Cancer Detection and Diagnosis Research	93.394	Direct		20,852,117	3,423,850
Cancer Detection and Diagnosis Research	93.394	Duke University	2R01CA182076-06A1	99,342	-
Cancer Detection and Diagnosis Research	93.394	ECOG-ACRIN Medical Research Foundation, Inc.	5U24CA196172-10	12,265	-
Cancer Detection and Diagnosis Research	93.394	Emory University	5R21CA256280-02	912	-
Cancer Detection and Diagnosis Research	93.394	Imagine Scientific, Inc.	R44CA268468	127,708	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5R01CA265742-04	222,249	-
Cancer Detection and Diagnosis Research	93.394	Massachusetts General Hospital	5U01CA233360-05	(60)	-
Cancer Detection and Diagnosis Research	93.394	Memorial Sloan Kettering Institute	5R37CA262662-02	28,874	-
Cancer Detection and Diagnosis Research	93.394	Navigation Sciences, Inc.	R41CA261420	21,742	-
Cancer Detection and Diagnosis Research	93.394	Ohio State University	5R01CA237133-05	130,519	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	1U24CA264024-03	111,549	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	1U24CA264029-01	2,713	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	1U24CA270823-01	59,980	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	1U24CA271075-01	28,196	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	5U24CA264024	57,687	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U01CA271492	3,219	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	U24CA271075	28,120	-
Cancer Detection and Diagnosis Research	93.394	The Broad Institute, Inc.	WU-23-0056	72,365	15,947
Cancer Detection and Diagnosis Research	93.394	Trustees of Boston University	5R01CA232056-05	138,285	-
Cancer Detection and Diagnosis Research	93.394	University of California at Davis	1U01CA269191-01	19,753	-
Cancer Detection and Diagnosis Research	93.394	University of Florida Board of Trustees	1R01CA277817-01A1	164,464	-
Cancer Detection and Diagnosis Research	93.394	University of Kentucky	5R21CA267152-02	21,358	-
Cancer Detection and Diagnosis Research	93.394	University of Texas - Southwestern Medical Center	1U01CA288375-01	79,439	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern Medical Center	1R37CA242070-01A1	(848)	-
Cancer Detection and Diagnosis Research	93.394	University of Texas Southwestern Medical Center	5U24CA086368-23	69,976	-
Cancer Detection and Diagnosis Research	93.394	University of Texas, MD Anderson Cancer Center	1R01CA276178-01A1	20,301	-
Cancer Detection and Diagnosis Research	93.394	University of Texas, MD Anderson Cancer Center	5U01CA200462-07	64,124	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5R01CA251803-03	71,966	-
Cancer Detection and Diagnosis Research	93.394	University of Washington	5U24CA264044-03	43,133	-
Cancer Detection and Diagnosis Research	93.394	Washington University, The	5U24CA196171-10	110,735	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Detection and Diagnosis Research	93.394	Yale University	5U01CA233364-05	22,588	-
Cancer Research Manpower	93.398	Beth Israel Deaconess Medical Center	2R25CA168544-11A1	15,409	-
Cancer Research Manpower	93.398	Direct		353,766	-
Cancer Research Manpower	93.398	Rutgers, the State University of New Jersey	4R00CA267557-03	33,111	-
Cancer Treatment Research	93.395	Alliance Data Innovations Lab, LLC	U10CA180821	396	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	1R01CA276107-01A1	55,603	-
Cancer Treatment Research	93.395	Beth Israel Deaconess Medical Center	5U01CA236489-04	13,529	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	2P01CA163205-11	11,350	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5P01CA236749-05	391,009	-
Cancer Treatment Research	93.395	Brigham and Women's Hospital, Inc.	5R01CA272637-03	303,722	-
Cancer Treatment Research	93.395	Brown University	7R01CA237063-06	34,313	-
Cancer Treatment Research	93.395	Curer, Inc	1R42CA268629-01A1	193,028	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1P01CA229092-02	(7)	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R01CA267726-01	15,279	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA263130	(85)	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA277316-02	45,071	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R21CA288234-01	5,362	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1R37CA279737-01A1	30,069	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	1UG1CA242609-01	4,598	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	2P01CA155258-11	128,628	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	2R01CA205406-06	22,817	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	4UM1CA186709-08	218,840	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA240804-05	82,846	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA258688-03	66,201	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R01CA272982-02	14,320	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	5R37CA269990-02	39,541	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	R01CA244936	2,920	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	R01CA272657	55,686	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	U01CA260369	7,451	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	U10 CA180886	16,308	-
Cancer Treatment Research	93.395	Dana-Farber Cancer Institute, Inc.	U10CA180886-10	8,156	-
Cancer Treatment Research	93.395	Direct		47,307,050	17,160,362
Cancer Treatment Research	93.395	Duo Oncology	1R41CA285174-01	81,730	-
Cancer Treatment Research	93.395	East Tennessee State University	5R01CA272760-02	57,386	-
Cancer Treatment Research	93.395	ECOG-ACRIN Medical Research Foundation, Inc.	5U10CA180820-11	187,511	-
Cancer Treatment Research	93.395	H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc.	5R01CA266803-02	267,477	-
Cancer Treatment Research	93.395	Health Research, Inc. -Roswell Park Cancer Institute Division	5R01CA267690-02	53,756	-
Cancer Treatment Research	93.395	Joan & Sanford I. Weill Medical College of Cornell University	1R01CA270245-03	174,198	-
Cancer Treatment Research	93.395	Massachusetts Institute of Technology	5R01CA247632-02	18,697	-
Cancer Treatment Research	93.395	Mayo Clinic	5R37CA276851-02	61,370	-
Cancer Treatment Research	93.395	Mayo Clinic	5U19CA264362-03	104,561	-
Cancer Treatment Research	93.395	Northeastern University	5R01CA226855-03	142,884	-
Cancer Treatment Research	93.395	NRG Oncology	5U10CA180868-11	18,666	-
Cancer Treatment Research	93.395	President and Fellows of Harvard College	5R01CA263776-03	201,033	-
Cancer Treatment Research	93.395	Public Health Institute	U10CA180886	3,464	-
Cancer Treatment Research	93.395	Stanford University Medical Center	5R01CA177684-09	91,667	-
Cancer Treatment Research	93.395	Stratagen Bio	1R43CA261401-1A1	5,646	-
Cancer Treatment Research	93.395	Ternalys Therapeutics, Inc.	R41CA278074	43,469	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	1P01CA229092	11,271	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	1R21CA267607-01	(93)	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	5P01CA206978	744	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	5U10CA180888-10	1,796	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	P01CA206978	48,572	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	R01CA155010	6,036	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	R21CA267807	12,949	-
Cancer Treatment Research	93.395	The Broad Institute, Inc.	UG1CA189955	5,352	-
Cancer Treatment Research	93.395	Transcode Therapeutics, Inc	1R44CA257093-01A1	217,043	-
Cancer Treatment Research	93.395	Trustees of Boston University	5R01CA227433-05	31,245	-
Cancer Treatment Research	93.395	Trustees of Boston University	5R01CA232708-05	229,911	-
Cancer Treatment Research	93.395	Trustees of Boston University	5U01CA265713-03	178,758	-
Cancer Treatment Research	93.395	Trustees of the University of Pennsylvania	1R01CA278682-01	54,521	-
Cancer Treatment Research	93.395	University of Arizona	5UG1CA242596-05	33,304	-
Cancer Treatment Research	93.395	University of Maryland, Baltimore	5R01CA260340-04	242,964	-
Cancer Treatment Research	93.395	University of Texas, MD Anderson Cancer Center	5R01CA260872-04	234,853	-
Cancer Treatment Research	93.395	Yale University	1R01CA278212-01A1	220,141	-
Cancer Treatment Research	93.395	Yale University	5R37CA279622-02	14,438	-
Cancer Treatment Research	93.395	Yale University	7P01CA240239-05	381,714	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cardiovascular Diseases Research	93.837	Africa Health Research Institute (AHRI)	5R01HL144848-04	240,531	-
Cardiovascular Diseases Research	93.837	Albany Medical College	5R01HL153019-04	60,161	-
Cardiovascular Diseases Research	93.837	Augusta University	5R01HL157665-03	63,719	-
Cardiovascular Diseases Research	93.837	Baylor College of Medicine	5R01HL148050-05	157,675	147,790
Cardiovascular Diseases Research	93.837	Beckman Research Institute of the City of Hope	5R01HL150069-05	17,527	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	2R01HL133870-06A1	2,696	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL129185-07	24,624	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL157991-04	55,905	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL158077-03	23,973	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5R01HL161697-02	18,381	-
Cardiovascular Diseases Research	93.837	Board of Regents of the University of Oklahoma Health Sciences Center	5R01HL161008-03	249,439	-
Cardiovascular Diseases Research	93.837	Board of Regents of the University of Wisconsin System, The	1R01HL163987-01	61,993	-
Cardiovascular Diseases Research	93.837	Boston Medical Center	1R56HL157367-01A1	35,782	-
Cardiovascular Diseases Research	93.837	Boston University School of Medicine	5R01HL127564-08	181,455	-
Cardiovascular Diseases Research	93.837	Boston VA Research Institute Inc	7R01HL126896-07	130,118	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL157457-01A1	133,051	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R01HL164409-01	75,031	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	1R56HL157457-01	456	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	5R01HL150401-04	(6,267)	-
Cardiovascular Diseases Research	93.837	Brigham and Women's Hospital, Inc.	5R01HL166487-02	25,286	-
Cardiovascular Diseases Research	93.837	Cedar-Sinai Medical Center	5R01HL151828-03	19,859	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	1R01HL165840-02	735,923	-
Cardiovascular Diseases Research	93.837	Cedars-Sinai Health System	5R35HL161195-03	233,466	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL156362-04	71,138	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL158097-04	49,237	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL162367-03	167,181	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	5U01HL098147-16	144,805	-
Cardiovascular Diseases Research	93.837	Children's Hospital Corporation dba Boston Children's Hospital	OT3HL147741-01	114,111	-
Cardiovascular Diseases Research	93.837	Columbia University Irving Medical Center (CUIMC)	5R01HL157216-04	45,532	-
Cardiovascular Diseases Research	93.837	Direct		59,672,894	11,114,869
Cardiovascular Diseases Research	93.837	Duke University	1R21HL157856-02	38,510	-
Cardiovascular Diseases Research	93.837	Duke University	5R01HL146145-04	11,888	-
Cardiovascular Diseases Research	93.837	Duke University	5U10HL084904-12	5,308	-
Cardiovascular Diseases Research	93.837	Dynocardia, Inc.	5R44HL158374-02	23,283	-
Cardiovascular Diseases Research	93.837	Emory University	5R01HL168894-02	104,084	-
Cardiovascular Diseases Research	93.837	George Washington University	5R01HL140977-04	20,405	-
Cardiovascular Diseases Research	93.837	Harvard Pilgrim Health Care	5R01HL150119-04	154,717	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	2P01HL131478-06A1	532,565	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	3U01HL088942-16S1	254,779	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5U01HL088942-16	3,568	-
Cardiovascular Diseases Research	93.837	Icahn School of Medicine at Mount Sinai	5U01HL088942-17	53,055	-
Cardiovascular Diseases Research	93.837	ICON Clinical Research, LLC	1U01HL117006-01A1	13,601	-
Cardiovascular Diseases Research	93.837	Iowa State University	1R01HL171098-01	43,032	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5R01HL159987-03	454,566	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161858-03	315,886	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL161864-03	155,279	-
Cardiovascular Diseases Research	93.837	LiquiGlide Inc.	1R43HL162196-01A1	117,702	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL149516-01A1	16,247	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1R01HL149647-03	20,865	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1U24HL164284-01	41,250	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	1UG3HL164285-01	3,307	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL140498-05	(37,440)	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL146267-04	(19,231)	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151293-05	67,497	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL151643-05	90,928	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL163234-02	62,956	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL123336-04	5,878	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL123336-06	42,299	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL160278-04	257,523	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital - Internal	5R01HL155301-03	(1,145)	-
Cardiovascular Diseases Research	93.837	Massachusetts Institute of Technology	5R01HL153857-05	296,605	-
Cardiovascular Diseases Research	93.837	Massachusetts Institute of Technology	5R01HL161069-03	96,516	-
Cardiovascular Diseases Research	93.837	Mayo Clinic Arizona	5R01HL165176-03	202,767	-
Cardiovascular Diseases Research	93.837	Mercator MedSystems, Inc.	R41HL160434	(4,215)	-
Cardiovascular Diseases Research	93.837	Minnesota HealthSolutions	1R43HL160298-01	(30,309)	-
Cardiovascular Diseases Research	93.837	Mount Sinai School of Medicine	5U01HL088942-17	203,232	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL157220-03	16,878	-
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL161090-02	393,575	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cardiovascular Diseases Research	93.837	New York University Grossman School of Medicine	5R01HL165208-02	8,213	-
Cardiovascular Diseases Research	93.837	Northwestern University	5U54HL160273-04	80,262	-
Cardiovascular Diseases Research	93.837	Northwestern University	5U54HL160273-04	87,532	-
Cardiovascular Diseases Research	93.837	Ohio State University	1R01HL168892-01	204,155	-
Cardiovascular Diseases Research	93.837	Oklahoma Medical Research Foundation	5R01HL167656-02	41,839	-
Cardiovascular Diseases Research	93.837	Physical Sciences, Inc.	1R43HL156359-01A1	10,234	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	1R03HL150412-01A1	(91)	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	1UG3HL170034-01	3,852	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5R01HL035464-33	90,522	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5R01HL126896-06	635	-
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5U01HL145386-06	1,373,591	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R01HL152957-04	38,084	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R01HL164337-02	53,219	-
Cardiovascular Diseases Research	93.837	Regents of the University of California, San Francisco	5R33HL141047-05	6,348	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	4UG3HL159134-02	5,567	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL146619-04	22,649	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R01HL155834-04	85,477	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5R35HL155318-05	263,084	-
Cardiovascular Diseases Research	93.837	Regents of the University of Michigan	5UH3HL159134-03	426	-
Cardiovascular Diseases Research	93.837	Research Triangle Institute International	5R01HL149352-04	98,611	-
Cardiovascular Diseases Research	93.837	Rutgers, the State University of New Jersey	5R01HL160326-04	47,225	-
Cardiovascular Diseases Research	93.837	Seattle Children's Hospital	5R01HL157166-03	13,795	-
Cardiovascular Diseases Research	93.837	The Administrators of the Tulane Educational Fund d/b/a Tulane University	5R21HL161718-02	15,456	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1OT3HL147154-13	(1,498)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL142711-01A1	6,293	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL156991-01	(11,754)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL157717-01A1	59,016	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL159176-01	7,714	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL164811-01	43,270	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	1R01HL170600-01	14,424	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	237407	26,727	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	240336	23,461	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	4500004030	10,960	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL143295-04	653,660	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL148050-04	(6,904)	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL151152	310	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL156991-03	13,411	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	5R01HL157717-03	121,165	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	62931232-207498	43,270	-
Cardiovascular Diseases Research	93.837	The Broad Institute, Inc.	R01HL143295	10,728	-
Cardiovascular Diseases Research	93.837	The Washington University	5R01HL143421-04	3,266	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL098028-10	135,992	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL131029-06	93,372	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL156975-03	32,237	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL159620-03	181,397	-
Cardiovascular Diseases Research	93.837	Trustees of Boston University	5R01HL166407-02	571,022	-
Cardiovascular Diseases Research	93.837	Trustees of Columbia University in the City of New York (The)	5R01HL168382-02	66,432	-
Cardiovascular Diseases Research	93.837	Trustees of the University of Pennsylvania	1R01HL168841-01A1	942	-
Cardiovascular Diseases Research	93.837	Trustees of the University of Pennsylvania	5R01HL148272-05	113,243	-
Cardiovascular Diseases Research	93.837	Tufts Medical Center, Inc.	R01HL149999	23,701	-
Cardiovascular Diseases Research	93.837	University of California at Davis	1R01HL157712-02	96,200	-
Cardiovascular Diseases Research	93.837	University of California at Davis	7R01HL150119-05	34,017	-
Cardiovascular Diseases Research	93.837	University of Michigan Medical School	5R01HL146619-05	46,855	-
Cardiovascular Diseases Research	93.837	University of North Carolina at Chapel Hill, The	5R01HL163262-02	143,994	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	2R01HL133040-06A1	23,105	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01HL142932-05	(668)	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01HL151386-03	6,319	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3HL153847-03	1,311	-
Cardiovascular Diseases Research	93.837	University of Pittsburgh Of the Commonwealth System of Higher Education	5UH3HL153847-04	(2,834)	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R01HL153390-04	169,666	-
Cardiovascular Diseases Research	93.837	University of Rochester	5R01HL160795-02	61,030	-
Cardiovascular Diseases Research	93.837	University of Texas Southwestern Medical Center	2R01HL135008-06	39,744	-
Cardiovascular Diseases Research	93.837	University of Texas Southwestern Medical Center	7R01HL148218-04	71,957	-
Cardiovascular Diseases Research	93.837	University of Utah	1R01HL164715-01A1	28,501	-
Cardiovascular Diseases Research	93.837	University of Washington	1R01HL167645-01A1	52,931	-
Cardiovascular Diseases Research	93.837	University of Washington - Seattle	5R01HL158765-03	385,623	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL159487-04	56,579	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL161516-03	22,307	-
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL164526-02	75,087	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Cardiovascular Diseases Research	93.837	Vanderbilt University Medical Center	5R01HL164675-03	164,950	-
Cardiovascular Diseases Research	93.837	Washington University, The	5R01HL156991-04	141,589	-
Cardiovascular Diseases Research	93.837	Washington University, The	5R21HL167126-02	14,372	-
Cardiovascular Diseases Research	93.837	Washington University, The	5UG3HL162970-02	48,624	-
Cardiovascular Diseases Research	93.837	Yale University	5R01HL148819-03	(67,682)	-
Child Health and Human Development Extramural Research	93.865	Ann & Robert H. Lurie Children's Hospital of Chicago	1R01HD109260-01A1	171,937	-
Child Health and Human Development Extramural Research	93.865	Auburn University	5R21HD101964-03	45,275	-
Child Health and Human Development Extramural Research	93.865	AutoLVF	4R44HD105529-02	168,856	-
Child Health and Human Development Extramural Research	93.865	Avera McKennan	5U54HD113179-02	176,614	-
Child Health and Human Development Extramural Research	93.865	Barrett Technology	1R43HD105546-01	(71,484)	-
Child Health and Human Development Extramural Research	93.865	Barrett Technology	1R44HD109106-01A1	27,609	-
Child Health and Human Development Extramural Research	93.865	Beth Israel Deaconess Medical Center	5R01HD108047-03	30,445	-
Child Health and Human Development Extramural Research	93.865	Bionic Skins LLC	1R44HD110327-01	341,208	-
Child Health and Human Development Extramural Research	93.865	BioSensics LLC	2R44HD084035-04	364,230	-
Child Health and Human Development Extramural Research	93.865	Boston College	5R01HD098421-05	225,033	-
Child Health and Human Development Extramural Research	93.865	Boston University School of Medicine	5R01HD086742-08	38,824	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	3R01HD093724-05	27,133	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD093724-05	33,216	-
Child Health and Human Development Extramural Research	93.865	Brigham and Women's Hospital, Inc.	5R01HD107772-03	44,266	-
Child Health and Human Development Extramural Research	93.865	Brown University	5P2CHD101895-03	15,848	-
Child Health and Human Development Extramural Research	93.865	Charles River Analytics, Inc.	1R43HD106834-01	(5,284)	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	1R03HD104891-02	4,419	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	1R21HD107515-01A1	551	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5R01HD100009-05	37,138	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5R21HD106553-02	22,014	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Los Angeles	5R21HD107983-02	(373)	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Los Angeles	5R33HD107983-04	17,602	-
Child Health and Human Development Extramural Research	93.865	Direct		41,736,919	10,549,482
Child Health and Human Development Extramural Research	93.865	Emma Pendleton Bradley Hospital	5R01HD103665-03	34,183	-
Child Health and Human Development Extramural Research	93.865	Emory University	5R01HD110480-02	47,435	-
Child Health and Human Development Extramural Research	93.865	Ferway Community Health Center	UM2HD111102	14,079	-
Child Health and Human Development Extramural Research	93.865	Florida State University	2P50HD052120-16	226,460	-
Child Health and Human Development Extramural Research	93.865	Florida State University	5UM2HD111102-02	625,762	-
Child Health and Human Development Extramural Research	93.865	Fred Hutchinson Cancer Center	5R21HD107577-02	90,335	-
Child Health and Human Development Extramural Research	93.865	George Washington University	5U24HD036801-27	153,325	-
Child Health and Human Development Extramural Research	93.865	Harvard Pilgrim Health Care	5R01HD094150-05	48,737	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD091067-05	32,226	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD105266-03	173,203	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	5R01HD107064-03	350,176	-
Child Health and Human Development Extramural Research	93.865	Massachusetts General Hospital	R33HD103099-05	4,444	-
Child Health and Human Development Extramural Research	93.865	Mayo Clinic Jacksonville	5R01HD106096-05	116,257	-
Child Health and Human Development Extramural Research	93.865	Mbarara University of Science and Technology	1R01HD111692-01	44,129	-
Child Health and Human Development Extramural Research	93.865	Mbarara University of Science and Technology	4R33HD107985-04	29,766	-
Child Health and Human Development Extramural Research	93.865	MGH Institute of Health Professions	5R01HD106122-03	130,121	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD094842-05	143,958	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD096033-05	310,252	-
Child Health and Human Development Extramural Research	93.865	Michigan State University	5R01HD107019-02	65,651	-
Child Health and Human Development Extramural Research	93.865	Northeastern University	5R37HD087089-08	59,208	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University (OHSU)	5U54HD100982-04	121,846	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1P01HD107670-03	6,069	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	1R01HD095766	5,601	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	3P01HD103133-04	12,670	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD103133-04	39,719	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD103133-05	17,932	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5P01HD107670-03	32,717	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD093761-05	16,014	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD094725-05	362,377	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD096033-05	8,331	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD097778-05	200,891	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD098232-04	26,531	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD101351-04	130,608	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R01HD102342-04	66,615	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	5R21HD103052-02	(1,577)	-
Child Health and Human Development Extramural Research	93.865	Regents of the University of California, San Francisco	R01HD098978	55,372	-
Child Health and Human Development Extramural Research	93.865	Regents of the University of Michigan	1R01HD111242-02	448,500	-
Child Health and Human Development Extramural Research	93.865	Research Foundation for the State University Of New York (SUNY), Albany	5R01HD097331-05	7,494	-
Child Health and Human Development Extramural Research	93.865	Rush University Medical Center	5R01HD107348-03	15,094	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	5R33HD099748-05	179,052	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Child Health and Human Development Extramural Research	93.865	Stellenbosch University	5R33HD103093-04	28,278	-
Child Health and Human Development Extramural Research	93.865	Stellenbosch University	R61HD103093	(1,177)	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	5R01HD094862-05	22,545	-
Child Health and Human Development Extramural Research	93.865	The Broad Institute, Inc.	6(GG014633-04)	6,168	-
Child Health and Human Development Extramural Research	93.865	Trustees of Columbia University in the City of New York (The)	5R01HD094793-05	70,712	-
Child Health and Human Development Extramural Research	93.865	Trustees of Indiana University	1R01HD110994-01A1	26,601	-
Child Health and Human Development Extramural Research	93.865	Tufts Medical Center, Inc.	5R01HD109206-02	5,598	-
Child Health and Human Development Extramural Research	93.865	University of Cape Town	5R21HD110305-02	19,809	-
Child Health and Human Development Extramural Research	93.865	University of Cincinnati	5R01HD105818-03	72,187	-
Child Health and Human Development Extramural Research	93.865	University of Colorado at Denver	5R01HD108133-03	287,002	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts at Lowell	5R00HD093814-05	6,740	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts Chan Medical School	5R01HD099543-06	213,253	-
Child Health and Human Development Extramural Research	93.865	University of Massachusetts Medical School	5R01HD104772-02	(2,057)	-
Child Health and Human Development Extramural Research	93.865	University of North Carolina at Chapel Hill, The	5R01HD092374-05	(80)	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	AWD00003188 (417136-6)	(280)	-
Child Health and Human Development Extramural Research	93.865	University of Pittsburgh Of the Commonwealth System of Higher Education	U24HD036801-26	201,966	-
Child Health and Human Development Extramural Research	93.865	Virginia Commonwealth University	1R01HD113711-01	137,652	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	7R01HD097081-04	329,806	-
Child Health and Human Development Extramural Research	93.865	Worcester Polytechnic Institute	1R15HD104169-01A1	22,499	-
COVID-19 Aging Research	93.866	COVID-19 Direct		1,687,222	343,624
COVID-19 Aging Research	93.866	COVID-19 Johns Hopkins Hospital	3R01AG050515-04S1	34	-
COVID-19 Aging Research	93.866	COVID-19 Johns Hopkins University	5R01AG050515-04	(103)	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	3P01AG032952-12S1	4,597	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	3P01AG032952-12S3	12,719	-
COVID-19 Aging Research	93.866	COVID-19 President and Fellows of Harvard College	5R01AG075507-03	6,948	-
COVID-19 Aging Research	93.866	COVID-19 Regents of the University of California, San Francisco	5R24AG065175-04	32,269	-
COVID-19 Aging Research	93.866	COVID-19 University of Texas Health Science Center at San Antonio	1R56AG074467-01	2,909	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Benaroya Research Institute at Virginia Mason	3UM1AI109565-08S1	(34)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Benaroya Research Institute at Virginia Mason	3UM1AI109565-10S1	27,772	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	1P01AI165072-01	2,367,550	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Brigham and Women's Hospital, Inc.	1R01AI176287-01A1	608,187	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Children's Hospital Corporation dba Boston Children's Hospital	R01AI174938-02	411,293	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Direct		8,802,347	3,528,306
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Emory University	3U19AI110483-08S4	747,676	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1AI068614-17S5	300,926	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Center	3UM1AI068614-18S1	43,390	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Fred Hutchinson Cancer Research Center	3UM1AI068614-14S1	696,200	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U19AI167899-02	498,362	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5U19AI167899-03	199,877	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Regents of the University of California, Los Angeles, The	UM1AI068636	418,730	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Scripps Research Institute	5U19AI135995-07	72,461	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	3U19AI110818-08S2	(1,748)	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	3U19AI110818-09S1	199,764	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	3U19AI110818-10	616,805	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 The Broad Institute, Inc.	5R21AI162662	2,495	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Washington University, The	1P01AI168347-01	422,345	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Brigham and Women's Hospital, Inc.	5R01AR080659-02	529,494	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Direct		1,026,406	518,482
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 Northwestern University	5R01AR080089-03	268,913	-
COVID-19 Arthritis, Musculoskeletal and Skin Diseases Research	93.846	COVID-19 University of Alabama, Birmingham	5R01MD019235-02	28,393	-
COVID-19 Biomedical Research and Research Training	93.859	COVID-19 Direct		1,040,459	-
COVID-19 Blood Diseases and Resources Research	93.839	COVID-19 Direct		487,604	162,902
COVID-19 Cancer Cause and Prevention Research	93.393	COVID-19 Direct		89,637	(2,663)
COVID-19 Cancer Detection and Diagnosis Research	93.394	COVID-19 Beth Israel Deaconess Medical Center	3U01CA260476-02S1	292,341	-
COVID-19 Cancer Detection and Diagnosis Research	93.394	COVID-19 Direct		26,857	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Beth Israel Deaconess Medical Center	5R01HL160003-03	198,946	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Direct		1,712,727	289,696
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Duke University	10T2HL156812-01	265,894	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Icahn School of Medicine at Mount Sinai	5R01HL159433-03	193,600	-
COVID-19 Cardiovascular Diseases Research	93.837	COVID-19 Icahn School of Medicine at Mount Sinai	5U01HL088942-14	(1,788)	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Direct		285,963	29,877
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Michigan State University	3R01HD094842-04S1	49,877	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 President and Fellows of Harvard College	3R01HD094725-02S1	(80)	-
COVID-19 Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	COVID-19 Direct		6,817	-
COVID-19 Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	COVID-19 Direct		2,491,229	76,529
COVID-19 Drug Abuse and Addiction Research Programs	93.279	COVID-19 Direct		563,667	5,962
COVID-19 Environmental Health	93.113	COVID-19 Direct		221,261	24,015
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Direct		637,984	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Regents of the University of Minnesota	5R01NS124065-02	166,149	-
COVID-19 Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	COVID-19 Trustees of Boston University	1R21NS123412-01	48,266	-
COVID-19 Human Genome Research	93.172	COVID-19 Direct		233,078	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Beth Israel Deaconess Medical Center	1OT2HL156812-01	(7,987)	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Brigham and Women's Hospital, Inc.	1OT2HL161847-01	1,274,120	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Brigham and Women's Hospital, Inc.	OT2HL161847	62,376	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Brigham and Women's Hospital, Inc.	OT2HL161847-01	62,402	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Direct		32,275,771	19,605,340
COVID-19 Lung Diseases Research	93.838	COVID-19 Duke University	1OT2HL156812-01	50,000	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Duke University	1OT2HL156812-01	11,314	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Duke University	1OT2HL156812-01	26,218	-
COVID-19 Lung Diseases Research	93.838	COVID-19 MaineHealth	1OT2HL161847-01	90,763	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1OT2HL161841-01	1,726,527	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	1OT2HL161847-01	30,613	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Massachusetts General Hospital	5R01HL162373-02	22,340	-
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University Grossman School of Medicine	1OT2HL161847-01	7,440,379	5,019,182
COVID-19 Lung Diseases Research	93.838	COVID-19 New York University School of Medicine	OT2HL156812	31,783	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Research Triangle Institute International	1OT2HL156812-01	64,922	620
COVID-19 Lung Diseases Research	93.838	COVID-19 The Administrators of the Tulane Educational Fund d/b/a Tulane University	3R01HL165265-01S1	63,039	-
COVID-19 Lung Diseases Research	93.838	COVID-19 Trustees of Columbia University in the City of New York (The)	RTI 22-312-0217571-66178	10,781	-
COVID-19 Lung Diseases Research	93.838	COVID-19 University of Pittsburgh Of the Commonwealth System of Higher Education	1OT2HL156812-01	1,062,891	493,891
COVID-19 Lung Diseases Research	93.838	COVID-19 Vanderbilt University Medical Center	1OT2HL156812-01	42,629	-
COVID-19 Medical Library Assistance	93.879	COVID-19 Direct		198,655	-
COVID-19 Mental Health Research Grants	93.242	COVID-19 Direct		2,726,443	734,355
COVID-19 Minority Health and Health Disparities Research	93.307	COVID-19 Direct		484,752	107,096
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 Direct		(3,282)	-
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 New York University Grossman School of Medicine	3UL1TR001445-06A1S2	64,860	-
COVID-19 National Center for Advancing Translational Sciences	93.350	COVID-19 New York University School of Medicine	3UL1TR001445-05S3	(22,499)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Duke University	HHSO100201400002I	(962)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Global Genomic Medicine Collaborative (G2MC)	31342020 C	(386)	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Johns Hopkins University	75N93021C00045	142,305	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Leidos Biomedical Research Inc	23PPA-DM0019	908	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 Leidos Biomedical Research Inc	75N91019D00024	450,557	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 New York University Grossman School of Medicine	OA00001212	7,200	-
COVID-19 National Institutes of Health Contracts	93.RD1	COVID-19 University of Chicago	75N92020D00021	54,429	-
COVID-19 Nursing Research	93.361	COVID-19 Washington University, The	5U01NR020555-03	42,448	-
COVID-19 Oral Diseases and Disorders Research	93.121	COVID-19 The Administrators of the Tulane Educational Fund d/b/a Tulane University	7R01DE031928-03	2,149	-
COVID-19 Oral Diseases and Disorders Research	93.121	COVID-19 University of Mississippi Medical Center	1R01DE031928-01A1	(1,233)	-
COVID-19 Research Related to Deafness and Communication Disorders	93.173	COVID-19 Direct		127,901	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Direct		723,913	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Duke University	4U24MD016258-03	(434)	-
COVID-19 Trans-NIH Research Support	93.310	COVID-19 Mbarara University of Science and Technology	U54TW012043	158,404	-
COVID-19 Vision Research	93.867	COVID-19 Rector and Visitors of the University of Virginia, The	5R01EY026171-06	48,793	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	AdventHealth	3R01DK112700-02S1	(2)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Albert Einstein College of Medicine	5R01DK115577-05	(5)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	7UM1DK072493-17	231,865	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK121003-05	72,998	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5R01DK133520-03	83,764	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK128851-03	20,630	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Beth Israel Deaconess Medical Center	5R01DK124502-03	19,981	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK118736-04	40,201	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Board of Trustees of the University of Illinois, The	5R01DK125782-05	86,622	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	1R01DK126685-01A1	193,489	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	1R01DK137856-01	52,464	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brigham and Women's Hospital, Inc.	5R01DK125786-05	73,782	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Broad Institute, inc.	5RC2DK135492-02	45,423	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Brown University	5R01DK127585-04	186,558	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK094157-14	360,192	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	1R01DK126448-02	160,971	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	1R01DK135884-01	42,392	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2P30DK034854-36	43,013	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2P30DK034854-38	27,058	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	2R01DK048106-31	20,356	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-38	89,979	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5P30DK034854-39	244,197	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK097112-08	14,538	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5R01DK125273-04	113,873	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5RC2DK131963-02	455,935	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Funder Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University	U01DK114156-05	17,611	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Dana-Farber Cancer Institute, Inc.	5R01DK124384-05	37,003	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		58,480,435	11,747,866
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	EMMES Corporation	1UC4DK114839-01	1,503	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK094176-10	253,330	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK098246-10	230,407	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Georgia Institute of Technology	5R01DK133702-02	250,966	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Icahn School of Medicine at Mount Sinai	5U54DK083909-15	1,765	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joan & Sanford I. Weill Medical College of Cornell University	5R01DK132427-03	17,079	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Johns Hopkins University	5R01DK124782-04	152,514	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	2R01DK106193-05A1	101,870	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK106193-08	101,764	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK121995-05	(1,290)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5R01DK125677-03	(236)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK134996-02	55,603	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5U01DK135095-02	163,118	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	R01DK122808	114,040	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R01DK133364-01A1	7,088	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1R21DK137432-01	62,800	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	1UM1NS132358-01	331,381	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	2P30DK040561-26	37,350	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	3P30DK040561-27S1	44,989	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	3R01DK124710-04	333,481	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5P30DK135043-02	751	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK101495-08	38,091	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124145-05	34,753	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Massachusetts General Hospital	5R01DK124223-04	22,620	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	MONTREAL HEART INSTITUTE	5U01DK062432-23	228,909	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University	1R01DK133871-01A1	150,110	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	New York University Grossman School of Medicine	5R01DK108803-07	166,723	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	North Carolina Agricultural and Technical State University	5R01DK131753-02	266,690	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute for Research and Education	R01DK120387	201,494	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	3U01DK123759-03S1	57,079	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5U01DK134321-02	4,694	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	1U2CDK129670	12,750	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120560-04	93,241	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120870	4,964	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK120870-04	14,140	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5R01DK126698-03	79,635	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5U2CDK129670-04	712,425	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5UC2DK126023-05	289,992	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, Los Angeles, The	5RC2DK118640-02	17,171	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK124318-03	(10)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK128803-05	132,300	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of California, San Diego	5R01DK135868-02	68,167	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents of the University of Michigan	5R01DK106618-09	105,686	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Reveal Pharmaceuticals	5U01DK133090-02	1,784	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Reveal Pharmaceuticals	4R44DK134295-02	377,643	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Reveal Pharmaceuticals	R44DK134295-01	(11,268)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rush University Medical Center	5R01DK084195-10	8,400	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Spaulding Rehabilitation Hospital	1R01DK136243-01A1	30,410	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Sylvatica Biotech, Inc	4R44DK124053-02	136,625	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5400001498	(324)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01DK120485-01 / 233311	5,815	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01DK127171-01A1	6,068	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1R01DK131482-01A1	33,932	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1RC2DK135492	7,377	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1RC2DK135492-01	33,890	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	1U01DK137242	26,239	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5125107	14,259	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5125107/5400001977	43,291	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5400001498	5,789	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5400002072	(1,126)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5P30DK043351-34	7,297	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK129464-03	24,462	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK132299-03	1,829	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5R01DK132900-02	195,640	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5RC2DK114784-05	(23,445)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	5RC2DK135492-02	472,362	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance		Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number	Direct Agency/Pass-Through Program	Number	Expenditures	Expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	FP068366-01A/5400001805	47,358	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK099465	5,423	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK131482	2,328	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	R01DK132900	64,665	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	U01DK114907	21,824	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Broad Institute, Inc.	UM1DK105554	2,939	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Boston University	1R01DK132576-01	(1,232)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Columbia University in the City of New York (The)	5R01DK135671-02	60,232	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Dartmouth College	5P30DK117469-06	6,725	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of Indiana University	R01DK112293-05	(2,512)	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK103225-07	44,398	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Trustees of the University of Pennsylvania	5U01DK126654-04	84,485	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Chicago	5U54DK118612-05	162,223	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Cincinnati	5R01DK123330-04	85,012	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127180-04	74,201	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Massachusetts, Worcester	1R01DK127207-03	107,395	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK125831-04	100,847	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of North Carolina at Chapel Hill, The	5R01DK127365-04	168,361	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Utah	5U24DK126127-04	34,736	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Utah	5U54DK110858-08	12,992	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	5U24DK114886-07	59,213	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK127912-04	98,741	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5R01DK131129-03	229,223	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	5U01DK112271-05	33,068	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Yale University	1R01DK135650-02	36,095	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Barrett Technology	2R44EB027525-02	225,793	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Board of Trustees of the Leland Stanford Junior University, The	1R01EB033206-01	162,903	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	1R56EB034702-01	21,739	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB032378-03	112,662	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Brigham and Women's Hospital, Inc.	5R01EB033866-03	29,351	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cedars-Sinai Health System	5R01EB034586-03	225,283	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Children's Hospital Corporation dba Boston Children's Hospital	1R01EB034757-01A1	37,709	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Children's Hospital Corporation dba Boston Children's Hospital	5R01EB032708-03	39,338	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	1U54EB034654-01	55,771	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Cornell University	2R56EB029259-05	38,047	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		39,043,787	7,324,870
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Duke University	5R01EB028143-04	24,409	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Georgia Institute of Technology	5R01EB034359-02	254,599	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	1U01EB034228-02	23,449	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5R01EB031008-04	280,212	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5R01EB033321-03	28,605	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts General Hospital	5U54EB033650-03	114,564	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts Institute of Technology	1R01EB031813-04	377,991	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Massachusetts Institute of Technology	5P41EB015871-35	(10)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Pennsylvania State University	1R01EB030130-02	113,809	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Pennsylvania State University	7R21EB030257-02	288,247	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Regents of the University of California	5U01EB025162-05	(414)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Rensselaer Polytechnic Institute	R01EB031102	74,031	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	1R21EB029154-01	43,417	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	5R21EB030197-03	(178)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of Boston University	5UG3EB034710-02	165,471	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Trustees of the University of Pennsylvania	5U24EB028941-05	24,090	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Houston	R21EB030257-01	(354)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Maryland	1R21EB034835-01	152,454	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	University of Massachusetts Amherst	5R01EB027777-04	117,222	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	1R21EB034911-01A1	8,551	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Yale University	5R01EB031114-03	547,084	-
Drug Abuse and Addiction Research Programs	93.279	Achieve Life Sciences, Inc.	4R44DA054784-02	123,242	-
Drug Abuse and Addiction Research Programs	93.279	Avera McKennan	5R01DA050696-04	117,252	-
Drug Abuse and Addiction Research Programs	93.279	Beth Israel Deaconess Medical Center	1UG3NS130592-01A1	60,022	-
Drug Abuse and Addiction Research Programs	93.279	Board of Regents of the University of Nebraska for the University of Nebraska	5R01DA046852-05	19,731	-
Drug Abuse and Addiction Research Programs	93.279	Board of Regents of the University of Nebraska for the University of Nebraska	5R21DA055858-02	17,824	-
Drug Abuse and Addiction Research Programs	93.279	Board of Trustees of the University of Alabama for the University of Alabama	5R01DA044112-05	108,166	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	1R01DA058367-01	72,394	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	5UM1DA049412-04	43,689	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	1U19NS130617-02	477,988	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R01DA044167-05	17,105	-
Drug Abuse and Addiction Research Programs	93.279	Brigham and Women's Hospital, Inc.	5R21DA056799-02	7,078	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Drug Abuse and Addiction Research Programs	93.279	Brown University	1R34DA052836-02	5,839	-
Drug Abuse and Addiction Research Programs	93.279	Brown University	5R01DA047975-05	5,836	-
Drug Abuse and Addiction Research Programs	93.279	Charles River Analytics, Inc.	1R44DA059018-01	98,699	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Corporation dba Boston Children's Hospital	1R21DA058072-01	41,757	-
Drug Abuse and Addiction Research Programs	93.279	Children's Hospital Corporation dba Boston Children's Hospital	5U01DA055353-04	120,053	-
Drug Abuse and Addiction Research Programs	93.279	Clear Scientific	U01DA053054-03	25,483	-
Drug Abuse and Addiction Research Programs	93.279	Dimagi, Inc	2R44DA050218-02	195,359	-
Drug Abuse and Addiction Research Programs	93.279	Direct		25,062,908	5,534,551
Drug Abuse and Addiction Research Programs	93.279	ExQor Technologies Inc	2R44DA044050-02A1	220,326	-
Drug Abuse and Addiction Research Programs	93.279	Fenway Community Health Center	1DP2DA056107-04	14,266	-
Drug Abuse and Addiction Research Programs	93.279	George Mason University	5U2CDA050097-04	65,291	-
Drug Abuse and Addiction Research Programs	93.279	Harvard Pilgrim Health Care	1U01DA059472-01	352,278	-
Drug Abuse and Addiction Research Programs	93.279	Hennepin Healthcare Research Institute	5UG1DA040316-10	237,171	-
Drug Abuse and Addiction Research Programs	93.279	Joan & Sanford I. Weill Medical College of Cornell University	5P30DA040500-09	14,466	-
Drug Abuse and Addiction Research Programs	93.279	Massachusetts General Hospital	4R33DA047034-04	280,525	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R01DA045632-04	15,241	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R01DA058315-02	115,365	-
Drug Abuse and Addiction Research Programs	93.279	McLean Hospital Corporation	5R21DA056864-02	41,831	-
Drug Abuse and Addiction Research Programs	93.279	Mindlight, LLC	2R44DA050358-02A1	511,284	-
Drug Abuse and Addiction Research Programs	93.279	New York University Grossman School of Medicine	5UG3CA261067-04	12,881	-
Drug Abuse and Addiction Research Programs	93.279	Nobilis Therapeutics	R41DA055403	(27)	-
Drug Abuse and Addiction Research Programs	93.279	Northeastern University	5R01DA047130-05	(988)	-
Drug Abuse and Addiction Research Programs	93.279	Northeastern University	7U18DA052509-02	62	-
Drug Abuse and Addiction Research Programs	93.279	Partnership to End Addiction	R24DA051946	150,375	-
Drug Abuse and Addiction Research Programs	93.279	PASCALL Systems, Inc.	4R42DA053075-02	(18,765)	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	1R01DA054601-01A1	15,010	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	523D32028/36C24123C0030	18,950	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5P30 DA035772-07	45,851	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5R01AA030539-02	77,917	-
Drug Abuse and Addiction Research Programs	93.279	President and Fellows of Harvard College	5R01DA048533-04	4,695	-
Drug Abuse and Addiction Research Programs	93.279	Regents of the University of Minnesota	R01DA047287	7,638	-
Drug Abuse and Addiction Research Programs	93.279	Research Triangle Institute International	1UM1DA049394-01	2,643	-
Drug Abuse and Addiction Research Programs	93.279	Research Triangle Institute International	4UM1DA049394-02	256,647	-
Drug Abuse and Addiction Research Programs	93.279	The Broad Institute, Inc.	1U01DA053631-01	52,903	-
Drug Abuse and Addiction Research Programs	93.279	Trustees of Boston University	5R01NS121419-03	242,144	-
Drug Abuse and Addiction Research Programs	93.279	Trustees of Boston University	5R33DA045148-05	259,271	-
Drug Abuse and Addiction Research Programs	93.279	Tufts Medical Center, Inc.	R61DA060588	30,864	-
Drug Abuse and Addiction Research Programs	93.279	Tulane University School of Medicine	1R01NS114286	154	-
Drug Abuse and Addiction Research Programs	93.279	University of Cincinnati	3UG1DA013732-25	55,746	-
Drug Abuse and Addiction Research Programs	93.279	University of Colorado at Denver	7DP2DA051864-02	37,119	-
Drug Abuse and Addiction Research Programs	93.279	University of Florida Board of Trustees	5R01DA055568-02	224,726	-
Drug Abuse and Addiction Research Programs	93.279	University of Texas Medical Branch at Galveston	3R01DA040621-07S1	48,406	-
Drug Abuse and Addiction Research Programs	93.279	Vox Biomedical LLC	4R42DA049655-03	84,708	-
Drug Abuse and Addiction Research Programs	93.279	Wake Forest University Health Sciences	5R24DA055306-02	11,785	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	1R61DA059169-01	7,001	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA 015831-23	8,779	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA015831-22	665,445	-
Drug Abuse and Addiction Research Programs	93.279	Yale University	5UG1DA015831-23	1,281,688	-
Environmental Health	93.113	Arizona State University	5R01ES033999-02	32,381	-
Environmental Health	93.113	Beth Israel Deaconess Medical Center	5R01ES028688-05	141	-
Environmental Health	93.113	Brown University	R01ES034014-02	204,111	-
Environmental Health	93.113	Dana-Farber Cancer Institute, Inc.	5U01ES029520-02	328	-
Environmental Health	93.113	Dartmouth-Hitchcock Clinic	5R01ES034133-03	63,647	-
Environmental Health	93.113	Direct		3,785,813	1,359,743
Environmental Health	93.113	Drexel University	5R01ES032469-04	148,239	-
Environmental Health	93.113	President and Fellows of Harvard College	1R01ES034021-01A1	15,551	-
Environmental Health	93.113	President and Fellows of Harvard College	5P30ES000002-59	15,096	-
Environmental Health	93.113	President and Fellows of Harvard College	5P30ES000002-60	43,350	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES014370-15	3,665	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES022981-09	137,633	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES028033-05	32,491	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031657-04	12,176	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031657-05	217,133	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES031943-05	3,292	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES032470-04	44,543	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES033185-02	63,643	-
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES034038-02	59,680	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Environmental Health	93.113	President and Fellows of Harvard College	5R01ES035106-02	268,902	-
Environmental Health	93.113	President and Fellows of Harvard College	5R24ES028521-05	127,082	-
Environmental Health	93.113	President and Fellows of Harvard College	5U01ES029520-05	(555)	-
Environmental Health	93.113	Regents of the University of California, Irvine	5R01ES023316-12	222,825	-
Environmental Health	93.113	Regents of the University of Michigan	5R01ES031591-04	102,246	-
Environmental Health	93.113	Rutgers, the State University of New Jersey	7R01ES034038-03	39,026	-
Environmental Health	93.113	Trustees of Columbia University in the City of New York (The)	5R01ES026991-07	78,647	-
Environmental Health	93.113	University of California at Irvine	5R01ES031139-04	101,528	-
Environmental Health	93.113	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01ES033519-04	(19,969)	-
Environmental Health	93.113	University of Washington	5R01ES027696-04	72	-
Environmental Health	93.113	University of Washington	5R21ES033343-02	(64)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Aalto-korkeakoulusaatio sr	7R01NS104585-06	356,580	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1R01NS126282-01A1	75,897	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	1R01NS128045-01A1	105,826	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01HL161253-03	200,208	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS105844-05	240,834	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5R01NS129156-03	203,857	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	5U01NS102289-04	50,278	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Beth Israel Deaconess Medical Center	7R01NS120947-02	46,311	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	BioSensics LLC	1R44NS122672-01A1	112,854	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Board of Trustees of the Leland Stanford Junior University, The	5U01NS123101-03	204,473	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS115951-04	8,026	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brigham and Women's Hospital, Inc.	5R01NS123557-03	41,820	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Brown University	5U24NS129945-02	53,010	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Caldara Medical LLC	R43NS127620	24,027	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R01NS128281-02	50,046	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R21NS121735-02	17,610	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital Corporation dba Boston Children's Hospital	5R61NS126792-03	44,174	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U01NS111671-04	27,880	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U54NS115052-05	64,026	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cook Children's Health Care System	5R01NS104116-05	92,290	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Dignity Health	1OT2NS136939-01	544,118	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		144,582,700	34,069,331
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	1DP2NS127291-01	134,354	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	7R01NS113541-03	84,625	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	George Washington University	5U54NS115054-04	1,626	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Highland Instruments	5R44NS110237-03	218,194	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hillhurst Biopharmaceuticals, Inc.	1R41NS122576-01	(4,960)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Huntington Medical Research Institute	5R01NS100808-05	(224)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS115268-01	278,931	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	1RF1NS128961-01	234,277	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5R01NS115957-05	148,800	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Icahn School of Medicine at Mount Sinai	5U01NS107016-05	69,676	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Jackson Laboratory, The	1R01NS125742-01	(66,422)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Joan & Sanford I. Weill Medical College of Cornell University	5U43NS095554-05	12,571	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	2RF1NS095969-06	21,593	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Loxagen, Inc.	R43NS124491-01A1	6,865	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1OT2NS122680-01	2,355	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R01NS130119-01A1	263,610	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1R61NS117210-01A1	11,264	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1RM1NS128741-01	139,461	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1RM1NS132996-01	471,825	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1U01NS136020-01	18,266	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	1U01NS136021-01	36,627	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2R01NS093870-07	331,670	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	2U24NS107243-06	14,143	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS102574-05	3,517	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS103824-05	117,613	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U19NS115388-06	135,933	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS107154-05	50,890	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS107243-05	(7,424)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U24NS113850-05	244,336	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS114001	707	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS120901	91,480	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5R01NS121073-03	58,245	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5R01NS121078-04	462,931	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5U01NS121471-04	413,881	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts Institute of Technology	5U19NS128613-02	150,769	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5R01NS076491-13	160,854	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic	5UH3NS103870-05	457,509	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5P01NS084974-10	178,876	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mayo Clinic Jacksonville	5U01NS080168-09	1,173	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	McLean Hospital Corporation	5U01NS109463-05	1,310	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Michigan State University	1RF1NS128611-01	254,080	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuro42	1U44NS136026-01A1	150,996	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	1UH3NS109557-01A1	263,873	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Neuropace, Inc.	5UH3NS109557-02	67,173	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northeastern University	1R01NS131467-01	261,562	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5R01NS085770-10	177,716	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	5UG3NS117844-04	190,691	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	PathMaker Neurosystems Inc.	1U44NS104138-01	115,896	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	1R01NS124017-01	24,995	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS104143-05	(1,913)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS126248-03	174,189	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	President and Fellows of Harvard College	5R01NS126260-03	197,769	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Diego	5R01NS112503-06	376,537	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Diego	5UG3NS123723-02	118,889	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	1RF1NS128217-01A1	530,392	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	5R01NS111166-04	44,657	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of California, San Francisco	5R01NS124051-03	54,940	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	1U01NS099046-01A1	145	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents of the University of Michigan	7R01NS125742-03	142,853	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Schepens Eye Research Institute, Inc.	1RF1NS110048-01	26	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Soterya, Inc.	1R43NS120394-01A1	(590)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	State University of New York at Buffalo, The	7R01NS058949-14	224,018	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Temple University - Of the Commonwealth System of Higher Education	5R01NS070267-15	9,078	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	5400001617	8,750	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	1U2NS132940	135,278	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	1UG3NS132135-01	11,458	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	231500	1,174	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Broad Institute, Inc.	5R01NS102371-05	5,831	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	The Methodist Hospital Research Institute	5U01NS104326-05	5,776	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	1R21NS136960-01	5,655	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	1U19NS128613-01	(106)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS110669-05	(3,488)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS121419-03	50,529	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5R01NS125307-02	495,447	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5U01NS093334-07	32,508	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Boston University	5U19NS123717-04	839,458	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5R01NS084142-10	64	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5R01NS131606-02	80,783	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of Columbia University in the City of New York (The)	5U54NS078059-11	155	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees of the University of Pennsylvania	5U01NS114140-04	27,999	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Buffalo	5R01NS058949-13	74,640	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	5R01NS116262-04	93,490	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS099043-01A1	10	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS102289-01A1	544	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS110772-01	19,995	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS120910-01	8,699	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1UF1NS120871-01	704	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1UG3NS125023-01A1	288	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS069763-08	773,492	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS095869-02	1,209	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS099043-02	438	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS106513-02	787	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS110728-02	428	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	7U01NS100699-03	2,903	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	U01NS117450	28	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	5U01NS119562-04	5,355	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Florida Board of Trustees	5U01NS124613-02	1,067,539	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Maryland	5R01NS122980-04	101,202	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5R01NS108769-05	196,898	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Massachusetts, Worcester	5U01NS114098-05	192,147	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Miami	5U54NS092091-10	34,549	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh Of the Commonwealth System of Higher Education	1U44NS121557-01A1	31,110	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01NS098023-07	211,181	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Rochester	5R01NS126933-02	52,486	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	5U54NS100064-05	24,568	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Southwestern Medical Center	5R01NS108115-05	(15,156)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	5U01NS120901-02	1,792,031	434,928
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Vanderbilt University Medical Center	5R01NS123281-03	22,782	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1R01NS130189-01	86,824	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	1U01NS099046-01A1	1,040	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS110721-05	1,784	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Yale University	5R01NS117904-03	60,950	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	Direct		(11,072)	-
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	University of Southern California	5R01CA260459-03	9,001	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	2U01HG008685-09	299,836	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	5R01HG012810-02	218,019	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	5U01HG012009-02	(5,615)	-
Human Genome Research	93.172	Brigham and Women's Hospital, Inc.	9U01NS134357-09	101,217	-
Human Genome Research	93.172	Children's Hospital Medical Center	5R01HG010730-03	130,195	-
Human Genome Research	93.172	Dana-Farber Cancer Institute, Inc.	1R56HG013083-01	131,328	-
Human Genome Research	93.172	Dana-Farber Cancer Institute, Inc.	5U24HG004059-20	425,419	-
Human Genome Research	93.172	Direct		10,492,902	3,266,331
Human Genome Research	93.172	Jackson Laboratory, The	5U24HG007497-08	12,544	-
Human Genome Research	93.172	Johns Hopkins University	5U24HG010263-05	(111)	-
Human Genome Research	93.172	Johns Hopkins University	5U24HG010263-06	188,875	-
Human Genome Research	93.172	Massachusetts General Hospital	5U01HG012010-04	269,559	-
Human Genome Research	93.172	New York University Grossman School of Medicine	2R01HG009491-06	23,923	-
Human Genome Research	93.172	President and Fellows of Harvard College	1R01HG012926-01	24,781	-
Human Genome Research	93.172	The Broad Institute, Inc.	5400001859	393,757	-
Human Genome Research	93.172	The Broad Institute, Inc.	5400001930	14,094	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011723-03	51,705	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011723-04	20,887	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011755-04	(3,281)	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG006834	18,289	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG011025	14,528	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U24HG011735-04	5,165	-
Human Genome Research	93.172	The Broad Institute, Inc.	5U01HG011986-02	(92)	-
Human Genome Research	93.172	The Broad Institute, Inc.	R01HG010647	11	-
Human Genome Research	93.172	The Broad Institute, Inc.	R01HG012781	86,533	-
Human Genome Research	93.172	The Broad Institute, Inc.	U01HG011723	69,964	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG006834-08	70,433	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG010262	(11,399)	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG011450	323,655	-
Human Genome Research	93.172	The Broad Institute, Inc.	U24HG012090	11,666	-
Human Genome Research	93.172	The Broad Institute, Inc.	U41HG009494	672	-
Human Genome Research	93.172	University of North Carolina at Chapel Hill, The	1R21HG012365-02	50,850	-
Human Genome Research	93.172	University of North Carolina at Chapel Hill, The	5U24HG009650-08	81,552	-
Human Genome Research	93.172	Vanderbilt University Medical Center	1U24HG013233-01	434,491	-
Human Genome Research	93.172	Vanderbilt University Medical Center	5U24HG013233-02	271,660	-
Human Genome Research	93.172	Whitehead Institute for Biomedical Research	2R01HG009490-06	(6,526)	-
International Research and Research Training	93.989	Les Centres GHESKIO	1R21TW012644-01	7,898	-
International Research and Research Training	93.989	President and Fellows of Harvard College	2D43TW009610-12	6,897	-
Lung Diseases Research	93.838	Baylor College of Medicine	5R01HL149744-05	27,265	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	1U24HL166784-01A1	173,626	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	1UG3HL166785-01A1	2,279	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	5R01HL149422-04	327,238	-
Lung Diseases Research	93.838	Beth Israel Deaconess Medical Center	5U01HL123009-07	(1,025)	-
Lung Diseases Research	93.838	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL118455-08	140,716	-
Lung Diseases Research	93.838	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL163513-02	269,036	-
Lung Diseases Research	93.838	Children's Hospital Los Angeles	5R01HL146541-04	7	-
Lung Diseases Research	93.838	Children's Hospital Medical Center	5U01HL148856-05	105,504	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5R61HL165366-02	471,809	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U24HL148865-04	(12,872)	-
Lung Diseases Research	93.838	Cleveland Clinic Lerner College of Medicine	4U01HL125177-06	(2,355)	-
Lung Diseases Research	93.838	Columbia University Irving Medical Center (CUIMC)	5R01HL159675-04	27,461	-
Lung Diseases Research	93.838	Direct		41,203,337	9,629,483
Lung Diseases Research	93.838	Duke University	1OT2HL156812-01	145,484	-
Lung Diseases Research	93.838	Duke University	1OT2HL156812-01	49,418	-
Lung Diseases Research	93.838	Emory University	1R01HL169373-01A1	24,162	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	5UH3HL147011-05	18,644	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	1R61HL158540-01A1	(15,377)	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4R33HL153011-03	78,196	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	4R33HL158540-02	118,972	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance		Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number	Direct Agency/Pass-Through Program	Number	Expenditures	Expenditures
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5P01HL114501-08	1,102,549	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5R33HL153011-03	201,480	-
Lung Diseases Research	93.838	Joan & Sanford I. Weill Medical College of Cornell University	5UH3HL154944-03	20,478	-
Lung Diseases Research	93.838	Johns Hopkins University	5R01HL160008-03	254,091	-
Lung Diseases Research	93.838	Massachusetts General Hospital	5R01HL154549-03	21,024	-
Lung Diseases Research	93.838	National Jewish Health	5R01HL109557-12	153,075	-
Lung Diseases Research	93.838	Northwestern University	5R01HL122477-09	93,533	-
Lung Diseases Research	93.838	Northwestern University	5R01HL159250-04	535,754	-
Lung Diseases Research	93.838	Northwestern University	5U01HL146408-06	631,514	-
Lung Diseases Research	93.838	President and Fellows of Harvard College	5R01HL150520-04	109,539	-
Lung Diseases Research	93.838	Rector and Visitors of the University of Virginia, The	5R01HL153248-03	645,270	-
Lung Diseases Research	93.838	Rector and Visitors of the University of Virginia, The	5R01HL167202-02	38,707	-
Lung Diseases Research	93.838	Regents of the University of California, Davis	R01HL148715	8,654	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	5R01HL161362-02	155,556	-
Lung Diseases Research	93.838	Regents of the University of California, San Diego	5R01HL162570-07	84,849	-
Lung Diseases Research	93.838	Regents of the University of Michigan	5U24HL145265-04	43,115	-
Lung Diseases Research	93.838	Research Triangle Institute International	1OT2HL167310-01	31,486	-
Lung Diseases Research	93.838	The University of Texas Health Science Center at Houston	5R01HL145025-05	321,489	-
Lung Diseases Research	93.838	Trustees of Boston University	1P01HL170952-01	8,937	-
Lung Diseases Research	93.838	Trustees of Boston University	5R01HL159644-03	274,533	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	5R01HL137234-04	49,571	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	5UH3HL140177-05	71,989	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	7R01HL121228-08	50,952	-
Lung Diseases Research	93.838	Trustees of Columbia University in the City of New York (The)	7UH3HL140177-04	45,356	-
Lung Diseases Research	93.838	Trustees of Tufts College	1R01HL171728-01	43,949	-
Lung Diseases Research	93.838	University of Cincinnati	7R01HL146541-05	21,974	-
Lung Diseases Research	93.838	University of Colorado at Denver	5R01HL152735-04	57,620	-
Lung Diseases Research	93.838	University of Florida Board of Trustees	5R01HL157879-03	447,071	-
Lung Diseases Research	93.838	University of North Carolina at Chapel Hill, The	5U24HL138998-06	597,204	-
Lung Diseases Research	93.838	University of Pittsburgh Of the Commonwealth System of Higher Education	R01HL161164-02	42,509	-
Lung Diseases Research	93.838	University of Vermont and State Agricultural College	5R01HL161220-02	27,816	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	1OT2HL156812-01	377,019	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL146588-03	(1,254)	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL158906-03	69,448	-
Lung Diseases Research	93.838	Vanderbilt University Medical Center	5R01HL163960-03	35,574	-
Medical Library Assistance	93.879	Dana-Farber Cancer Institute, Inc.	5R01LM013352-04	37,906	-
Medical Library Assistance	93.879	Direct		1,228,040	292,725
Medical Library Assistance	93.879	Northwestern University	5R01LM013772-02	226,190	-
Medical Library Assistance	93.879	Northwestern University	1R01LM13337-03	18,069	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5R01LM013614-04	40,625	-
Medical Library Assistance	93.879	University of Massachusetts Amherst	5R01LM013444-03	16,982	-
Mental Health Research Grants	93.242	Allen Institute	5UM1MH130981-03	921,861	-
Mental Health Research Grants	93.242	Baylor College of Medicine	5R01MH115793-05	(8,495)	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH16170-05	(1,434)	-
Mental Health Research Grants	93.242	Beth Israel Deaconess Medical Center	5R01MH127174-03	96,820	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	5R01MH116173-05	(20,977)	-
Mental Health Research Grants	93.242	Board of Trustees of the Leland Stanford Junior University, The	5R01MH132074-02	301,532	-
Mental Health Research Grants	93.242	Board of Trustees of the University of Alabama for the University of Alabama	R34RMH118044A	32,408	-
Mental Health Research Grants	93.242	Board of Trustees of the University of Illinois, The	1R34MH132432-01A1	6,023	-
Mental Health Research Grants	93.242	Boston University School of Medicine	5R01MH128377-03	218,598	-
Mental Health Research Grants	93.242	Boston VA Research Institute Inc	7R33MH113751-05	120,528	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	1R01MH132610-01	271,556	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH113929-09	183,973	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH125860-04	295,283	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5R01MH130666-03	40,022	-
Mental Health Research Grants	93.242	Brigham and Women's Hospital, Inc.	5U24MH124629-05	1,738,054	-
Mental Health Research Grants	93.242	Broad Institute, inc.	2R01MH115957-06	1,878	-
Mental Health Research Grants	93.242	Cambridge Health Alliance	5P50MH126283-04	123,388	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	1R01MH126977-02	195,463	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	8U01MH136558-02	90,615	-
Mental Health Research Grants	93.242	Cleveland Clinic Lerner College of Medicine of Case Western Reserve University	5R01MH125214-03	158,603	-
Mental Health Research Grants	93.242	Direct		71,130,602	15,195,852
Mental Health Research Grants	93.242	Emory University	5R01MH131434-02	50,718	-
Mental Health Research Grants	93.242	Huntington Medical Research Institute	5R01MH110438-08	112,148	-
Mental Health Research Grants	93.242	Icahn School of Medicine at Mount Sinai	1R01MH131537-01A1	134,983	-
Mental Health Research Grants	93.242	Johns Hopkins University	5P50MH115842-04	(3,972)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Mental Health Research Grants	93.242	King's College London	5R01MH114708-05	189,696	-
Mental Health Research Grants	93.242	London School of Hygiene & Tropical Medicine	5R01MH115504-04	17,176	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	1R01MH128246-03	175,505	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	1R61MH129331-01A1	179,479	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH113930-08	1,672	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH116205-05	114,363	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R01MH130442-02	23,247	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5U54MH118919-05	50,678	-
Mental Health Research Grants	93.242	Massachusetts Institute of Technology	1RF1MH121885-01A1	254,878	-
Mental Health Research Grants	93.242	Massachusetts Institute of Technology	5U01MH117072-05	(1,151)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	1R01MH134074-01A1	54,152	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	1R01MH135093-01	29,652	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	1R56MH125995-01	(535)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	2P50MH115846-05	220,939	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH115846-03	(65)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH115846-04	(13,746)	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5P50MH119467-05	611,200	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH117012-05	95,271	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH120991-05	158,266	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R01MH122427-04	353,661	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R37MH068376-19	73,141	-
Mental Health Research Grants	93.242	McLean Hospital Corporation	5R61MH121640-02	99,352	-
Mental Health Research Grants	93.242	National Network of Depression Centers	1R01MH121542-01	48,278	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R01MH126981-03	55,660	-
Mental Health Research Grants	93.242	New York University School of Medicine	5R33MH122647-04	404,129	-
Mental Health Research Grants	93.242	Northeastern University	5R01MH113234-05	245,948	-
Mental Health Research Grants	93.242	NIOUS Imaging Inc.	R44MH124567	(15,656)	-
Mental Health Research Grants	93.242	Ocean State Research Institute, Inc.	1U01MH123427-04	86,730	-
Mental Health Research Grants	93.242	Paradromics, Inc.	1R44MH125700-01A1	268,399	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R01MH121191-04	14,921	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1R01MH133657-01	4,803	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	1RF1MH128861-01	251,717	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	4R33MH113751-03	(2,019)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101244-12	79,242	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101244-13	231,760	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH101269-08	141,428	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH112829-07	29,797	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH120642-04	(11,083)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH121632-03	57,362	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH124004-03	24,509	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5R01MH131414-02	38,066	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5U01MH116928-04	(643)	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	R01MH121191-04	22,765	-
Mental Health Research Grants	93.242	RAND Corporation	5R01MH117760-04	59,036	-
Mental Health Research Grants	93.242	RAND Corporation	5R34MH126478-03	10,916	-
Mental Health Research Grants	93.242	Regents of the University of California, San Diego	5R01MH106595-08	42,761	-
Mental Health Research Grants	93.242	Regents of the University of Michigan	5R01MH110872-04	(1,938)	-
Mental Health Research Grants	93.242	Research Foundation for Mental Hygiene, Inc.	5R33MH116089-05	(722)	-
Mental Health Research Grants	93.242	Rhode Island Hospital	5P50MH106435-08	10,147	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	3R34MH113757-03S1	60,431	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	3T34MH113757-03S1	10,979	-
Mental Health Research Grants	93.242	Rutgers, the State University of New Jersey	5R01MH124899-03	65,454	-
Mental Health Research Grants	93.242	State University of New York Downstate Health Sciences University, The	5R01MH125938-03	49,217	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5400001919	32,614	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1R01MH134468	23,890	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1R01MH134468-01	24,383	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1RF1MH124598-01	(871)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1RF1MH130468-01A1	86,192	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	1UM1MH130966-01	(23,438)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	2R01MH115957-06	574,872	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	3U01MH125047-04S1	31,033	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	3U24MH124629-04S1	26,182	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH104964-11	60,198	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH106595-08	(302)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH107649-08	(33,870)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH115957-04	(64)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH115957-05	(93,908)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH116037-05	2,754	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH120642-05	10,843	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH123451-04	35,430	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH129722-03	43,779	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH130675-02	64,253	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R01MH134468-02	28,600	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R37MH107649-08	696	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5R37MH107649-10	182,079	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5U01MH119689-05	(470)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	5U01MH125047-04	123,696	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	GR1162-80003672	4,695	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	R01MH111813	(697)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	R01MH115957	(6,147)	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	R01MH120642	16,542	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	R01MH130675	50,665	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	U01MH119689	27,391	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	U01MH124602	16,441	-
Mental Health Research Grants	93.242	The Broad Institute, Inc.	UM1MH130966	154,529	-
Mental Health Research Grants	93.242	Trustees of Boston University	1R01MH128280-02	43,217	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH122867-04	2,052	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH125703-02	45,523	-
Mental Health Research Grants	93.242	Trustees of Boston University	5R01MH128280-02	30,630	-
Mental Health Research Grants	93.242	Trustees of Tufts College	1R01MH136641-01	8,433	-
Mental Health Research Grants	93.242	Turing Medical Technologies Inc.	R44MH124567-04	188,353	-
Mental Health Research Grants	93.242	University of Delaware	1R01MH126196-01A1	64,116	-
Mental Health Research Grants	93.242	University of Florida Board of Trustees	R01MH117114	76,907	-
Mental Health Research Grants	93.242	University of Massachusetts Amherst	5R01MH122371-04	118,184	-
Mental Health Research Grants	93.242	University of Massachusetts Chan Medical School	5R01MH128275-03	149,275	-
Mental Health Research Grants	93.242	University of Massachusetts, Worcester	5R01MH128904-03	113,232	-
Mental Health Research Grants	93.242	University of Miami	R01MH118043	49,782	-
Mental Health Research Grants	93.242	University of Mississippi Medical Center	5R01MH125833-03	12,567	-
Mental Health Research Grants	93.242	University of Rochester	2P50MH106435-06A1	(20,360)	-
Mental Health Research Grants	93.242	University of Rochester	5P50MH106435-08	736,689	-
Mental Health Research Grants	93.242	University of Rochester	5R01MH045573-32	183,729	-
Mental Health Research Grants	93.242	University of Texas at Austin	R01MH120219	76,600	-
Mental Health Research Grants	93.242	Vanderbilt University	5R01MH130364-02	33,612	-
Mental Health Research Grants	93.242	Vanderbilt University Medical Center	5R01MH113478-05	188	-
Mental Health Research Grants	93.242	Worcester Polytechnic Institute	2R01MH130490-02	156,315	-
Mental Health Research Grants	93.242	Yale University	5R01MH120080-05	(4,455)	-
Mental Health Research Grants	93.242	Yale University	5R01MH123155-04	140,082	-
Mental Health Research Grants	93.242	Yale University	5R01MH127259-03	174,126	-
Minority Health and Health Disparities Research	93.307	Brandeis University	7R01MD013837-05	8,730	-
Minority Health and Health Disparities Research	93.307	Direct		4,517,376	1,271,246
Minority Health and Health Disparities Research	93.307	Environment and Health Group, Inc.	1R43MD018244-01	7,788	-
Minority Health and Health Disparities Research	93.307	Fenway Community Health Center	5R01MD013498-05	1,749	-
Minority Health and Health Disparities Research	93.307	Harvard Pilgrim Health Care	5R01MD015256-05	154,613	-
Minority Health and Health Disparities Research	93.307	Michigan State University	5R01MD015763-04	31,194	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD012793-05	5,102	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD014304-04	15,792	-
Minority Health and Health Disparities Research	93.307	President and Fellows of Harvard College	5R01MD017747-03	70,082	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R01MD013913-05	25,691	-
Minority Health and Health Disparities Research	93.307	Regents of the University of California, Los Angeles, The	5R21MD017499-02	99,312	-
Minority Health and Health Disparities Research	93.307	Trustees of Boston University	5R01MD014312-04	31,034	-
Minority Health and Health Disparities Research	93.307	Tufts University	1R01MD016026-01	4	-
Minority Health and Health Disparities Research	93.307	University of California at Irvine	5R01MD015186-04	122,768	-
Minority Health and Health Disparities Research	93.307	University of North Carolina at Chapel Hill, The	1R01MD016755-01A1	1,473	-
Minority Health and Health Disparities Research	93.307	University of Pittsburgh Of the Commonwealth System of Higher Education	1R21MD018106-01A1	31,816	-
National Center for Advancing Translational Sciences	93.350	Boston Medical Center	5U01TR002070-05	(18)	-
National Center for Advancing Translational Sciences	93.350	Brigham and Women's Hospital, Inc.	5UH3TR002155-05	4,384	-
National Center for Advancing Translational Sciences	93.350	Direct		3,085,099	1,692,895
National Center for Advancing Translational Sciences	93.350	Phase, Inc.	2R44TR003968-02	26,504	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1UM1TR0044001-01	99,040	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1UM1TR004408-01	79,878	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UL1TR002541-05	(18,100)	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5UM1TR004408-02	2,874,238	-
National Center for Advancing Translational Sciences	93.350	The Broad Institute, Inc.	125846/5400001915	2,819	-
National Center for Advancing Translational Sciences	93.350	University of Pittsburgh Of the Commonwealth System of Higher Education	5U24TR004111-03	236,837	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	1R21NS128815-01	21,875	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	5P01HL149630-04	307,595	-
National Center on Sleep Disorders Research	93.233	Beth Israel Deaconess Medical Center	7R01HL161012-02	142,915	-
National Center on Sleep Disorders Research	93.233	Children's Hospital Corporation dba Boston Children's Hospital	5R01HL137192-04	42,563	-
National Center on Sleep Disorders Research	93.233	Children's Hospital of Philadelphia (The)	4R33HL151253-04	(193)	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
National Center on Sleep Disorders Research	93.233	Children's Hospital of Philadelphia (The)	5R33HL151253-03S1	(257)	-
National Center on Sleep Disorders Research	93.233	Direct		11,001,741	1,050,095
National Center on Sleep Disorders Research	93.233	Icahn School of Medicine at Mount Sinai	5R01HL147328-05	55,977	-
National Center on Sleep Disorders Research	93.233	Regents of the University of California, Los Angeles, The	7R01HL160993-02	58,143	-
National Center on Sleep Disorders Research	93.233	Regents of the University of Michigan	5R01HL164755-02	32,599	-
National Center on Sleep Disorders Research	93.233	Stanford University Medical Center	5R01HL148704-04	347,608	-
National Center on Sleep Disorders Research	93.233	University of Miami	3R33HL151253-05S1	63,349	-
National Center on Sleep Disorders Research	93.233	University of Miami	7R33HL151253-05	36,116	-
National Center on Sleep Disorders Research	93.233	University of Washington	1R01HL162311-01A1	53,895	-
National Institutes of Health Contracts	93.RD1	Altec, Inc.	75N95023C00005	54,824	-
National Institutes of Health Contracts	93.RD1	Battelle, Columbus Division	HHSN272201800013I	36,600	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children's Hospital	75N93019C00044	(645)	-
National Institutes of Health Contracts	93.RD1	Children's Hospital Corporation dba Boston Children's Hospital	75N93020C00038	12,340	-
National Institutes of Health Contracts	93.RD1	CRDF Global	OISE-9531011	53,313	-
National Institutes of Health Contracts	93.RD1	Cure Systems, LLC	75N93022C00021	10,384	-
National Institutes of Health Contracts	93.RD1	Direct		7,557,441	-
National Institutes of Health Contracts	93.RD1	Duke Clinical Research Institute	HHSN275201800003I	6,054	-
National Institutes of Health Contracts	93.RD1	Duke University	75N93019C00050	408,081	-
National Institutes of Health Contracts	93.RD1	Duke University	HHSN275201000003I	43	-
National Institutes of Health Contracts	93.RD1	Duke University	HHSN275201800003I	67,205	-
National Institutes of Health Contracts	93.RD1	ExQor Technologies Inc	2R44MH108481-03	(19,305)	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013	127,867	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	20X013F	545,471	-
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	75N91019D00024	947,167	79,104
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261200800001E	3,200,959	1,717,518
National Institutes of Health Contracts	93.RD1	Leidos Biomedical Research Inc	HHSN261201500003I	82,962	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N93019C00071	1,377,239	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	75N95023C00008	334,583	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	CFAR-BWH-24-1-Li	46,957	-
National Institutes of Health Contracts	93.RD1	President and Fellows of Harvard College	P30CA006516-59	7,647	-
National Institutes of Health Contracts	93.RD1	Public Health Institute	HSN261201500003I	116,239	725
National Institutes of Health Contracts	93.RD1	Regents of the University of California, San Diego	1R21MH132406-01A1	23,168	-
National Institutes of Health Contracts	93.RD1	Research Foundation for The SUNY on behalf of University of Buffalo	75N92021D00002-P00002	179,406	-
National Institutes of Health Contracts	93.RD1	Seattle Children's Hospital	75N93021C00029	255,807	-
National Institutes of Health Contracts	93.RD1	Social and Scientific Systems, Inc.	HHSN273201600003I	(1,674)	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	239748	2,918	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001695	3,053	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001919	3,053	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001923	31,502	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400001981	54,690	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	5400002018	215	-
National Institutes of Health Contracts	93.RD1	The Broad Institute, Inc.	HHSN272201800013I	241	-
National Institutes of Health Contracts	93.RD1	University of Georgia Research Foundation, Inc. (UGARF)	75N93019C00052	121,200	-
National Institutes of Health Contracts	93.RD1	University of Mississippi Medical Center	HHSN268201800011I	(10,474)	-
National Institutes of Health Contracts	93.RD1	Vanderbilt University Medical Center	75N91019D00024	92,881	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	HHSN261201800043C	5,533	-
National Institutes of Health Contracts	93.RD1	Wyss Institute at Harvard University	75N95024P00263	5,007	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	President and Fellows of Harvard College	5P42ES030990-05	119,819	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93.143	University of Rhode Island	5P42ES027708-08	31,300	-
Nursing Research	93.361	Brigham and Women's Hospital, Inc.	5R01NR020765-03	97,577	-
Nursing Research	93.361	Columbia University Medical Center	5R01NR016941-06	(167)	-
Nursing Research	93.361	Direct		3,512,759	720,451
Nursing Research	93.361	electRx, Inc.	1R43NR020289-01A1	4,219	-
Nursing Research	93.361	Harvard Pilgrim Health Care	1R01NR021137-01	35,564	-
Nursing Research	93.361	Trustees of Columbia University in the City of New York (The)	5R01NR016941-08	123,058	-
Nursing Research	93.361	UMass Memorial Medical Center, Inc.	5R01NR020439-03	87,178	-
Nursing Research	93.361	University of Colorado at Denver	5U2CNR014637-10	(17,251)	-
Nursing Research	93.361	University of Massachusetts Medical School	5R01NR020439-03	35,545	-
Nursing Research	93.361	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01NR020031-04	64,682	-
Nursing Research	93.361	Yale University School of Medicine	5R01NR018335-05	6,680	-
Oral Diseases and Disorders Research	93.121	Atrium Health	1UG3DE031250-01	(689)	-
Oral Diseases and Disorders Research	93.121	Atrium Health	4UH3DE031250-02	13,344	-
Oral Diseases and Disorders Research	93.121	Carolinas HealthCare System	5U01DE022939-10	(42,114)	-
Oral Diseases and Disorders Research	93.121	Cincinnati Children's Hospital Medical Center	5UH3DE030401-03	14,578	-
Oral Diseases and Disorders Research	93.121	Dana-Farber Cancer Institute, Inc.	5R01DE027736-05	1,404	-
Oral Diseases and Disorders Research	93.121	Direct		7,374,988	2,121,351
Oral Diseases and Disorders Research	93.121	Emory University	5R01DE030342-04	237,077	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Oral Diseases and Disorders Research	93.121	Forsyth Institute, The	3R01DE025020-09S1	96,767	-
Oral Diseases and Disorders Research	93.121	Forsyth Institute, The	5R01DE025020-09	60,981	-
Oral Diseases and Disorders Research	93.121	Hennepin Healthcare Research Institute	UH3DE029973-04	7,891	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1R01DE027989-01A1	4,964	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1R01DE030464-02	194,697	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	1UG3DE031920-01	(5,744)	-
Oral Diseases and Disorders Research	93.121	Massachusetts General Hospital	5UH3DE031920-03	383,745	-
Oral Diseases and Disorders Research	93.121	Nova Southeastern University Inc	7R01DE027249-04	8,334	-
Oral Diseases and Disorders Research	93.121	Ohio State University	5R01DE032334-03	15,940	-
Oral Diseases and Disorders Research	93.121	Ohio State University	7R01DE028565-02	128,891	-
Oral Diseases and Disorders Research	93.121	SingleO2 Therapeutics LLC	R44DE026083	36	-
Oral Diseases and Disorders Research	93.121	The University of Texas Health Science Center at Houston	1R01DE030416-01A1	59,329	-
Oral Diseases and Disorders Research	93.121	University of Illinois at Urbana Champaign	R01DE027989	196,233	7,818
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01DE026155-05	14,223	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5R01DE031299-02	166,899	-
Oral Diseases and Disorders Research	93.121	University of Pittsburgh Of the Commonwealth System of Higher Education	5U01DE029759-04	71,935	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	5R01DE031285-03	76,945	-
Oral Diseases and Disorders Research	93.121	Wake Forest University Health Sciences	6U01DE022939-11	205,260	-
Research and Training in Complementary and Integrative Health	93.213	Altec, Inc.	5R43AT012003-02	50,422	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R01AT012072-02	102,086	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R01AT012166-01A1	69,759	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R21AT012284-01	7,540	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	1R61AT012284-01	430,919	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	R01AT012072	60,409	-
Research and Training in Complementary and Integrative Health	93.213	Brigham and Women's Hospital, Inc.	3R01AT011729-14S1	36,524	-
Research and Training in Complementary and Integrative Health	93.213	Direct		9,090,385	2,506,348
Research and Training in Complementary and Integrative Health	93.213	Duke University	5U24AT009150-08	(18,455)	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5P01AT009965-05	386,496	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5R01AT011429-04	161,129	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts General Hospital	5R33AT009306-05	79,889	-
Research and Training in Complementary and Integrative Health	93.213	Massachusetts Neuro Technology, Inc.	3R41AT011822-01A1S1	55,107	-
Research and Training in Complementary and Integrative Health	93.213	New York University School of Medicine	4UG3AT009844-05	13,848	-
Research and Training in Complementary and Integrative Health	93.213	RAND Corporation	3R01AT010402-03S1	1,003	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5R01AT012144-02	204,893	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5R21AT011918-02	16,644	-
Research and Training in Complementary and Integrative Health	93.213	Spaulding Rehabilitation Hospital	5U24AT012560-02	320,567	-
Research and Training in Complementary and Integrative Health	93.213	Trustees of Boston University	1UG3AT012530-01	227,758	-
Research and Training in Complementary and Integrative Health	93.213	University of Alabama, Birmingham	5U24AT011969-03	12,821	-
Research and Training in Complementary and Integrative Health	93.213	University of Kentucky	5R34AT010370-03	78,791	-
Research and Training in Complementary and Integrative Health	93.213	University of Utah	5R33AT012329-02	187,115	-
Research Infrastructure Programs	93.351	Direct		4,830,037	5,978
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5R01DC014034-09	74,360	-
Research Related to Deafness and Communication Disorders	93.173	Board of Trustees of the Leland Stanford Junior University, The	5U01DC019430-04	138,688	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	3R01DC020965-02S1	37,110	-
Research Related to Deafness and Communication Disorders	93.173	Brigham and Women's Hospital, Inc.	5R01DC020965-02	195,380	-
Research Related to Deafness and Communication Disorders	93.173	Brown University	3U01DC017844-03S1	125,025	-
Research Related to Deafness and Communication Disorders	93.173	Brown University	5U01DC017844-04	183,331	-
Research Related to Deafness and Communication Disorders	93.173	Children's Hospital Corporation dba Boston Children's Hospital	2R01DC008853-11A1	37,103	-
Research Related to Deafness and Communication Disorders	93.173	Direct		28,834,256	6,455,669
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5U01DC019279- 05	76,169	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts Eye and Ear Infirmary	5U01DC019279-05	132,964	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	242793	50,349	-
Research Related to Deafness and Communication Disorders	93.173	Massachusetts General Hospital	5R01DC019916-02	211,955	-
Research Related to Deafness and Communication Disorders	93.173	MEEI - Internal	5R01DC011805-13	139,834	-
Research Related to Deafness and Communication Disorders	93.173	MGH Institute of Health Professions	1R15DC018944-01A1	10,707	-
Research Related to Deafness and Communication Disorders	93.173	Modality.AI, Inc.	4R42DC019877-02	412,466	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	2R01DC017717-04A1	9,090	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	5R01DC016932-05	72	-
Research Related to Deafness and Communication Disorders	93.173	President and Fellows of Harvard College	5R01DC017717-03	8,146	-
Research Related to Deafness and Communication Disorders	93.173	Ripple Neuro, LLC	1R41DC020869-01A1	157,153	-
Research Related to Deafness and Communication Disorders	93.173	Sunnybrook Research Institute	1R01DC017291-05	68,122	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	4500004965	175,014	-
Research Related to Deafness and Communication Disorders	93.173	Trustees of Boston University	5R01DC020867-02	109,549	-
Research Related to Deafness and Communication Disorders	93.173	University of Miami	1R01DC019404-01A1	288,046	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		1,234,491	396,912
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Johns Hopkins University	4UH3HL154280-04	29,307	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-03	(6,031)	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-04	66,020	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying	Total	Subrecipient
	Listing Number		Number	Expenditures	Expenditures
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	President and Fellows of Harvard College	5R01HL149912-05	36,294	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Wits Reproductive Health and HIV Institute (WRHI)	4UH3HL156388-03	58,792	-
Trans-NIH Research Support	93.310	Beth Israel Deaconess Medical Center	5U54HL165440-03	51,943	-
Trans-NIH Research Support	93.310	Board of Regents of the University of Wisconsin System, The	5UH3OD023282-07	5,369	-
Trans-NIH Research Support	93.310	Board of Trustees of the University of Illinois, The	5UH3OD023272-07	425	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	1U01HL166060-02	119,211	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	3U01HG007690-08S1	(8,282)	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	5U01HG007690-08	(4,007)	-
Trans-NIH Research Support	93.310	Brigham and Women's Hospital, Inc.	U01HG007690-08S2	(4,030)	-
Trans-NIH Research Support	93.310	Direct		33,588,954	12,683,578
Trans-NIH Research Support	93.310	Henry Ford Health + Michigan State University Health Sciences	UG3OD023285	35,415	-
Trans-NIH Research Support	93.310	Jackson Laboratory, The	5U19NS132304-02	197,626	-
Trans-NIH Research Support	93.310	Ludwig Institute for Cancer Research	5R01NS112503-03	(8,951)	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	1OT2OD037638-01	205,334	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	1UF1NS131791-01	154,452	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	3OT2OD026553-01S5	1,992,882	-
Trans-NIH Research Support	93.310	Massachusetts General Hospital	5U01DK127587-04	55,348	-
Trans-NIH Research Support	93.310	Michigan State University	5UH3OD023285-07	(747)	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UG3OD023286-07	(323)	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UH3OD023282-07	(1,679)	-
Trans-NIH Research Support	93.310	President and Fellows of Harvard College	5UM1DA058230-02	164,041	-
Trans-NIH Research Support	93.310	Regents of the University of California, San Diego	5UG3CA241687	25,420	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	1UM1DA058235	27,195	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	3U24HG006834-10S1	270,275	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	5DP5OD024582-05	(1,083)	-
Trans-NIH Research Support	93.310	The Broad Institute, Inc.	U24HD090743	14,594	-
Trans-NIH Research Support	93.310	Tufts University	5UG1HD107691-03	1,022,590	-
Trans-NIH Research Support	93.310	Tufts University	UG1HD107691	139,001	-
Trans-NIH Research Support	93.310	University of Connecticut Health Center	5U54AG075941-03	45,869	-
Vision Research	93.867	Brigham and Women's Hospital, Inc.	5R24EY028767-04	(7,497)	-
Vision Research	93.867	Brown University	5R01EY030569-03	46,432	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	1R01EY034135-01A1	57,229	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	1U01EY034686-01	47,090	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	2R01EY025794-06A1	352,326	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	5R01EY025794-07	331,055	-
Vision Research	93.867	Children's Hospital Corporation dba Boston Children's Hospital	5U01EY034686-02	74,621	-
Vision Research	93.867	Dana-Farber Cancer Institute, Inc.	5UG1EY027726-04	120,498	-
Vision Research	93.867	Direct		29,098,305	3,555,904
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	1R21EY032522-01	(16)	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY015473-17	(32)	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY032559-02	431,138	-
Vision Research	93.867	Icahn School of Medicine at Mount Sinai	5R01EY032559-04	98,912	-
Vision Research	93.867	Jaeb Center for Health Research	1UG1EY030030-01A1	23,181	-
Vision Research	93.867	Johns Hopkins University	1UG1EY033293-01	56,779	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY020928-12	364,040	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY031300-04	18,518	-
Vision Research	93.867	Massachusetts Eye and Ear Infirmary	5R01EY031708-03	129,021	-
Vision Research	93.867	Massachusetts General Hospital	5R01EY029544-03	(543)	-
Vision Research	93.867	Massachusetts General Hospital	5R01EY033356-02	26,254	-
Vision Research	93.867	Massachusetts General Hospital	7R01EY030877-04	35,583	-
Vision Research	93.867	Massachusetts General Hospital	R01EY034857	22,503	-
Vision Research	93.867	New York University Grossman School of Medicine	3U10EY026869-05S3	70,311	-
Vision Research	93.867	Oregon Health & Science University (OHSU)	8R01EY019474-10	3,320	-
Vision Research	93.867	Pennsylvania State University	5UG1EY023533-08	34,370	-
Vision Research	93.867	Physical Sciences, Inc.	1R44EY034409-01	121,540	-
Vision Research	93.867	Regents of the University of California, San Francisco	1UG1EY033703-01A1	26,003	-
Vision Research	93.867	Research Foundation for The SUNY on behalf of University of Buffalo	1R01EY028553-01	2,418	-
Vision Research	93.867	Schepens Eye Research Institute, Inc.	1R01EY031696-01A1	123,427	-
Vision Research	93.867	Schepens Eye Research Institute, Inc.	5R01EY019470-14	17,935	-
Vision Research	93.867	Scripps Research Institute	2R01EY026202-06A1	52,986	-
Vision Research	93.867	The Broad Institute, Inc.	530795	15,879	-
Vision Research	93.867	Trustees of Boston University	5R21EY035437-02	52,112	-
Vision Research	93.867	University of New England	1U01EY034709-02	707,296	-
Vision Research	93.867	University of New Mexico Health Sciences Center	5R01EY013124-22	139,848	-
Vision Research	93.867	University of Pittsburgh Of the Commonwealth System of Higher Education	5UG1EY031651-02	19,777	-
Vision Research	93.867	University of Tennessee Health Science Center	1R01EY033005-01A1	53,703	-
Vision Research	93.867	University of Tennessee Health Science Center	1R21EY031725-01	(2,466)	-
Vision Research	93.867	Vanderbilt University Medical Center	U24EY029893-03	(95,968)	-
Subtotal				1,349,593,263	269,110,244

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
NATIONAL SCIENCE FOUNDATION, NATIONAL SCIENCE FOUNDATION					
Biological Sciences	47.074	Direct		600,587	278,203
Biological Sciences	47.074	Regents of the University of California, Riverside	2211661	51,686	-
Computer and Information Science and Engineering	47.070	Direct		222,468	-
Computer and Information Science and Engineering	47.070	Research Foundation for The SUNY Stony Brook University, The	IIS1926781	53,625	-
Computer and Information Science and Engineering	47.070	University of Massachusetts Amherst	1915481	403	-
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 University of California at Berkeley	2413624	39,440	-
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 University of California at Davis	2116859	8,026	-
COVID-19 Social, Behavioral, and Economic Sciences	47.075	COVID-19 University of California at Irvine	SES-2241846	9,096	-
Engineering	47.041	Direct		294,325	-
Engineering	47.041	Duke University	HRD-2222336	28,998	-
Engineering	47.041	George Washington University	1830941	(5,632)	-
Engineering	47.041	Regents of the University of Minnesota	2220611	15,090	-
Engineering	47.041	Regents of the University of Minnesota	EEC-194153	1,950,576	-
Engineering	47.041	Vulcan Biologics, Inc.	2126838	(563)	-
Integrative Activities	47.083	Direct		22,765	-
Mathematical and Physical Sciences	47.049	Children's Hospital Corporation dba Boston Children's Hospital	1707865	(2,001)	-
Mathematical and Physical Sciences	47.049	President and Fellows of Harvard College	2127882	97,084	-
Mathematical and Physical Sciences	47.049	Virginia Polytechnic Institute and State University	DMS-2229819	57,716	-
NSF Technology, Innovation, and Partnerships	47.084	Direct		3,540	-
NSF Technology, Innovation, and Partnerships	47.084	INIA Biosciences, Inc.	2312694	9,590	-
NSF Technology, Innovation, and Partnerships	47.084	President and Fellows of Harvard College	ITE-2236157	84,155	-
NSF Technology, Innovation, and Partnerships	47.084	President and Fellows of Harvard College	ITE-2345107	152,779	-
Office of International Science and Engineering	47.079	President and Fellows of Harvard College	59-0210-6-004	6,480	-
Social, Behavioral, and Economic Sciences	47.075	Direct		250,610	-
STEM Education (formerly Education and Human Resources)	47.076	Direct		896,964	104,625
				Subtotal	4,847,807
OFFICE OF ELEMENTARY AND SECONDARY EDUCATION, DEPARTMENT OF Education Innovation and Research (formerly Investing in Innovation (i3) Fund)	84.411	United Way of Massachusetts Bay and Merrimack Valley	U411C170195	(22,320)	-
				Subtotal	(22,320)
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF Opioid Affected Youth Initiative	16.842	Direct		209,033	-
Services for Trafficking Victims	16.320	Beth Israel Deaconess Medical Center	15POVC-23-GG-04064-HT	50,988	-
Services for Trafficking Victims	16.320	Beth Israel Deaconess Medical Center	2019-VT-BX-K012	(17,297)	-
U.S. Department of Justice Contracts	93.RD3	Direct		63,804	-
				Subtotal	306,528
OFFICE OF THE SECRETARY, TRANSPORTATION, DEPARTMENT OF U.S. Department of Transportation Contracts	93.RD12	Direct		19,560	-
				Subtotal	19,560
OFFICE OF THE UNDER SECRETARY FOR PUBLIC DIPLOMACY AND PUBLIC AFFAIRS, STATE, DEPARTMENT OF Public Diplomacy Programs	19.040	Direct		(1,661)	-
				Subtotal	(1,661)
STATE, DEPARTMENT OF, STATE, DEPARTMENT OF U.S. Department of State Contracts	93.RD6	Direct		217,588	-
				Subtotal	217,588
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF Block Grants for Community Mental Health Services	93.958	University of Puerto Rico Medical Sciences Campus	2022951719	(60,766)	-
Opioid STR	93.788	American Academy of Addiction Psychiatry (AAAP)	5H79TI083343	2,569	-
Opioid STR	93.788	Fenway Community Health Center	5H79TI083343	7,020	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	American Academy of Addiction Psychiatry (AAAP)	1H79TI085588-02	268,759	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	Massachusetts Department of Mental Health	SCDMH8220024MCLEANHO	121,303	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	Victory Programs, Inc.	1H79SP083251-01	25,764	-
				Subtotal	364,649
UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (USUHS), DEPT OF DEFENSE COVID-19 Uniformed Services University Medical Research Projects	12.750	COVID-19 Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012120089	587,414	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920009	955,438	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00011920056	30,489	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00012020011	531,474	-
Uniformed Services University Medical Research Projects	12.750	Geneva Foundation, The	HU00012420044	44,218	-
Uniformed Services University Medical Research Projects	12.750	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00011920125	91,861	-
Uniformed Services University Medical Research Projects	12.750	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012320020	89,591	-
Uniformed Services University Medical Research Projects	12.750	Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.	HU00012320021	111,986	-
				Subtotal	2,442,471
VA HEALTH ADMINISTRATION CENTER, VETERANS AFFAIRS, DEPARTMENT OF Department of Veterans Affairs Contracts	93.RD2	Direct		2,398,397	-
Department of Veterans Affairs Contracts	93.RD2	President and Fellows of Harvard College	36C24E18D0048	36,687	-
Research and Development	64.054	Direct		291,255	-
				Subtotal	2,726,339
				Total Research and Development	\$ 1,461,585,656
					\$ 277,912,123

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Research Training					
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Research on Healthcare Costs, Quality and Outcomes	93.226	COVID-19 Direct		92,445	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Beth Israel Deaconess Medical Center	1P30HS029762-01	44,192	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Children's Hospital Corporation dba Boston Children's Hospital	5T32HS000063-28	(2,992)	-
Research on Healthcare Costs, Quality and Outcomes	93.226	Direct		359,495	-
			Subtotal	493,140	-
DEPT OF THE ARMY, DEPT OF DEFENSE					
Military Medical Research and Development	12.420	Direct		774,604	-
			Subtotal	774,604	-
EMPLOYMENT AND TRAINING ADMINISTRATION, LABOR, DEPARTMENT OF					
H-1B Job Training Grants	17.268	Direct		568,118	33,000
			Subtotal	568,118	33,000
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Geriatric Academic Career Awards Department of Health and Human Services	93.250	President and Fellows of Harvard College	2K01HP49053-02-00	101,250	-
Maternal and Child Health Federal Consolidated Programs	93.110	President and Fellows of Harvard College	5T76MC00001 69	8,271	-
Mental and Behavioral Health Education and Training Grants	93.732	Direct		1,694,460	140,771
Mental and Behavioral Health Education and Training Grants	93.732	Massachusetts General Hospital	6T25HP37602-04-01	96,747	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	5M01HP41980 02 00	5,123	-
Mental and Behavioral Health Education and Training Grants	93.732	MGH Institute of Health Professions	5M01HP41980 04 00	15,876	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	5T32HP42013-03-00	17,821	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	6T32HP42013-01-01	3,000	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	6T32HP42013-02-03	80,626	-
National Research Service Award in Primary Care Medicine	93.186	Beth Israel Deaconess Medical Center	6T32HP42013-03	73,273	-
Nurse Education, Practice Quality and Retention Grants	93.359	Direct		1,075,718	14,998
Nurse Education, Practice Quality and Retention Grants	93.359	MGH Institute of Health Professions	5UK1HP46057 02 00	13,333	-
			Subtotal	3,185,498	155,769
NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Aging Research	93.866	Direct		7,795,408	95,530
Aging Research	93.866	Hebrew Rehabilitation Center for Aged	T32 AG 23480-19	85,845	-
Aging Research	93.866	Hebrew Senior Life	T32 AG023480-18	17,799	-
Aging Research	93.866	Hebrew Senior Life	T32AG023480-18	62,744	-
Aging Research	93.866	Massachusetts General Hospital	5K23AG061276-04	449	-
Aging Research	93.866	President and Fellows of Harvard College	2T32AG000222-31	91,395	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-31	65,133	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AG000222-32	124,805	-
Aging Research	93.866	President and Fellows of Harvard College	5T32AI007245-37	(1,818)	-
Alcohol Research Programs	93.273	Direct		1,369,473	31,354
Allergy and Infectious Diseases Research	93.855	Boston Medical Center	2T32AI052074-17	(10,716)	-
Allergy and Infectious Diseases Research	93.855	Boston Medical Center	5T32AI052074-17	49,498	-
Allergy and Infectious Diseases Research	93.855	Dana-Farber Cancer Institute, Inc.	5T32AI007386-29	38,850	-
Allergy and Infectious Diseases Research	93.855	Direct		6,053,697	93,438
Allergy and Infectious Diseases Research	93.855	FHI 360	UM1AI068619	45,780	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5P30AI060354-20	28,192	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	5T32AI007245-39	46,484	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	CFAR-MGH-21-2	8,443	-
Allergy and Infectious Diseases Research	93.855	President and Fellows of Harvard College	T32AI007245-40	23,700	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Direct		4,329,303	10,118
Biomedical Research and Research Training	93.859	Direct		1,580,117	-
Blood Diseases and Resources Research	93.839	Beth Israel Deaconess Medical Center	5T32HL007917-24	43,956	-
Blood Diseases and Resources Research	93.839	Brigham and Women's Hospital, Inc.	5K12HL141953-05	130,522	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	2T32HL066987-22	93,147	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5T32HL066987-19	(5,604)	-
Blood Diseases and Resources Research	93.839	Children's Hospital Corporation dba Boston Children's Hospital	5T32HL066987-22	30,896	-
Blood Diseases and Resources Research	93.839	Direct		2,121,628	358,795
Blood Diseases and Resources Research	93.839	Emory University	5T32HL069769-19	107,253	-
Cancer Cause and Prevention Research	93.393	Dana-Farber Cancer Institute, Inc.	5UE5CA246746-03	5,062	-
Cancer Cause and Prevention Research	93.393	Direct		340,295	-
Cancer Research Manpower	93.398	Beth Israel Deaconess Medical Center	5K08CA248473-05	91,709	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	2R25CA246746-04A1	44,848	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5R25CA181000-10	66,746	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5T32CA092203	1,529	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	5T32CA092203-20	67,543	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	T32CA092203	137,849	-
Cancer Research Manpower	93.398	Dana-Farber Cancer Institute, Inc.	T32CA236754	32,949	-
Cancer Research Manpower	93.398	Direct		12,443,359	220,194
Cancer Research Manpower	93.398	Massachusetts General Hospital	5K12CA090354-23	3,953	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	1K22CA258960-03	155,930	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-46	56,712	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-47	44,008	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA009001-48	134,768	-
Cancer Research Manpower	93.398	President and Fellows of Harvard College	5T32CA057711-30	60,247	-
Cancer Research Manpower	93.398	Regents of the University of Michigan	5T32CA009672-32	51,865	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	1T32HL160522-01A1	85,965	-
Cardiovascular Diseases Research	93.837	Beth Israel Deaconess Medical Center	5T32HL155020-03	68,352	-
Cardiovascular Diseases Research	93.837	Direct		9,789,823	10,066
Cardiovascular Diseases Research	93.837	President and Fellows of Harvard College	5T32HL098048-15	64,823	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5K08HD100595-04	58,690	-
Child Health and Human Development Extramural Research	93.865	Children's Hospital Corporation dba Boston Children's Hospital	5T32HD040128-20	68,609	-
Child Health and Human Development Extramural Research	93.865	Direct		2,908,391	204,494
Child Health and Human Development Extramural Research	93.865	Duke University	5K12HD000849-38	135,001	-
Child Health and Human Development Extramural Research	93.865	President and Fellows of Harvard College	T32HD104612	56,307	-
COVID-19 Alcohol Research Programs	93.273	COVID-19 Direct		97,200	-
COVID-19 Allergy and Infectious Diseases Research	93.855	COVID-19 Direct		327,461	-
COVID-19 Cancer Research Manpower	93.398	COVID-19 President and Fellows of Harvard College	5T32CA009001-47	41,418	-
COVID-19 Child Health and Human Development Extramural Research	93.865	COVID-19 Brigham and Women's Hospital, Inc.	5K12HD103096-04	135,266	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Corporation dba Boston Children's Hospital	5T32DK007477-38	1,469	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Direct		9,445,186	132,231
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Joslin Diabetes Center	5T32DK007260-46	7,963	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	President and Fellows of Harvard College	5T32DK007703-28	50,841	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286	Direct		1,543,566	-
Drug Abuse and Addiction Research Programs	93.279	American Academy of Child and Adolescent Psychiatry	K12DA000357	159,000	-
Drug Abuse and Addiction Research Programs	93.279	Boston Medical Center	2R25DA013582-21	2	-
Drug Abuse and Addiction Research Programs	93.279	Direct		2,031,439	21,425
Drug Abuse and Addiction Research Programs	93.279	University of Massachusetts Chan Medical School	1R25DA058490-02	47,083	-
Environmental Health	93.113	Direct		607,506	32,647
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's Hospital of Philadelphia (The)	5U54NS115052-05	81,509	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Direct		5,928,732	64,433
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Kennedy Krieger Institute Inc	5K12NS098482-07	215,629	-
Human Genome Research	93.172	Direct		1,183,830	-
International Research and Research Training	93.989	American University of Beirut	2D43TW009118-06	17,561	-
International Research and Research Training	93.989	Direct		890,476	427,138
International Research and Research Training	93.989	Mbarara University of Science and Technology	5D43TW011632-04	29,272	-
Lung Diseases Research	93.838	Direct		6,691,092	83,037
Medical Library Assistance	93.879	Direct		4,549	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	2T15LM007092-31	14,722	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092-32	14,898	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092-32	30,793	-
Medical Library Assistance	93.879	President and Fellows of Harvard College	5T15LM007092-33	56,836	-
Mental Health Research Grants	93.242	Boston Medical Center	5T32MH116140-03	10,397	-
Mental Health Research Grants	93.242	Boston Medical Center	5T32MH116140-05	1,791	-
Mental Health Research Grants	93.242	Children's Hospital Corporation dba Boston Children's Hospital	2T32MH112510-07	55,319	-
Mental Health Research Grants	93.242	Direct		8,588,728	355,708
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-41	15,945	-
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-42	53,118	-
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-43	178,497	-
Mental Health Research Grants	93.242	Judge Baker Children's Center	5T32MH016259-43	54,438	-
Mental Health Research Grants	93.242	Massachusetts General Hospital	5R25MH119857-05	10,564	-
Mental Health Research Grants	93.242	Northeastern University	7K23MH113805-05	8,490	-
Mental Health Research Grants	93.242	President and Fellows of Harvard College	5T32MH125815-02	54,840	-
Minority Health and Health Disparities Research	93.307	Direct		503,415	-
National Center for Advancing Translational Sciences	93.350	Harvard Catalyst - The Harvard Clinical and Translational Science Center	5K12TR004381-02	174,702	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1K12TR004381-01	71,820	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance	Direct Agency/Pass-Through Program	Pass-Through Entity	Total	Subrecipient
	Listing Number		Identifying Number	Expenditures	Expenditures
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	1K12TR004381-01	46,800	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5K12TR004381-02	862,041	-
National Center for Advancing Translational Sciences	93.350	President and Fellows of Harvard College	5KL2TR002542-05	(276,949)	-
National Center on Sleep Disorders Research	93.233	Direct		1,244,116	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021F00229-P00002-0-1	29,418	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021F00229-P00002-0-1	38,222	-
National Institutes of Health Contracts	93.RD1	Westat, Inc.	75N92021Q0072	28,531	-
Oral Diseases and Disorders Research	93.121	Direct		547,562	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5T32AT000051-23	(677)	-
Research and Training in Complementary and Integrative Health	93.213	Beth Israel Deaconess Medical Center	5T32AT000051-24	236,756	-
Research and Training in Complementary and Integrative Health	93.213	Direct		1,434,249	-
Research Related to Deafness and Communication Disorders	93.173	Direct		1,840,952	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	93.840	Direct		380,530	-
Vision Research	93.867	Direct		1,773,800	-
			Subtotal	98,924,426	2,140,608
VA HEALTH ADMINISTRATION CENTER, VETERANS AFFAIRS, DEPARTMENT OF					
Department of Veterans Affairs Contracts	93.RD2	Direct		5,319	-
			Subtotal	5,319	-
			Total Research Training	\$ 103,951,105	\$ 2,329,377
			Total Research and Development and Research Training	\$ 1,565,536,761	\$ 280,241,500

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates
Schedule of Expenditures of Federal Awards
Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Student Financial Aid					
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) FY23 Outstanding Loans	Direct	119,940	-
Nurse Faculty Loan Program (NFLP)	93.264	Nurse Faculty Loan Program (NFLP) New Loans Issued During FY24	Direct	43,601	-
			Subtotal	163,541	-
OFFICE OF FEDERAL STUDENT AID, EDUCATION, DEPARTMENT OF					
Federal Direct Student Loans	84.268	Department of Education	Direct	39,938,423	-
			Subtotal	39,938,423	-
Total Student Financial Aid				\$ 40,101,964	\$ -

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
Food Distribution Cluster					
FOOD AND NUTRITION SERVICE, AGRICULTURE, DEPARTMENT OF Emergency Food Assistance Program (Food Commodities)	10.569	Direct	Agency2273	10,192	-
			Subtotal	10,192	-
SNAP Cluster					
FOOD AND NUTRITION SERVICE, AGRICULTURE, DEPARTMENT OF State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	University of Massachusetts Medical Center	OutreachPartnerAmendment1-4-2016	(16,685)	-
			Subtotal	(16,685)	-
Special Supplemental Nutrition Program for Women, Infant, and Children					
FOOD AND NUTRITION SERVICE, AGRICULTURE, DEPARTMENT OF WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726104	966,739	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	INTF3502M03162726128	924,375	-
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10.557	Massachusetts Department of Public Health	WICVoucher	5,153,653	-
			Subtotal	7,044,767	-
Economic Development Cluster					
ECONOMIC DEVELOPMENT ADMINISTRATION, COMMERCE, DEPARTMENT OF Economic Adjustment Assistance	11.307	Massachusetts Technology Park Corporation	ED21HDQ3070023	8,852	-
			Subtotal	8,852	-
Highway Safety Cluster					
NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION, TRANSPORTATION, DEPARTMENT OF National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants and Cooperative Agre	20.614	KEA Technologies, Inc.	DTNH22-13-H-00433	148,634	-
			Subtotal	148,634	-
Coronavirus Relief Fund					
DEPARTMENTAL OFFICES, TREASURY, DEPARTMENT OF THE COVID-19 Coronavirus Relief Fund	21.019	COVID-19 Foundation for Healthy Communities	CoronavirusReliefFundGrant	669	-
			Subtotal	669	-
Aging Cluster					
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF National Family Caregiver Support, Title III, Part E	93.052	Highland Valley Elder Services	Title III-E	4,000	-
			Subtotal	4,000	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF Special Programs for the Aging, Title IV, and Title II, Discretionary Projects	93.048	Oasis Institute	90CCDG0001-04-00	29,271	-
			Subtotal	29,271	-
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers	93.044	Highland Valley Elder Services	Title III-B	3,878	-
Special Programs for the Aging, Title III, Part B, Grants for Supportive Services and Senior Centers	93.044	Mystic Valley Elder Services	Title III-B	22,728	-
			Subtotal	26,606	-
Other Programs					
ADMINISTRATION FOR CHILDREN AND FAMILIES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF Title V State Sexual Risk Avoidance Education (Title V State SRAE) Program	93.235	Massachusetts Department of Public Health	INTF3211MM3W19020007	57,388	15,400
			Subtotal	57,388	15,400
AGENCY FOR INTERNATIONAL DEVELOPMENT, AGENCY FOR INTERNATIONAL DEVELOPMENT Foreign Assistance to American Schools and Hospitals Abroad (ASHA)	98.006	Direct	72ASHA19GR00002	(8,454)	-
			Subtotal	(8,454)	-
AGENCY FOR INTERNATIONAL DEVELOPMENT, AGENCY FOR INTERNATIONAL DEVELOPMENT USAID Foreign Assistance for Programs Overseas	98.001	Cloudburst Consulting Group, Inc.	GS10F0218U/7200AA18M0017	33,880	-
USAID Foreign Assistance for Programs Overseas	98.001	Direct	AID-440-A-16-00002	1,544,246	972,837
USAID Foreign Assistance for Programs Overseas	98.001	Eastern Virginia Medical School	7200AA20CA00019	123,117	-
USAID Foreign Assistance for Programs Overseas	98.001	Fenway Community Health Center	72038619CA0001	30,714	-
USAID Foreign Assistance for Programs Overseas	98.001	International AIDS Vaccine Initiative (IAVI)	AID-0AA-A-16-00032	176,734	-
USAID Foreign Assistance for Programs Overseas	98.001	Invisible Children	7260518CA00001	(13,995)	-
USAID Foreign Assistance for Programs Overseas	98.001	National Opinion Research Center	GS10F0033M /7200AA18M00016	(1,137)	-
USAID Foreign Assistance for Programs Overseas	98.001	Palladium Group, The	7200AA22CA00023	11,432	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	7200AA19APS00003	140,822	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	720BHA23CA00012	38,252	-
USAID Foreign Assistance for Programs Overseas	98.001	President and Fellows of Harvard College	720FDA20GR00043	(1,671)	-
USAID Foreign Assistance for Programs Overseas	98.001	The KonTerra Group	GS10F0418Y/7200AA20M00001	(10,345)	-
			Subtotal	2,072,049	972,837

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Assistance Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
ASSISTANT SECRETARY FOR COMMUNITY PLANNING AND DEVELOPMENT, HOUSING AND URBAN DEVELOPMENT, DEPARTMENT OF					
Continuum of Care Program	14.267	Community Action of Pioneer Valley	MA0401L1T072110	5,917	-
Continuum of Care Program	14.267	Community Action of Pioneer Valley	MA0401L1T072211	97,822	-
Continuum of Care Program	14.267	Massachusetts Department of Public Health	INTF4944MM3181926016	28,683	-
			Subtotal	132,422	-
ASSISTANT SECRETARY FOR COMMUNITY PLANNING AND DEVELOPMENT, HOUSING AND URBAN DEVELOPMENT, DEPARTMENT OF					
Housing Opportunities for Persons with AIDS	14.241	City of Springfield	20210144	(974)	-
Housing Opportunities for Persons with AIDS	14.241	City of Springfield	20240090	299,093	-
			Subtotal	298,119	-
CDC NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Drug-Free Communities Support Program Grants	93.276	Direct	6NH28CE002705-07-01	115,577	-
			Subtotal	115,577	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Centers for Diseases Control and Prevention Contracts	93.U03	Massachusetts Department of Public Health	INTF5104HH4226732342	242,410	-
Centers for Diseases Control and Prevention Contracts	93.U03	Massachusetts Department of Public Health	INTF5104HH4226732367	73,401	-
			Subtotal	315,811	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Birth Defects and Developmental Disabilities - Prevention and Surveillance	93.073	Massachusetts Department of Public Health	5U01DD001224-03-00	(4,197)	-
			Subtotal	(4,197)	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Community Health Workers for Public Health Response and Resilient	93.495	COVID-19 Massachusetts Department of Public Health	INTF4207M03225031014	192,516	4,562
			Subtotal	192,516	4,562
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Syst	93.318	COVID-19 Direct	5NU50CK000611-04-00	335,174	-
COVID-19 Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Syst	93.318	COVID-19 Direct	6NU50CK000611-02-01	14,583	-
			Subtotal	349,757	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Disabilities Prevention	93.184	University of Alabama, Birmingham	5NU27DD000022-03-00	107,552	-
			Subtotal	107,552	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
HIV Prevention Activities Health Department Based	93.940	Massachusetts Department of Public Health	INTF4944MM3181926038	1,220,718	-
			Subtotal	1,220,718	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Injury Prevention and Control Research and State and Community Based Programs	93.136	Massachusetts Department of Public Health	1NU17CE010190-01-00	237,444	-
			Subtotal	237,444	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Prevention of Disease, Disability, and Death by Infectious Diseases	93.084	Massachusetts Department of Public Health	INTF5104H78W22195363	752,076	-
			Subtotal	752,076	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	6NU62PS924585	143,338	-
Sexually Transmitted Diseases (STD) Provider Education Grants	93.978	Massachusetts Department of Public Health	NU62PS924585	47,396	-
			Subtotal	190,734	-
CENTERS FOR DISEASE CONTROL AND PREVENTION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect th	93.421	Direct	5NU50CK000622-03-00	446,785	12,665
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect th	93.421	Direct	6NU50CK000622-02-05	205,116	-
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect th	93.421	Direct	6NU50CK000622-03-00	585,532	225,000
			Subtotal	1,237,433	237,665
HEALTH AND HUMAN SERVICES, DEPARTMENT OF, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Congressional Directives	93.493	Direct	1CE1HS46369-01	300,354	-
			Subtotal	300,354	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	Dimock Community Health Center	2H12HA24846-06-00	98,045	-
			Subtotal	98,045	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	COVID-19 BOSTON PUBLIC HEALTH COMMISSION	5UT8HA33922-05-00	79,936	-
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	5UT8HA33922-05-00	121,399	-
Ending the HIV Epidemic: A Plan for America — Ryan White HIV/AIDS Program Parts A and B	93.686	BOSTON PUBLIC HEALTH COMMISSION	6UT8HA33922-02-03	800	-
			Subtotal	202,135	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
HIV Care Formula Grants	93.917	Massachusetts Department of Public Health	INTF4944MM3181926016	603,859	-
			Subtotal	603,859	-

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Schedule of Expenditures of Federal Awards

Year Ended September 30, 2024

Cluster Title/Federal Program/Agency	Listing Number	Direct Agency/Pass-Through Program	Pass-Through Entity Identifying Number	Total Expenditures	Subrecipient Expenditures
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
HIV Emergency Relief Project Grants	93.914	BOSTON PUBLIC HEALTH COMMISSION	6H89HA00011-34-03	469,666	-
			Subtotal	469,666	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Maternal and Child Health Federal Consolidated Programs	93.110	COMMONWEALTH OF MASSACHUSETTS	INTF3000H78W23011288	161,485	-
Maternal and Child Health Federal Consolidated Programs	93.110	Icahn School of Medicine at Mount Sinai	5H30MC24048-10	18,104	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	INTF3121MM3W23005040	10,834	-
Maternal and Child Health Federal Consolidated Programs	93.110	Massachusetts Department of Public Health	INTF3121MM3W23005041	23,125	-
Maternal and Child Health Federal Consolidated Programs	93.110	University of Colorado at Denver	2UA6MC31101 07 00	87,720	-
			Subtotal	301,268	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226202	354,410	-
Maternal, Infant and Early Childhood Home Visiting Grant	93.870	Massachusetts Department of Public Health	INTF3617MM3220226207	241,821	-
			Subtotal	596,231	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Small Rural Hospital Improvement Grant Program	93.301	Massachusetts Health and Hospital Association Inc.	6H3HRH0011-22-01	12,912	-
			Subtotal	12,912	-
HEALTH RESOURCES AND SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Telehealth Programs	93.211	Direct	4P13RH33168 01 03	(717)	-
			Subtotal	(717)	-
IMMED OFFICE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
COVID-19 Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	COVID-19 Direct	5U3REP220683-02-00	1,066,888	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Advanced Regenerative Manufacturing Institute	IDSEP220058-01-003	310,074	-
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	6HITEP180042-01-18	449,199	172,780
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Direct	6HITEP180042-01-19	1,118,316	47,409
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817	Massachusetts Department of Public Health	INTF6208PP1W22146333	3,295	-
			Subtotal	2,947,772	220,189
NATIONAL INSTITUTES OF HEALTH, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Drug Abuse and Addiction Research Programs	93.279	Salem Board of Health	5UM1DA049412-02	(624)	-
			Subtotal	(624)	-
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF					
Crime Victim Assistance	16.575	COMMONWEALTH OF MASSACHUSETTS	15POVC-22-GG-00755ASSI	66,146	-
			Subtotal	66,146	-
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF					
Crime Victim Assistance/Discretionary Grants	16.582	Direct	2018-V3-GX-K036	12,900	-
			Subtotal	12,900	-
OFFICE OF JUSTICE PROGRAMS, JUSTICE, DEPARTMENT OF					
U.S. Department of Justice Contracts	93.UO1	COMMONWEALTHOFMASSACHUSETTS	24VOCAVWA	256,974	-
			Subtotal	256,974	-
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Foundation for Healthy Communities	05-95-49-491510-2990	73,259	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Foundation for Healthy Communities	NUMBER NOT AVAILABLE	55,855	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626051	270,636	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626053	311,680	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	Massachusetts Department of Public Health	INTF2351M03183626061	251,576	-
			Subtotal	963,006	-
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Substance Abuse and Mental Health Services Administration Contracts	93.UO2	City of Chelsea	2024-277	170,878	-
			Subtotal	170,878	-
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, HEALTH AND HUMAN SERVICES, DEPARTMENT OF					
Opioid STR	93.788	New Hampshire Department of Health and Human Services	05-95-92-7040-500731	1,862,586	-
			Subtotal	1,862,586	-
FEDERAL EMERGENCY MANAGEMENT AGENCY, HOMELAND SECURITY, DEPARTMENT OF					
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036	Direct	FY2024 FEMA	39,399,739	-
			Subtotal	39,399,739	-
Total Other Programs				\$ 62,786,381	\$ 1,450,653
Total Federal Expenditures				\$1,668,425,106	\$281,692,153

The accompanying notes are an integral part of the schedule of expenditures of federal awards.

Mass General Brigham Incorporated and Affiliates

Notes to Schedule of Expenditures of Federal Awards

September 30, 2024

1. Organization

Mass General Brigham Incorporated (the Company) is the parent organization and sole corporate member of numerous organizations whose financial condition and operations are described in the consolidated financial statements. The terms Mass General Brigham, We, Our or Us as used herein, unless otherwise stated or indicated by context, refer collectively to the Company and its affiliated organizations.

Mass General Brigham operates academic medical centers, community acute care hospitals, inpatient and outpatient mental health services facilities, urgent care centers, facilities that provide rehabilitation medicine and long-term care services, physician organizations, home health services, nursing homes and a graduate level program for health professions. Our mission is to provide world class health care services to the local communities in which we operate as well as to patients across the United States and the world. In addition, we are a nonuniversity-based nonprofit private medical research enterprise and a principal teaching affiliate of the medical and dental schools of Harvard University. Our licensed, not-for-profit managed care organization (Mass General Brigham Health Plan, Inc.) and licensed, for-profit insurance company (Mass General Brigham Health Insurance Company) (collectively referred to as Mass General Brigham Health Plan) provide health insurance products and administrative services to the Massachusetts Medicaid program (MassHealth), Medicare Advantage program, ConnectorCare (a state subsidized program for adults who meet income and immigration guidelines) and commercial populations..

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) includes the Federal award activity of Mass General Brigham and is recorded on the accrual basis of accounting.

The information in the Schedule is presented in accordance with Title 2 U.S. Code of Federal Regulations (CFR) 200 Uniform Administrative Requirements Cost Principles and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in or used in the preparation of the basic consolidated financial statements. Negative amounts represent adjustments to amounts reported as expenditures in prior years in the normal course of business. Assistance Listing Number (ALN) and pass-through award numbers are provided where available. The Schedule combines expenditures of The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a The Massachusetts General Hospital, Massachusetts Eye and Ear Infirmary, including The Schepens Eye Research Institute, Inc., The McLean Hospital Corporation, The MGH Institute of Health Professions, Inc., The Spaulding Rehabilitation Hospital Corporation, Cooley Dickinson Hospital, Inc., North Shore Medical Center, Inc. d/b/a Salem Hospital, Newton-Wellesley Hospital, Martha's Vineyard Hospital, Inc., Wentworth-Douglass Hospital, and Mass General Brigham Incorporated. These entities are all affiliates of Mass General Brigham.

2. Facilities and Administrative and Fringe Benefit Costs

Federal expenditures for Research and Development and Research and Development Training for Brigham and Women's Hospital, Massachusetts General Hospital, McLean, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital and the MGH Institute of Health Professions include facilities and administrative cost recoveries and fringe benefit cost recoveries in the amounts reported in the Schedule based on rates negotiated and awarded with the DHHS Division of Cost Allocation. These rates are based on financial information

Mass General Brigham Incorporated and Affiliates

Notes to Schedule of Expenditures of Federal Awards

September 30, 2024

submitted utilizing the methods prescribed in Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts with Hospitals, contained in the Code of Federal Regulation, Title 45, Part 74, Appendix E (OASC-3). The predetermined facilities and administrative cost rates for IHP are based on financial information submitted utilizing the simplified method for small institutions prescribed in Indirect (F&A) Costs Identification and Assignment, and Rate Determination for Institutions of Higher Education (IHEs), contained in the Code of Federal Regulation, Title 2, Part 200, Appendix III. Expenditures reported in Training and Other include the maximum facilities and administrative recoveries approved by the sponsor. The 10% de-minimis rate is not utilized on Research and Development or Research and Development Training by Mass General Brigham because they have approved negotiated rate agreements. The 10% de-minimis rate is used for Other awards where allowed.

3. Federal Student Loan Programs

The amounts reported in the Student Financial Aid Cluster of the Schedule represent the beginning balances and newly issued loans in fiscal year 2024. As of September 30, 2024, the MGH Institute of Health Professions (IHP) had loans outstanding of \$163,541 for loans issued as part of the Nurse Faculty Loan Program (ALN 93.264). IHP had Direct Loans issued by the Department of Education of \$39,938,423 as of September 30, 2024 for ALN 84.268.

4. Federal Emergency Management Agency (FEMA) Public Assistance

Mass General Brigham applied for reimbursement of certain expenses related to the COVID-19 pandemic under Assistance Listing #97.036, FEMA Public Assistance through the Commonwealth of Massachusetts and the State of New Hampshire. Expenditures are reflected in the Schedule of Federal Expenditures (SEFA) in the year in which a project application is obligated. The Schedule thus includes \$39,399,739 of expenditures incurred in Fiscal years 2020, 2021 and 2022, which were obligated in fiscal year 2024 and represents a reconciling item between the federal expenses in Mass General Brigham's financial statements and the amount included on the Schedule.

Part II
Reports on Compliance and Internal Control



**Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance
and Other Matters Based on an Audit of Financial Statements Performed in Accordance with
*Government Auditing Standards***

To the Board of Directors of
Mass General Brigham Incorporated

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Mass General Brigham Incorporated (the "Company") and its affiliates, which comprise the consolidated balance sheet as of September 30, 2024 and 2023, and the related consolidated statements of operations, changes in net assets and cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated December 18, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Company and its affiliates internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates internal control. Accordingly, we do not express an opinion on the effectiveness of the Company and its affiliates internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the Company and its affiliates financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company and its affiliates financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company and its affiliates internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company and its affiliates internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 18, 2024



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance

To the Board of Directors of
Mass General Brigham Incorporated

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Mass General Brigham Incorporated (the "Company") and its affiliates' compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company and its affiliates' major federal programs for the year ended September 30, 2024. The Company and its affiliates' major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company and its affiliates complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and its affiliates and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company and its affiliates' compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company and its affiliates' federal programs.

Auditors' Responsibilities for the Audit of Compliance



Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company and its affiliates' compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company and its affiliates' compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company and its affiliates' compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company and its affiliates' internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company and its affiliates' internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

Financial Assistance cluster as a major program. Also, as indicated in the first paragraph of this report, we performed our audit of compliance using the compliance requirements contained in the OMB Compliance Supplement, including those contained in Part V 5.3, Compliance Requirement N, Special Tests and Provisions, Section 11 "Gramm-Leach-Bliley Act-Student Information Security." This section includes two suggested audit procedures with respect to verification that the institution (1) designated a Qualified Individual responsible for implementing and monitoring the institution's information security program, and (2) has a written information security program that addresses the remaining six required minimum elements that are detailed in the OMB Compliance Supplement, Part Five, Student Financial Assistance Cluster, Special Tests and Provisions, item 11, Gramm-Leach-Bliley Act – Student Information Security. Our procedures in relation to these two items were limited to inquiry of and obtaining written representation from management and obtaining and reading management's documentation related to these two items. Our procedures did not include an analysis of the adequacy or completeness of the minimum required elements of the institution's information security program.



The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2024-001, 2024-002, and 2024-003. Our opinion on each major federal program is not modified with respect to these matters.

Government Auditing Standards requires the auditor to perform limited procedures on the Company and its affiliates' response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs and corrective action plan. The Company and its affiliates' response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Boston, Massachusetts
December 18, 2024

Part III
Federal Award Findings and Questioned Cost

Mass General Brigham Incorporated and Affiliates

Schedule of Findings and Questioned Costs

Fiscal Year Ended September 30, 2024

1. Summary of Auditor's Results

Financial Statements

Type of auditor's report issued

Internal control over financial reporting

Unmodified

Material weakness(es) identified?

___yes___X___no

Significant deficiency(ies) identified that are not considered to be material weaknesses?

___yes___X___none reported

Noncompliance material to financial statements noted?

___yes___X___no

Federal Awards

Internal control over major programs

Material weakness(es) identified?

___yes___X___no

Significant deficiency(ies) identified that are not considered to be material weaknesses?

___yes___X___none reported

Type of auditor's report issued on compliance for major programs Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200, 516(a)

__X__yes____no

Identification of Major Programs

Name of Federal Program or Cluster

Various Assistance Listing Numbers

Research and Development,
Research Training Cluster

84.268

Student Financial Assistance

93.817

Hospital Preparedness Program (HPP)
Ebola Preparedness and Response

Dollar threshold used to distinguish between Type A and Type B programs Auditee qualified as low-risk auditee?

\$5,005,275

Auditee qualified as low-risk auditee?

___X___yes____no

2. Financial Statement Findings

No findings to report.

Mass General Brigham Incorporated and Affiliates

Schedule of Findings and Questioned Costs

Fiscal Year Ended September 30, 2024

3. Federal Findings and Questioned Costs

2024-001 – Non-Compliance with Monthly Direct Loan Reconciliations

Grantor: U.S. Department of Education

Cluster: Student Financial Assistance Cluster

Award Names: Federal Direct Loan Program

Award Numbers: Not applicable

Assistance Listing Number: 84.268

Award Year: 2023 – 2024

Criteria

In accordance with 34 CFR 685.300(b)(5), on a monthly basis, institutions are required to reconcile institutional records with Direct Loan funds received from the Department of Education and Direct Loan disbursement records submitted to and accepted by the Department of Education.

Condition

The Company could not evidence that a monthly reconciliation was being performed between Direct Loan funds received from the Department of Education and Direct Loan disbursement records submitted to the Department of Education.

Cause

The Company indicated it performs a weekly reconciliation between funds received and funds disbursed to the Department of Education in order to determine the amount to return to or request from the Department. However, evidence of this reconciliation is not retained.

Effect

There is no evidence that the reconciliations were performed during the fiscal year. We could not observe evidence of this weekly reconciliation as part of audit procedures.

Questioned Costs

There are no questioned costs, as this is a documentation matter with no evidence of erroneous drawdowns and disbursements found in our testing.

Recommendation

We recommend that the Company update/enhance its procedures related to ensuring reconciliations are performed monthly and the audit evidence associated with the direct loan reconciliation and disbursements process is retained.

Management's Views and Corrective Action Plan

Management's Views and Corrective Action Plan are included at the end of this report after the summary schedule of prior audit findings and status.

2024-002 – Equipment Management

Grantor: Various

Cluster: Research & Development

Award Names: Various

Award Numbers: Various

Assistance Listing Number: Various

Award Year: Various

Criteria

2 CFR 200.313 (d)(1-2) indicates that a physical inventory of federal equipment must be taken and the results reconciled with property records at least once every two years. Additionally, accurate property

Mass General Brigham Incorporated and Affiliates

Schedule of Findings and Questioned Costs

Fiscal Year Ended September 30, 2024

records must be maintained which include various identifying information, such as the location, use and condition of the property and any ultimate disposition data, including the date of disposal and sale of the property.

Condition

In testing the Company's conformity with the compliance requirements for equipment management, we selected 25 pieces of equipment from the detailed listings provided to physically inspect. Additionally, in order to test the completeness of the detailed listings, we selected 25 pieces of equipment from the "floor" and traced these to the detailed listings provided. Through our testing, we noted the following:

- Two pieces of equipment out of the 25 selections made from the detailed listings for physical inspection were incorrectly included in the listings.
 - One asset was moved to another institution with the associated principal investigator. The asset was not included in the list of equipment approved for the transfer with the departure of the principal investigator. The department continued to certify the asset was in service after the transfer of the asset. The acquisition price of the asset was \$6,023.36.
 - The second asset was acquired in 2008 and sold in 2023, at the direction of the principal investigator, with the proceeds of the sale allocated to a non-federal internal research fund. The department continued to certify the asset was in service after the disposal of the asset.

Cause

For the first asset that was improperly included in the detailed listing, two pieces of the same equipment were purchased together, and one of the two pieces of equipment was retained, which caused the department to inadvertently certify that both assets were still in service. Further, the asset was not included on the list of equipment approved for transfer with the principal investigator's departure from the Company.

For the second asset, the principal investigator in charge of the equipment is in the process of leaving the Company, and the department is moving or disposing of his equipment. The equipment management team was waiting until the Investigator's space was completely cleared before updating the inventory listings.

Effect

The process around the transfer and/or disposal of equipment when there is a transfer of an award, or a transfer of the principal investigator is not properly reflected in the Company's inventory records.

Questioned Costs

There are no questioned costs. Under the Federal Grant and Cooperative Agreement Act, 31 U.S.C. 6306, NIH permits institutions to obtain title to equipment for support of basic or applied scientific research without further obligation to the Federal government. NIH has the right to require transfer of title to equipment with an acquisition cost of \$5,000 or more to the Federal government within 120 of the completion of the award. The associated award ended prior to FY24, so the title transfer period has expired. Therefore, the equipment disposal did not result in questioned costs.

Recommendation

We recommend that the Company provide additional training to the principal investigators and other grant personnel focusing on the policies and procedures around federal equipment management. Specifically, the training should emphasize the importance of accuracy in the disposal request forms, including federal funding. The training should also focus on the importance of timely updates to the equipment inventory listing to ensure the listing is complete and accurate.

Management's Views and Corrective Action Plan

Management's Views and Corrective Action Plan are included at the end of this report after the summary schedule of prior audit findings and status.

Mass General Brigham Incorporated and Affiliates

Schedule of Findings and Questioned Costs

Fiscal Year Ended September 30, 2024

2024-003 – Cash Management

Grantor: Department of Health and Human Services

Pass Through Entity: Advanced Regenerative Manufacturing Institute, Inc.

Award Name: Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities

Award Number: IDSEP22005-003

Assistance Listing Number: 93.817

Award Year: June 1, 2023-September 30, 2023

Criteria

In accordance with 2 CFR 200.305 (b)(3), reimbursement is the preferred method when the requirements in paragraph (b) cannot be met, when the Federal awarding agency sets a specific condition per 2 CFR 200.208, or when the non-Federal entity requests payment by reimbursement.

In accordance with 2 CFR 200.334 (c) and (e), a subrecipient must liquidate all financial obligations incurred under a subaward no later than 90 calendar days after the conclusion of the period of performance of the subaward (or an earlier date as agreed upon by the pass-through entity and subrecipient). The subrecipient must promptly refund any unobligated funds that the pass-through entity paid and that are not authorized to be retained.

Condition

In testing the period of performance compliance requirement in accordance with the OMB Compliance Supplement, we requested support for the expenditures on the FY2024 Schedule of Federal Awards, as they were outside of the period of performance of the subaward, which ended September 30, 2023. The Company issued an invoice to Advanced Regenerative Manufacturing Institute, the Prime awardee, for \$215,192 on September 14, 2023, but did not incur those expenses until after the period of performance of the subaward. Therefore, the Company requested and received the funds in advance of incurring the expenses.

Further, the Company did not liquidate its obligations under the subaward within the required 90 calendar days after the conclusion of the performance of the subaward, as expenditures were recorded through August 2024. There were no terms in the award that allowed retention of unused funds.

Cause

The grant personnel were not aware of the invoicing requirements under the reimbursement method and invoiced the Prime awardee in advance of incurring the associated costs.

Effect

Federal funds were obtained in advance of incurring costs and outside of the period of performance of the subaward.

Questioned Costs

\$215,192

Recommendation

We recommend that the Company return the advance funds received to the Prime. Further, the Company should consider the need for clarifying and/or enhancing existing internal control procedures to ensure expenditures are paid in compliance with Federal reimbursement requirements and that requests for reimbursement are reviewed and validated against supporting documentation to identify any discrepancies prior to requesting reimbursement.

Management's Views and Corrective Action Plan

Management's Views and Corrective Action Plan are included at the end of this report after the summary schedule of prior audit findings and status.

Mass General Brigham Incorporated and Affiliates
Summary Schedule of Prior Audit Findings and Status
Fiscal Year Ended September 30, 2024

No findings noted in the prior year which required follow ups in the current year.

Management's View and Corrective Action Plan
For the Fiscal Year Ended September 30, 2024

2024-001 – Non-Compliance with Monthly Direct Loan Reconciliations

Management agrees with the finding and the auditor's recommendation. Mass General Brigham (MGB) will update existing procedures to include a formal monthly Direct Loan reconciliation with applicable supporting documentation. This will be implemented February 2025 for the period beginning January 2025. Updates will be prepared by the Director of Student Financial Aid and the Director of Finance for review and approval by the Controller's Office prior to implementation.

2024-002 – Equipment Management

Management agrees with the finding and the auditor's recommendation. Mass General Brigham (MGB) will develop supplemental training materials focusing on the policies and procedures around federal equipment management. The training materials will emphasize the importance of accuracy in the disposal request forms including identification of assets purchased with federal funding. In addition, updates to equipment disposals that are already complete will no longer be held for processing once all other disposals associated with a transfer or sale are complete. Management believes these are isolated incidents that will be avoided going forward through enhanced training and escalation when delays occur. Training materials will be developed by Research Space Management Directors for implementation April 2025 to coincide with annual Asset Certification.

2024-003 – Cash Management

Management agrees with the finding and the auditor's recommendation. There was confusion at the time of this agreement as the nature of the work was in line with providing institutional services rather than a federal grant agreement. This led to a misunderstanding of cash management requirements due to the nature of the award. Mass General Brigham (MGB) has removed the \$215K of questioned costs from the Schedule of Expenditures of Federal Awards (SEFA). The funding will be returned to Advanced Regenerative Manufacturing Institute, Inc. in January 2025. Additionally, management will review the limited instances where departments have been previously approved to request federal cash. This review is to confirm that an exception to the standard practice of managing this through the central Research Finance team is appropriate. Based on results of this review, to be completed by March 2025, management will determine criteria and prior approval requirements for departments to request federal cash if MGB concludes this practice will continue on a limited exception basis. The review will be conducted with oversight by the MGB Vice President of Research Management and Research Finance and the MGB Research Controller.

Rhonda Lowe
Rhonda Lowe
Research Controller
rlowe2@mgb.org
Phone: 857-282-0711

December 18, 2024
Date